In response to the COVID-19 pandemic, the DrugBank team has created this information dashboard to provide a comprehensive summary of research in an effort to help interested parties find the information they need quickly and effectively. If you are interested in licensing DrugBank data for commercial use, please contact us.

COVID-19 OUTBREAK SUMMARY: Coronavirus disease 2019 (named COVID-19 on February 11, 2020 by the World Health Organization (WHO) 2,4) was first identified in Wuhan, China near the end of 2019 2. It is caused by the virus known as SARS-CoV-2 (previously called 2019-nCoV). This name was chosen because the virus is related to the coronavirus that caused the SARS outbreak of 2003. The two viruses are different despite their genetic similarity 1. COVID-19 is believed to be less lethal but much more infectious than SARS-CoV 3. Until the recent outbreak, this virus had not been identified in humans 5.

Disclaimer: This dashboard is intended for research purposes only, and is not to be used for self-diagnosis. If you believe you are experiencing symptoms of COVID-19, please reach out to a medical professional. While we do our best to maintain accuracy and provide up-to-date data and information, we do not guarantee that.
Covid drug dev
COVID-19: Finding the Right Fit

Identifying Potential Treatments Using a Data-Driven Approach

Download the White Paper
COVID-19 Highlights
Sep 8, 2020

Reports of a serious adverse event in a participant of a Phase III trial for an AstraZeneca COVID-19 vaccine has put the trial on pause while researchers review safety data. A spokesperson for the pharmaceutical company confirmed that this is part of standard protocol to maintain the integrity of the vaccine development process.

Aug 24, 2020

China announces "urgent use" regulations that allowed for limited public use of Sinopharm's trial COVID-19 vaccines as far back as July 22.

Aug 15, 2020

A rapid saliva-based COVID-19 test has been approved by the FDA for Emergency Use Authorization. The test was developed by researchers at Yale University and is set to be cheaper and faster than traditional testing methods, such as the nasopharyngeal (NP) swab, while delivering nearly identical outcomes to NP swabbing.

Aug 13, 2020

Researchers from UC San Francisco have developed a product called ‘AeroNabs’, which utilizes engineered nanobodies to prevent the SARS-CoV-2 virus spike proteins from binding to ACE2 receptors in the airway and lungs. In contrast to vaccines, AeroNabs are aerosolized and may be delivered via inhaler or nasal spray. The efficacy and safety of the product have yet to be determined in clinical trials.

Aug 11, 2020

Russia approves the SARS-CoV-2 vaccine called "Sputnik V". The vaccine was developed by the Gamaleya Research Institute of Epidemiology and Microbiology.

Aug 4, 2020

A synthetic monoclonal antibody derived from a patient who recovered from COVID-19 termed LY-CoV555 is set to enter phase three clinical trials as part of the NIH's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. The trial will be carried out globally through existing clinical trial networks, including INSIGHT, PETAL, CTSN, and CONNECTS.

Jul 28, 2020

Health Canada authorizes the use of remdesivir for the treatment of severe COVID-19 symptoms.

Jul 27, 2020

Moderna's MRNA-1273 begins phase 3 clinical trials.

Jul 27, 2020

The joint vaccine development program between BioNTech and Pfizer announces their lead candidate to begin a global phase 2/3 clinical trials will be BNT162b2. BNT162b2 is one of two candidates, along with BNT162b1, to have received FDA fast-track designation on July 13, 2020, and is a nucleoside modified mRNA vaccine encoding an optimized full-length version of the SARS-CoV-2 spike (S) protein.

Jul 20, 2020

A clinical trial at the University of Oxford demonstrated that the novel vaccine, ChAdOx1 nCoV-19, induces a T-cell mediated immune response and neutralizing antibodies against SARS-CoV-2, the virus responsible for causing COVID-19.

Jul 14, 2020

Moderna's SARS-CoV-2 vaccine, MRNA-1273, has phase 1 trial results published in the New England Journal of Medicine

Jul 13, 2020

Two vaccine candidates jointly developed by Pfizer and BioNTech, termed BNT162b1 and BNT162b2, have been granted fast track designation by the FDA. The companies have announced their intention to make 100 million doses by the end of 2020, pending further regulatory approval.

Jul 10, 2020

Gilead reports a 62% reduction in mortality risk and improved clinical outcome (https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19) in patients treated with remdesivir (https://www.drugbank.ca/drugs/DB14761)

Jul 10, 2020

Anecdotal evidence from smaller studies, combined with evidence from a more extensive Swedish study, suggests that memory T cell responses may be present in patients previously exposed to SARS-CoV-2, regardless of their serological status.

Jul 7, 2020

Regeneron Pharmaceuticals receives $450 million from the U.S. government for the manufacture of their double-antibody cocktail REGN-COV2. The agreement covers production and storage of between 70,000 to 300,000 treatment doses or between 420,000 to 1,300,000 prevention doses, with an anticipated completion date of fall 2020.

Jun 30, 2020

FDA publishes guidelines for the development of COVID-19 vaccines.

Jun 26, 2020

FDA approves the phase II clinical trial conducted by Celltex Therapeutics to investigate the prophylactic efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) in subjects who have never been infected with COVID-19 but are at a high risk of contracting the virus.

Jun 23, 2020

INOVIO pharmaceuticals has received $71 million in funding from the U.S. Department of Defence for the large-scale manufacture of CELLECTRA® 3PSP devices. These devices are used to deliver DNA vaccines, such as INOVIO's COVID-19 INO-4800 vaccine, into a patient's skin using electroporation technology.

Jun 22, 2020

Preliminary serological survey data out of New Jersey suggests the asymptomatic spread of SARS-CoV-2 may be a less significant driver of infection rates than previously thought. Further large-scale assessments of serological data are required to confirm these findings.

Jun 16, 2020

Researchers have screened over 1000 unique B cell clones from recovered COVID-19 patients to identify blocking and neutralizing antibodies. These antibodies represent a starting point for large-scale production and potential use in protecting at-risk groups such as healthcare workers.

Jun 16, 2020

Interim results from the RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial ongoing through the University of Oxford has shown clinical benefit with the use of dexamethasone. This inexpensive steroid medication reduced deaths for COVID-19 patients requiring a ventilator by one third and for patients requiring oxygen by one fifth. The beneficial effects observed are believed to be due to the ability of dexamethasone to mitigate the severity of host immune-derived cytokine storms.

Jun 16, 2020

Early clinical trial results with dexamethasone show that this drug improves survival of COVID-19 patients with severe respiratory symptoms.

Jun 15, 2020

FDA revokes emergency use authorization for hydroxychloroquine

Jun 14, 2020

AstraZeneca has signed a deal with the European Inclusive Vaccines Alliance (IVA) for 400 million doses of the AZD1222 vaccine currently under development by the University of Oxford, pending final approval. Globally, AstraZeneca has set a target of two billion vaccine doses.

Jun 11, 2020

Regeneron commences clinical trials with REGN-COV2, an experimental antibody cocktail for both the prevention and treatment of COVID-19.

Jun 8, 2020

New Zealand ends social distancing as their last known COVID-19 patient recovers.

Jun 8, 2020

Lilly has partnered with Shanghai-based biotech company, Junshi, to commence clinical trials in China with an experimental COVID-19 antibody.

Jun 4, 2020

On June 4th, a previously published study that challenged the safety and effectiveness of hydroxychloroquine and chloroquine for the treatment fo COVID-19 was retracted. This decision appears to have been made based on an inability to confirm the quality of the original data.

May 28, 2020

Mounting evidence suggests an involvement of the vascular endothelium in explaining COVID-19 symptomatology. The presence of blood clots combined with symptoms including peripheral hypoxia, heart attacks, and stroke suggest that blood vessel damage may be a hallmark of COVID-19 infection.

May 28, 2020

The LIBERATE clinical trial investigates the efficacy of a unique formulation of ibuprofen in hospitalized UK patients with COVID-19 after animal studies show promising results of ibuprofen ameliorating acute respiratory distress syndrome associated with the infection. Opinions differ over the use of ibuprofen in COVID-19, as there is inconclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients.

May 25, 2020

The World Health Organization has temporarily suspended the hydroxychloroquine arm of the Solidarity Trial for the treatment for COVID-19 due to safety concerns raised in other trials.

May 22, 2020

A multinational registry analysis published in The Lancet involving data for 96 032 patients from 671 hospitals across six continents was unable to confirm a benefit to hydroxychloroquine or chloroquine, either alone or combined with a macrolide antibiotic, for the treatment of Covid-19. Rather, these treatments were associated with decreased survival and increased incidence of ventricular arrhythmias.

May 18, 2020

Moderna reported encouraging results from phase I trials of a novel lipid nanoparticle (NLP)-encapsulated mRNA vaccine (designated mRNA-1273) encoding a stabilized form of the SARS-CoV-2 Spike (S) protein. The phase I results reported that all 45 participants across three dose levels seroconverted within 15 days and, out of eight tested for neutralizing ability, all antibody samples are capable of neutralizing live SARS-Cov-2 in vitro. Moderna has been granted clearance to begin phase II trials as of May 6.

May 16, 2020

Health Canada approves the first Canadian vaccine trials, led by a team of researchers at Dalhousie University in partnership with the Chinese manufacturer, CanSino Biologics. The Canadian Phase I study will build on the Ad5-nCoV vaccine trials that have already begun in China.

May 13, 2020

A possible link is made between COVID-19 and a novel severe Kawasaki-like disease in children, which involves the inflammation in the walls of arteries and other symptoms such as persistent fever, rash, red eyes. Further investigations are ongoing.

May 6, 2020

Laurent Pharmaceuticals, a Montreal-based company, receives Health Canada's approval to initiate its RESOLUTION clinical trial. This Phase II clinical trial investigates the potential therapeutic use of LAU-7b in reducing the severity of COVID-19 and preventing further disease progression into Acute Respiratory Distress Syndrome (ARDS).

May 4, 2020

Researchers in the Netherlands have developed a humanized monoclonal antibody, 47D11, capable of inhibiting both SARS-CoV and SARS-CoV-2 cell infection through binding to the S1B domain of the viral spike protein.

May 1, 2020

FDA grants emergency use authorization for remdesivir

Apr 24, 2020

FDA issues a warning against the use of both hydroxychloroquine and chloroquine outside of medical facilities, due to serious and potentially life-threatening heart rhythm complications.

Apr 23, 2020

Alongside more than 100 projects for the development of the COVID-19 vaccine around the world, a research team at Oxford University begins the Phase I clinical trial for its ChAdOx1 nCoV-19 vaccine in healthy volunteers.

Mar 28, 2020

FDA grants emergency use authorization for hydroxychloroquine

Mar 18, 2020

The WHO launches the Solidarity clinical trial. The study will compare four treatment options - remdesivir, lopinavir/ritonavir (with and without interferon beta-1a), and hydroxychloroquine or chloroquine - against standard of care to assess their effectiveness against COVID-19.

Mar 16, 2020

Moderna Therapeutics begins Phase I trial for its potential COVID-19 vaccine, mRNA-1273

Experimental Unapproved Treatments for COVID-19
DrugDescription
RemdesivirA nucleoside analog used to treat RNA virus infections including COVID-19.
RitonavirAn HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection.
ChloroquineAn antimalarial drug used to treat susceptible infections with P. vivax, P. malariae, P. ovale, and P. falciparum. It is also used for second line treatment for rheumatoid arthritis.
DarunavirA HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies.
LopinavirAn HIV-1 protease inhibitor used in combination with ritonavir to treat human immunodeficiency virus (HIV) infection.
GalidesivirGalidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various...
FavipiravirAn antiviral used to manage influenza, and that has the potential to target other viral infections.
UmifenovirA dual direct-acting antiviral/host-targeting agent used in the treatment and prophylaxis of influenza and other respiratory viruses.
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
TriazavirinAn antiviral used to treat several strains of influenza.
TMC-310911TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections....
mRNA-1273mRNA-1273 is a vaccine developed by Moderna that is currently undergoing investigation for the prophylaxis of SARS-CoV-2 infection. It is a novel mRNA-based vaccine, encapsulated in a lipid nanoparticle, that...
Ad5-nCoVAd5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute...
AZD1222AZD1222 (previously known as ChAdOx1 nCoV-19) is a vaccine currently being investigated for prophylaxis against SARS-CoV-2. The ChAdOx1 viral vector was developed at the University of Oxford and has been...
FingolimodA sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19.
MethylprednisoloneA corticosteroid used to treat inflammation or immune reactions across a variety of organ systems, endocrine conditions, and neoplastic diseases.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
LeronlimabA humanized monoclonal antibody being investigated
AzithromycinA macrolide antibiotic used to treat a variety of bacterial infections.
N4-HydroxycytidineA cytidine analog being investigated to treat COVID-19.
EIDD-2801An orally bioavailable isopropylester cytidine analog being investigated to treat COVID-19.
ElbasvirAn antiviral and NS5A inhibitor used to treat hepatitis C infections.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
GS-441524An experimental nucleoside analog antiviral investigated for its use in the treatment of Ebola and SARS-CoV-2 infections.
TridecactideAn investigational modified alpha melanocyte stimulating hormone being studied for the treatment of COVID-19.
MetenkefalinAn investigational endogenous opioid being studied for the treatment of COVID-19.
VazegepantVazegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will...
IbuprofenAn NSAID and non-selective COX inhibitor used to treat mild-moderate pain, fever, and inflammation.
Anti-SARS-CoV-2 REGN-COV2Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
DexamethasoneA glucocorticoid available in various modes of administration that is used for the treatment of various inflammatory conditions, including bronchial asthma, as well as endocrine and rheumatic disorders.
COVID-19 convalescent plasmaCOVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. This investigational COVID-19 treatment is...
INO-4800INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that...
BNT162b1 SARS-CoV-2 VaccineBNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding...
BNT162b2 SARS-CoV-2 VaccineBNT162b2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b2 is a nucleoside modified mRNA (modRNA) vaccine encoding...
BNT162a1 SARS-CoV-2 VaccineBNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in...
BNT162c2 SARS-CoV-2 VaccineBNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in...
ColchicineAn alkaloid used in the symptomatic relief of pain in attacks of gout and to treat the inflammatory symptoms of Familial Mediterranean Fever (FMF).
LY-CoV555LY-CoV555, also known as LY3819253, is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples taken in the United States from a patient who recovered from...
AZD7442AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
GC-376 free acidGC-376 is a 3C-like protease (3CLpro or Mpro) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells . The compound...
GC-373GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that...
IfenprodilN-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer...
Potential Drug Targets
DrugTarget
RitonavirHuman immunodeficiency virus type 1 protease
DarunavirHuman immunodeficiency virus type 1 protease
LopinavirHuman immunodeficiency virus type 1 protease
MethylprednisoloneGlucocorticoid receptor
LeronlimabC-C chemokine receptor type 5
TocilizumabInterleukin-6 receptor subunit alpha
ColchicineTubulin beta chain
RemdesivirReplicase polyprotein 1ab
GalidesivirRNA-directed RNA polymerase L
FavipiravirRNA-directed RNA polymerase catalytic subunit
TMC-310911HIV-1 protease
FingolimodSphingosine 1-phosphate receptor 5
BevacizumabVascular endothelial growth factor A
Azithromycin23S ribosomal RNA
ElbasvirNonstructural protein 5A
GS-441524Replicase polyprotein 1ab
VazegepantCalcitonin gene-related peptide type 1 receptor
IbuprofenProstaglandin G/H synthase 2
GC-376 free acidReplicase polyprotein 1ab
GC-373Replicase polyprotein 1ab
IfenprodilGlutamate receptor ionotropic, NMDA 2B
RemdesivirRNA-directed RNA polymerase L
ChloroquineTumor necrosis factor
ChloroquineGlutathione S-transferase A2
Human interferon betaInterferon alpha/beta receptor 1
BevacizumabComplement C1q subcomponent subunit A
AzithromycinProtein-arginine deiminase type-4
GS-441524RNA-directed RNA polymerase L
MetenkefalinDelta-type opioid receptor
IbuprofenProstaglandin G/H synthase 1
GC-376 free acidReplicase polyprotein 1a
GC-373Replicase polyprotein 1a
IfenprodilGlutamate receptor ionotropic, NMDA 1
ChloroquineToll-like receptor 9
BevacizumabComplement C1q subcomponent subunit B
MetenkefalinMu-type opioid receptor
GC-376 free acidReplicase polyprotein 1ab
GC-373Replicase polyprotein 1ab
IfenprodilG protein-activated inward rectifier potassium channel 1
BevacizumabComplement C1q subcomponent subunit C
DexamethasoneGlucocorticoid receptor
GC-376 free acidReplicase polyprotein 1a
GC-373Replicase polyprotein 1ab
IfenprodilG protein-activated inward rectifier potassium channel 2
ChloroquineGlutathione S-transferase
FingolimodHistone deacetylase 1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-A
GC-376 free acidReplicase polyprotein 1ab
GC-373Replicase polyprotein 1a
IfenprodilG protein-activated inward rectifier potassium channel 4
BevacizumabHigh affinity immunoglobulin gamma Fc receptor I
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-a
DexamethasoneNuclear receptor subfamily 0 group B member 1
DexamethasoneAnnexin A1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-b
IbuprofenApoptosis regulator Bcl-2
ChloroquineHigh mobility group protein B1
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-c
IbuprofenThrombomodulin
ChloroquineGlutathione S-transferase Mu 1
FingolimodSphingosine 1-phosphate receptor 1
IbuprofenFatty acid-binding protein, intestinal
ChloroquineAngiotensin-converting enzyme 2
FingolimodSphingosine 1-phosphate receptor 4
MethylprednisoloneAnnexin A1
IbuprofenPeroxisome proliferator-activated receptor gamma
FingolimodSphingosine 1-phosphate receptor 3
IbuprofenCystic fibrosis transmembrane conductance regulator
IbuprofenPeroxisome proliferator-activated receptor alpha
IbuprofenPlatelet glycoprotein Ib alpha chain
IbuprofenProtein S100-A7
RitonavirNuclear receptor subfamily 1 group I member 2
DexamethasoneNitric oxide synthase, inducible
DexamethasoneNuclear receptor subfamily 1 group I member 2
<
Start DateDrugTitlePurposePhaseStatusIdentifier
2021-01-10BudesonideOlfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04374474
2020-11-01PH94BA Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19Treatment2Active Not RecruitingNCT04404192
2020-10-27LenalidomideDouble-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 DiseaseTreatment4Active Not RecruitingNCT04361643
2020-10-01HydroxychloroquinePROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT)Treatment2, 3Active Not RecruitingISRCTN88057279
2020-10-01Remestemcel-LProspective Phase II Study : MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDSTreatment2Active Not RecruitingNCT04377334
2020-10-01Ascorbic acidEarly Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI)Treatment2Active Not RecruitingNCT04344184
2020-10-01SirolimusEffects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)Treatment1, 2Active Not RecruitingNCT04482712
2020-09-30Tranexamic acidExploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in InpatientsTreatment2Active Not RecruitingNCT04338126
2020-09-30DuvelisibA Pilot Study of Duvelisib to Combat COVID-19Treatment2Active Not RecruitingNCT04372602
2020-09-15RemdesivirA Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy VolunteersTreatment1Active Not RecruitingNCT04480333
2020-09-06PiclidenosonPiclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled TrialTreatment2Active Not RecruitingNCT04333472
2020-09-01Human Umbilical Cord Mesenchymal Stem CellsA Phase 1 Study of the Safety and Tolerability of BX-U001 for the Treatment of Severe COVID-19 Pneumonia With Mild to Moderate Acute Respiratory Distress Syndrome (ARDS).Treatment1Active Not RecruitingNCT04452097
2020-09-01Nitric OxideMulti-Center, Double-Blinded, Placebo-Controlled, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19Treatment2Active Not RecruitingNCT04443868
2020-09-01TocilizumabAn Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseTreatment3Active Not RecruitingNCT04424056
2020-09-01AnakinraAn Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseTreatment3Active Not RecruitingNCT04424056
2020-09-01RuxolitinibAn Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated DiseaseTreatment3Active Not RecruitingNCT04424056
2020-09-01LosartanSafety and efficacy of a pharmacological strategy using Losartan in hospital patients with COVID-19Treatment1Active Not RecruitingACTRN12620000731998
2020-09-01MaravirocOpen-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2Treatment1Active Not RecruitingNCT04435522
2020-09-01COVID-19 convalescent plasmaA Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.Treatment2, 3Active Not RecruitingNCT04395170
2020-09-01ChloroquineIMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORTBasic ScienceNot AvailableActive Not RecruitingNCT04347798
2020-09-01HydroxychloroquineIMPACT RAPPORT : IMPact of Antimalarials on Covid Infections : a Case Control sTudy of RAPPORTBasic ScienceNot AvailableActive Not RecruitingNCT04347798
2020-09-01Virus Specific T-CellViral Specific T-cells (VSTs) for Treatment of SARS-CoV-2 / COVID-19Treatment2Active Not RecruitingNCT04406064
2020-09-01OxytocinPhase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19Treatment2Active Not RecruitingNCT04386447
2020-09-01Human Umbilical Cord Mesenchymal Stem CellsSafety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19 : A Randomized Controlled TrialTreatment1, 2Active Not RecruitingNCT04390152
2020-09-01Peginterferon lambda-1aA Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical IllnessTreatment2Active Not RecruitingNCT04388709
2020-09-01HydroxychloroquinePROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT) : a Basket Trial of Prophylactic Interventions Amongst At-risk PatientsPrevention2, 3Active Not RecruitingNCT04389359
2020-09-01BicalutamideA Phase II Trial to Promote Recovery From COVID-19 With Endocrine TherapyTreatment2Active Not RecruitingNCT04374279
2020-09-01RuxolitinibRuxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe / Very Severe COVID-19 IllnessTreatmentNot AvailableActive Not RecruitingNCT04337359
2020-09-01DexamethasoneTargeted Steroids for ARDS Due to COVID-19 Pneumonia : A Pilot Randomized Clinical TrialTreatment2Active Not RecruitingNCT04360876
2020-09-01RibavirinAn Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19Treatment1Active Not RecruitingNCT04356677
2020-09-01Remestemcel-LAn open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumoniaTreatment1Active Not RecruitingChiCTR2000030944
2020-09-01Natural Killer CellAn open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumoniaTreatment1Active Not RecruitingChiCTR2000030944
2020-09-01AcetylcysteineInflammatory regulation effect of N-acetylcysteine on COVID-19 treatment, pilot, double blinded randomized placebo controlled multicenter clinical trialTreatment3, 4Active Not RecruitingISRCTN60069084
2020-09-01Stem-cell derived exosome vesicle productsExtracellular Vesicle Infusion Treatment for Severe COVID-19Treatment2Active Not RecruitingNCT04493242
2020-09-01ColchicinePhase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care CenterTreatment2, 3Active Not RecruitingNCT04492358
2020-09-01PrednisonePhase 2 / 3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate / Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care CenterTreatment2, 3Active Not RecruitingNCT04492358
2020-09-01MVC-COV1901A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901Prevention1Active Not RecruitingNCT04487210
2020-09-01DisulfiramVirologic and Immunologic Response to Disulfiram in Early Symptomatic COVID+ OutpatientsTreatment2Active Not RecruitingNCT04485130
2020-09-01CholecalciferolPRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams (PROTECT)Prevention3Active Not RecruitingNCT04483635
2020-09-01GenisteinA Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 PatientsTreatment2Active Not RecruitingNCT04482595
2020-09-01HydroxychloroquineReal-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and / or Gougerot's DiseaseTreatmentNot AvailableActive Not RecruitingNCT04481633
2020-09-01RamelteonAdjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19Treatment2Active Not RecruitingNCT04470297
2020-09-01Interferon beta-1bRandomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-ß-1a (IFNß-1a) in COVID-19 PatientsTreatment2Active Not RecruitingNCT04449380
2020-09-01Vitamin DReducing Asymptomatic Infection With Vitamin D in Coronavirus DiseasePreventionNot AvailableActive Not RecruitingNCT04476680
2020-08-31Fish oilRandomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and / or Steroid-resistant Asthma Population With COVID-19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04465513
2020-08-31RemdesivirExpanded Access Treatment Protocol : Remdesivir (RDV ; GS-5734) for the Treatment of SARS-CoV2 (CoV) InfectionTreatmentNot AvailableActive Not RecruitingNCT04323761
2020-08-30LinagliptinEffects of DPP4 Inhibition on COVID-19 Patients With Type 2 DiabetesTreatment4Active Not RecruitingNCT04341935
2020-08-30CK0802Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)Treatment1Active Not RecruitingNCT04468971
2020-08-20CyclosporineRandomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of Covid-19(+) Non-ICU Hospital InpatientsTreatment2Active Not RecruitingNCT04492891
2020-08-17Mumps virus strain B level jeryl lynn live antigenUse of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / InflammationPrevention3Active Not RecruitingNCT04475081
2020-08-17Rubella virus vaccineUse of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / InflammationPrevention3Active Not RecruitingNCT04475081
2020-08-17Measles virus vaccine live attenuatedUse of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis / InflammationPrevention3Active Not RecruitingNCT04475081
2020-08-15AtazanavirRandomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 InfectionPrevention2, 3Active Not RecruitingNCT04452565
2020-08-15DexamethasoneRandomized Controlled Phase 2 / 3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 InfectionPrevention2, 3Active Not RecruitingNCT04452565
2020-08-15IbrutinibRandomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-InTreatment2Active Not RecruitingNCT04439006
2020-08-15LopinavirPreventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-SurgTreatment3, 4Active Not RecruitingCTRI/2020/06/026196
2020-08-15RitonavirPreventing Pulmonary Complications In Surgical Patients At Risk Of COVID-19 - PROTECT-SurgTreatment3, 4Active Not RecruitingCTRI/2020/06/026196
2020-08-15AcetylcysteineDetermination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe DiseaseTreatment4Active Not RecruitingNCT04419025
2020-08-15Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsCOVID-19 Stem Cell Therapy : A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem CellsTreatment1Active Not RecruitingNCT04486001
2020-08-15EpoprostenolDouble-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical VentilationTreatment2Active Not RecruitingNCT04452669
2020-08-13PentoxifyllineEfficacy of Pentoxifylline as Add on Therapy in COVID19 PatientsTreatment1, 2Active Not RecruitingNCT04433988
2020-08-11MelatoninA Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 InfectionTreatment2Active Not RecruitingNCT04474483
2020-08-07TofacitinibA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04469114
2020-08-05Omega-3 fatty acidsThe Effect of Omega-3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian PeoplePreventionNot AvailableActive Not RecruitingNCT04483271
2020-08-05Cepeginterferon alfa-2BA Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - a2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)Treatment2Active Not RecruitingNCT04480138
2020-08-05TocilizumabCOVIDOSE-2 : A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive VentilationTreatment2Active Not RecruitingNCT04479358
2020-08-05CholecalciferolThe Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19 ; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D DeficiencyPreventionNot AvailableActive Not RecruitingNCT04476745
2020-08-04LanadelumabA Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 PneumoniaTreatment1Active Not RecruitingNCT04460105
2020-08-03LosartanRAAS blockagE in SARS COV-2 Critically ill patiEnts– a Randomized controlled trialTreatment4Active Not RecruitingISRCTN48734830
2020-08-03LanadelumabLanadelumab for Treatment of COVID-19 DiseaseTreatment1, 2Active Not RecruitingNCT04422509
2020-08-03Platelet LysateAutologous Nebulized Platelet Lysate for Post COVID-19 SyndromeTreatmentNot AvailableActive Not RecruitingNCT04487691
2020-08-01Remestemcel-LA Multi-center, Randomized, Sham Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement TherapyTreatment1, 2Active Not RecruitingNCT04445220
2020-08-01AcetylcysteinePilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19Treatment3Active Not RecruitingNCT04455243
2020-08-01Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsClinical Study for the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus 2019 (COVID-19)Treatment2Active Not RecruitingNCT04428801
2020-08-01AbivertinibA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19Treatment2Active Not RecruitingNCT04440007
2020-08-01NiclosamidePhase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and SymptomsTreatment2Active Not RecruitingNCT04436458
2020-08-01CamostatThe Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsTreatment1, 2Active Not RecruitingNCT04435015
2020-08-01SofosbuvirAntiviral Agents Against SARS-CoV-2 Infection : a Randomized, Double Blinded, Placebo Controlled, Multi-arm, Multi-stage Clinical TrialTreatment2, 3Active Not RecruitingNCT04468087
2020-08-01AtazanavirAntiviral Agents Against SARS-CoV-2 Infection : a Randomized, Double Blinded, Placebo Controlled, Multi-arm, Multi-stage Clinical TrialTreatment2, 3Active Not RecruitingNCT04468087
2020-08-01DaclatasvirAntiviral Agents Against SARS-CoV-2 Infection : a Randomized, Double Blinded, Placebo Controlled, Multi-arm, Multi-stage Clinical TrialTreatment2, 3Active Not RecruitingNCT04468087
2020-08-01Human Umbilical Cord Mesenchymal Stem CellsMulti-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)Treatment2Active Not RecruitingNCT04466098
2020-08-01MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04463004
2020-08-01COVID-19 convalescent plasmaPhase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2Treatment1Active Not RecruitingNCT04462848
2020-08-01NelfinavirClinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian PatientsTreatment2Active Not RecruitingNCT04471662
2020-08-01FavipiravirClinical Trial Evaluating the Therapeutic Potential of Nelfinavir and Favipiravir Combination in Newly Diagnosed COVID19 Egyptian PatientsTreatment2Active Not RecruitingNCT04471662
2020-08-01DaclatasvirSofosbuvir With and Without Ribavirin in Treatment of COVID 19 PatientsTreatment2, 3Active Not RecruitingNCT04460443
2020-08-01RibavirinSofosbuvir With and Without Ribavirin in Treatment of COVID 19 PatientsTreatment2, 3Active Not RecruitingNCT04460443
2020-08-01SofosbuvirSofosbuvir With and Without Ribavirin in Treatment of COVID 19 PatientsTreatment2, 3Active Not RecruitingNCT04460443
2020-08-01RitonavirA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04459286
2020-08-01AtazanavirA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04459286
2020-08-01NitazoxanideA Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir / Ritonavir for the Treatment of COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04459286
2020-08-01CholecalciferolRandomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01Vitamin K7Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01MenadioneRandomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01MagnesiumRandomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01Menaquinone 6Randomized, Double Blind, Comparative, Parallel group study of Vitamin D3 ( Cholecalciferol ) Vitamin K2-7 & magnesium in prophylaxis of COVID-19 infection in health care professionals - Covid19Treatment2Active Not RecruitingCTRI/2020/06/026191
2020-08-01Magnesium glycinateRandomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - CovidTreatment2Active Not RecruitingCTRI/2020/06/026189
2020-08-01Vitamin DRandomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - CovidTreatment2Active Not RecruitingCTRI/2020/06/026189
2020-08-01RivaroxabanEffect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)Prevention3Active Not RecruitingNCT04416048
2020-08-01Conestat alfaRecombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 : a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).Treatment2Active Not RecruitingNCT04414631
2020-08-01ProtoporphyrinEfficacy of Based MRI Contrast Media Against Covid-19Treatment1Active Not RecruitingNCT04371822
2020-08-01Ad5-nCoVA Randomized, Observer-Blind, Dose-escalation Phase I / II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in CanadaPrevention1, 2Active Not RecruitingNCT04398147
2020-08-01SilibininTrial of Silymarin in Adults With COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04394208
2020-08-01Recombinant Bacterial ACE2 Receptors-like EnzymeA Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Bacterial ACE2 Receptors -Like Enzyme 2 (rbACE2) and Isotretinoin Adult Patients With COVID-19Treatment1Active Not RecruitingNCT04375046
2020-08-01Povidone-iodinePovidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2Treatment2Active Not RecruitingNCT04371965
2020-08-01Remestemcel-LSingle Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID19-Induced ARDS : A Randomized, Controlled StudyTreatment1Active Not RecruitingNCT04345601
2020-08-01ChlorpromazineAdministration of Chlorpromazine as a Treatment for COVID-19Treatment2, 3Active Not RecruitingNCT04354805
2020-08-01Bardoxolone methylBARCONA : A Phase II / III, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)Treatment2, 3Active Not RecruitingNCT04494646
2020-08-01Human Umbilical Cord Mesenchymal Stem CellsPhase I, Randomized, Double Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe SymptomsTreatment1Active Not RecruitingNCT04490486
2020-08-01HeparinIntranasal Heparin Tolerability StudyPrevention1Active Not RecruitingNCT04490239
2020-08-01SildenafilSildenafil for Treating Patients With COVID-19 and Perfusion Mismatch : A Pilot Randomised TrialTreatment1, 2Active Not RecruitingNCT04489446
2020-08-01DuvelisibDuvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus InfectionTreatment2Active Not RecruitingNCT04487886
2020-08-01Mometasone furoateRole of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 PatientsTreatment3Active Not RecruitingNCT04484493
2020-08-01EbselenA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 PatientsTreatment2Active Not RecruitingNCT04484025
2020-08-01EbselenA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 PatientsTreatment2Active Not RecruitingNCT04483973
2020-08-01COVID-19 convalescent plasmaA Multi-Center, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of the Safety and Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Hospitalized Patients in Lagos StateTreatment3Active Not RecruitingPACTR202006760881890
2020-08-01IvermectinA Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04482686
2020-08-01DoxycyclineA Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04482686
2020-08-01COVID-19 convalescent plasmaTherapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaféresis terapéutica en Pacientes Adultos críticamente Enfermos Con diagnóstico Confirmado de COVID-19Treatment2Active Not RecruitingNCT04480632
2020-08-01RosuvastatinColchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) TrialTreatment3Active Not RecruitingNCT04472611
2020-08-01ColchicineColchicine / Statins for the Prevention of COVID-19 Complications (COLSTAT) TrialTreatment3Active Not RecruitingNCT04472611
2020-08-01COVID-19 convalescent plasmaA Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19Treatment2Active Not RecruitingNCT04467151
2020-08-01IMM-101COV-IMMUNO : A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of ExposureTreatment3Active Not RecruitingNCT04442048
2020-08-01VadadustatVadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04478071
2020-08-01AbataceptAbatacept for Patients With COVID-19 and Respiratory DistressTreatment1, 2Active Not RecruitingNCT04477642
2020-07-31IbudilastA Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress SyndromeTreatment2Active Not RecruitingNCT04429555
2020-07-31Tenofovir alafenamideRandomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Prevention3Active Not RecruitingNCT04405271
2020-07-31EmtricitabineRandomized, Double-blind, Placebo-controlled Trial of TAF / FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Prevention3Active Not RecruitingNCT04405271
2020-07-31AZD-1656A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCADIA Trial - ARCADIATreatment2Active Not RecruitingEUCTR2020-002211-21-GB
2020-07-31KBP-COVID-19A Phase I / II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 Vaccine in Healthy Seronegative Adults Aged 18-49 and 50-70Prevention1, 2Active Not RecruitingNCT04473690
2020-07-30EpigallocatechinA Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon® as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD StudyPrevention2, 3Active Not RecruitingNCT04446065
2020-07-30Lithium carbonateA randomized control study to evaluate the therapeutic effects of Lithium in Covid-19 patientsTreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026193
2020-07-30TocilizumabA Nested Interventional Cohort Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin-6 Receptor Blocker Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation Related Mortality in SARS-Cov2 Positive PatientsTreatment3Active Not RecruitingNCT04423042
2020-07-30Virus Specific T-CellBAT IT : Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19Treatment1Active Not RecruitingNCT04401410
2020-07-30Interferon alfa-2bPhase 1 / 2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 InfectionSupportive Care1, 2Active Not RecruitingNCT04379518
2020-07-30Recombinant Human Plasma GelsolinA Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 PneumoniaTreatment2Active Not RecruitingNCT04358406
2020-07-30RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)Treatment3Active Not RecruitingNCT04492475
2020-07-30Interferon beta-1aA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)Treatment3Active Not RecruitingNCT04492475
2020-07-30EnoxaparinIntermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19Treatment3Active Not RecruitingNCT04486508
2020-07-30AtorvastatinIntermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19Treatment3Active Not RecruitingNCT04486508
2020-07-30HeparinIntermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19 : An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19Treatment3Active Not RecruitingNCT04486508
2020-07-30NitazoxanidePhase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19Treatment3Active Not RecruitingNCT04486313
2020-07-30RUTI® VaccineDouble-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI® Vaccine to Prevent SARS-CoV-2 InfectionPrevention3Active Not RecruitingNCT04453488
2020-07-29SitagliptinThe Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic PatientsTreatment3Active Not RecruitingNCT04365517
2020-07-29RibavirinAn Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 InfectionTreatment2Active Not RecruitingNCT04494399
2020-07-29Interferon beta-1bAn Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 InfectionTreatment2Active Not RecruitingNCT04494399
2020-07-29DecitabineDecitabine for COVID-19 Pneumonia-ARDS Treatment : DART TrialTreatment2Active Not RecruitingNCT04482621
2020-07-29Nitric OxideA Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04476992
2020-07-28DipyridamoleA Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 InfectionTreatment3Active Not RecruitingNCT04410328
2020-07-28Acetylsalicylic acidA Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 InfectionTreatment3Active Not RecruitingNCT04410328
2020-07-27ChloroquineEfficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 PatientsPrevention1Active Not RecruitingNCT04443270
2020-07-27CamostatA Randomised Phase II / III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane FusionTreatment2, 3Active Not RecruitingNCT04455815
2020-07-27mRNA-1273A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and OlderPrevention3Active Not RecruitingNCT04470427
2020-07-25Human Umbilical Cord Mesenchymal Stem CellsSafety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19Treatment1Active Not RecruitingNCT04467047
2020-07-25SirolimusEfficacy and Safety of Sirolimus for Treating COVID-19 InfectionTreatment2Active Not RecruitingNCT04461340
2020-07-25IcatibantI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-25RemdesivirI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-25ApremilastI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-25CenicrivirocI-SPY COVID TRIAL : An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsTreatment2Active Not RecruitingNCT04488081
2020-07-24ClazakizumabA study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. - CLiCK StudyTreatment2Active Not RecruitingEUCTR2020-002476-13-GB
2020-07-23Human Umbilical Cord Mesenchymal Stem CellsPhase 1 / 2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19Treatment1, 2Active Not RecruitingNCT04494386
2020-07-23Aspartyl-alanyl-diketopiperazineA Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion™ in Adult COVID-19 Patients Requiring Oxygen SupplementationTreatment1Active Not RecruitingNCT04456452
2020-07-23LosartanRandomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19Treatment2Active Not RecruitingNCT04447235
2020-07-23IvermectinRandomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19Treatment2Active Not RecruitingNCT04447235
2020-07-22Nitrous acidTreatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite : A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical StudyTreatment2Active Not RecruitingNCT04401527
2020-07-22Human Umbilical Cord Mesenchymal Stem CellsClinical trial of efficacy and safety of mesenchymal stem cell transplantation in patients with COVID-19 pneumoniaTreatment3Active Not RecruitingIRCT20200426047206N2
2020-07-22AtovaquoneAtovaquone for Treatment of COVID-19Treatment2Active Not RecruitingNCT04456153
2020-07-21CAP-1002A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19TreatmentNot AvailableActive Not RecruitingNCT04338347
2020-07-21LeflunomideTargeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19) - DEFEAT- Covid StudyTreatment2Active Not RecruitingEUCTR2020-002952-18-GB
2020-07-21LopinavirAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21COVID-19 convalescent plasmaAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21HydroxychloroquineAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21RitonavirAn International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)Treatment3Active Not RecruitingNCT04483960
2020-07-21AviptadilRLF-100 (Aviptadil) Intermediate Population Expanded Access ProtocolTreatmentNot AvailableActive Not RecruitingNCT04453839
2020-07-21RemdesivirA Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19Treatment2, 3Active Not RecruitingNCT04431453
2020-07-20LopinavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-07-20RitonavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-07-20TelmisartanCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-07-20AtorvastatinCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2, 3Active Not RecruitingNCT04466241
2020-07-20HeparinEfficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial StudyTreatment3Active Not RecruitingNCT04485429
2020-07-20MethylprednisoloneEfficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia : A Randomized, Controlled, 2x2 Factorial StudyTreatment3Active Not RecruitingNCT04485429
2020-07-20RitonavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2Active Not RecruitingPACTR202007720062393
2020-07-20LopinavirCombination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV) : a Phase IIb Randomized Clinical TrialTreatment2Active Not RecruitingPACTR202007720062393
2020-07-20LopinavirAn open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19Treatment3Active Not RecruitingPACTR202006537901307
2020-07-20RitonavirAn open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19Treatment3Active Not RecruitingPACTR202006537901307
2020-07-20HydroxychloroquineAn open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19Treatment3Active Not RecruitingPACTR202006537901307
2020-07-20CholecalciferolThe Role of Vitamin D in Mitigating COVID-19 Infection Severity : Focusing on Reducing Health Disparities in South CarolinaPrevention4Active Not RecruitingNCT04482673
2020-07-20AbataceptPhase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory CompromiseTreatment2Active Not RecruitingNCT04472494
2020-07-20COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's InjectionFollow NCT03305341 - Conducting an Initial Small, Controlled Clinical Trial to Assess for COVID-19 Therapeutic Vaccine Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients.Treatment1Active Not RecruitingNCT03348670
2020-07-20BNT162b1 SARS-CoV-2 VaccineSafety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects : A Phase I, Randomized, Placebo-controlled, Observer-blind StudyTreatment1RecruitingChiCTR2000034825
2020-07-17RuxolitinibRandomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 InfectionTreatment2, 3Active Not RecruitingNCT04477993
2020-07-16FavipiravirFavipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARETreatment2Active Not RecruitingEUCTR2020-002106-68-GB
2020-07-16LopinavirFavipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARETreatment2Active Not RecruitingEUCTR2020-002106-68-GB
2020-07-16RitonavirFavipiravir, lopinavir / ritonavir or combination therapy : a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 - FLARETreatment2Active Not RecruitingEUCTR2020-002106-68-GB
2020-07-16Inactivated SARS-Cov-2 VaccineRandomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and aboveTreatment3RecruitingChiCTR2000034780
2020-07-16BudesonideUse of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and HospitalisationTreatment2Active Not RecruitingNCT04416399
2020-07-16TocilizumabComparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19Treatment2Active Not RecruitingNCT04476979
2020-07-16DexamethasoneComparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19Treatment2Active Not RecruitingNCT04476979
2020-07-15CamostatRECOVER : Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 InhibitorTreatment2Active Not RecruitingNCT04470544
2020-07-15ApilimodA Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19Treatment2Active Not RecruitingNCT04446377
2020-07-15Oral Polio VaccineOral Polio Vaccine as Potential Protection Against COVID-19 : A Cluster-randomised Trial in Guinea-BissauPrevention4Active Not RecruitingNCT04445428
2020-07-15Cinnamonâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Cow milkâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Gingerâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15Turmericâ??To study the efficacy of add on Ayurvedic treatment to the standard of care for prevention and management of asymptomatic, mild & moderate cases of COVID-19.â??TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/026231
2020-07-15COVID-19 convalescent plasmaA Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized ChildrenTreatment2Active Not RecruitingNCT04377568
2020-07-15ChloroquineA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-07-15LopinavirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-07-15OseltamivirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-07-15DarunavirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-07-15RitonavirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-07-15FavipiravirA 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir / Ritonavir Plus Oseltamivir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir / Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir / Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19Treatment3Active Not RecruitingNCT04303299
2020-07-15Nitric OxideInhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2Treatment2Active Not RecruitingNCT04456088
2020-07-15HydroxychloroquineDevelopment and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19TreatmentNot AvailableActive Not RecruitingNCT04477083
2020-07-15EnzalutamideA Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04475601
2020-07-14IodineEfficacy of Iodine Complex in Mild to Moderate COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04473261
2020-07-14IvermectinSub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04472585
2020-07-14ZincSub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa : a Placebo Randomized Control Trial on Mild to Moderate COVID-19 PatientsTreatment1, 2Active Not RecruitingNCT04472585
2020-07-14ClofazimineAn Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 InfectionTreatment2Active Not RecruitingNCT04465695
2020-07-14Interferon beta-1bAn Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 InfectionTreatment2Active Not RecruitingNCT04465695
2020-07-14RemdesivirA Phase 2 / 3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19Treatment2Active Not RecruitingEUCTR2020-001803-17-GB
2020-07-14COVID-19 convalescent plasmaANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)Treatment2Active Not RecruitingNCT04432272
2020-07-14COVID-19 convalescent plasmaUse of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic OutbreakTreatment2Active Not RecruitingNCT04408040
2020-07-14IvermectinRandomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Cali, Colombia With Early Stages of SARS COV2 / COVID-19Treatment2, 3Active Not RecruitingNCT04405843
2020-07-14HydroxychloroquineTreatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator TrialTreatment2, 3Active Not RecruitingNCT04387760
2020-07-14FavipiravirTreatment of Covid-19 With Favipiravir Versus Hydroxychloroquine : a Randomized Comparator TrialTreatment2, 3Active Not RecruitingNCT04387760
2020-07-13BBV152An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of the BBV152 in Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04471519
2020-07-13EnzalutamideA prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) - COVIDENZATreatment2Active Not RecruitingEUCTR2020-002027-10-SE
2020-07-13Ad26.COV2.SA Randomized, Double-blind, Placebo-controlled Phase 1 / 2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and OlderTreatment1, 2Active Not RecruitingNCT04436276
2020-07-13TurmericA clinical study to evaluate the effect of AYUSH medicines in the management of COVID-19Treatment3, 4Active Not RecruitingCTRI/2020/07/026371
2020-07-13OzonePhase I / II randomized controlled clinical trial to assess safety and efficacy of ozone therapy via rectal insufflation and minor auto haemotherapy as an adjuvant in mild to moderate Covid-19 subjects. - NilTreatment1, 2Active Not RecruitingCTRI/2020/07/026354
2020-07-13Alkaline PhosphataseAlkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)TreatmentNot AvailableActive Not RecruitingNL8578
2020-07-13Rubella virus vaccineEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)Prevention3Active Not RecruitingNCT04357028
2020-07-13Measles virus vaccine live attenuatedEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)Prevention3Active Not RecruitingNCT04357028
2020-07-13Mumps virus strain B level jeryl lynn live antigenEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)Prevention3Active Not RecruitingNCT04357028
2020-07-13SARS-CoV-2 SclampA Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study To Evaluate The Safety And Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine (COVID-19 vaccine) In Healthy Adults Aged 18 To 55 Years OldTreatment1Active Not RecruitingACTRN12620000674932
2020-07-13ClazakizumabA Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 InfectionTreatment2Active Not RecruitingNCT04494724
2020-07-12Nitric OxideA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)Treatment3Active Not RecruitingNCT04421508
2020-07-12FavipiravirA Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19Treatment2Active Not RecruitingNCT04346628
2020-07-11ZincProspective study to assess therapeutic role of Zinc in COVID-19 patientsTreatmentNot AvailableActive Not RecruitingCTRI/2020/07/026340
2020-07-11NafamostatAn Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 DiseaseTreatment2Active Not RecruitingCTRI/2020/06/026220
2020-07-11DactolisibRandomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults =65 Years in a Nursing Home in Which =1 Person(s) Have Lab Confirmed COVID19Prevention3Active Not RecruitingNCT04409327
2020-07-10Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)A Randomized, Double-blind, Placebo-controlled, Phase Ib / IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ?60 YearsPrevention1, 2Active Not RecruitingNCT04470609
2020-07-10Coronavirus-Like Particle COVID-19 VaccineA Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of AgePrevention1Active Not RecruitingNCT04450004
2020-07-10IvermectinA Clinical Trial to Study the Efficacy of â??Ivermectinâ?? in the prevention of Covid-19. .A Single Arm Study. â??Treatment3Active Not RecruitingCTRI/2020/06/026232
2020-07-10Cepeginterferon alfa-2BA phase II, randomized, controlled, open-label study to evaluate the efficacy and safety of Pegylated IFN alfa-2b in the treatment of adult patients diagnosed with SARS-CoV2 (COVID-19).Treatment2Active Not RecruitingCTRI/2020/06/026087
2020-07-10SecukinumabUse of Anti-IL-17 in patients with the severe acute respiratory syndrome (SARS) associated with Covid-19Treatment2Active Not RecruitingRBR-5vpyh4
2020-07-09CrizanlizumabCrizanlizumab for Treating COVID-19 VasculopathyTreatment2Active Not RecruitingNCT04435184
2020-07-09RuxolitinibMATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)Treatment2Active Not RecruitingEUCTR2020-001750-22-GB
2020-07-09FostamatinibMATIS : Phase 2 / 3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia - Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS)Treatment2Active Not RecruitingEUCTR2020-001750-22-GB
2020-07-09CysteineEffective of Elman tablet on illness severity and length of hospital stay in the patients with COVID-19 infectionTreatment3Active Not RecruitingIRCT20200609047707N1
2020-07-09PTC299Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)Treatment2, 3Active Not RecruitingNCT04439071
2020-07-09IcatibantRandomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilation compared with standard care - HUB-MdI-ICAT-COVID-201Treatment2Unknown StatusEUCTR2020-002166-13-ES
2020-07-08Acetylsalicylic acidDynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical TrialTreatment3Active Not RecruitingNCT04466670
2020-07-08HeparinDynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical TrialTreatment3Active Not RecruitingNCT04466670
2020-07-08EnoxaparinDynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical TrialTreatment3Active Not RecruitingNCT04466670
2020-07-08BCG vaccineBCG vaccination to Reduce the impact of COVID-19 in healthcare workers following Coronavirus Exposure (BRACE) Trial - BRACETreatment3Active Not RecruitingEUCTR2020-002503-19-NL
2020-07-08SofosbuvirEvaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : A randomized double-blind clinical trialTreatment3Active Not RecruitingIRCT20200624047908N1
2020-07-08DaclatasvirEvaluation of the effect of sofosbuvir / daclatasvir in COVID-19 patients : A randomized double-blind clinical trialTreatment3Active Not RecruitingIRCT20200624047908N1
2020-07-07ProbiorinseRandomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04458519
2020-07-07Povidone-iodineRole of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission : SHIELD StudyPrevention1Active Not RecruitingNCT04478019
2020-07-06COVID-19 convalescent plasmaEvaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19Treatment2Active Not RecruitingNCT04438057
2020-07-06MontelukastImpact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19) : an investigator-initiated open labelled randomized controlled pragmatic trialTreatment4Active Not RecruitingEUCTR2020-001747-21-PT
2020-07-06CannabidiolCannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019 : A Randomized, Double-blind, Placebo-controlled Clinical TrialTreatment2, 3Active Not RecruitingNCT04467918
2020-07-06BCG vaccinePrevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical TrialPrevention3Active Not RecruitingNCT04461379
2020-07-06COVID-19 convalescent plasmaPilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04452812
2020-07-06Placental Mesenchymal Stem CellsDSC-COVID-19 : An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19TreatmentNot AvailableActive Not RecruitingNCT04451291
2020-07-06TofacitinibA MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID-19 PNEUMONIA WHO ARE RECEIVING STANDARD OF CARE THERAPYTreatment2Active Not RecruitingNCT04412252
2020-07-06DegarelixHormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) : A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus DegarelixTreatment2Active Not RecruitingNCT04397718
2020-07-06OzanimodEfficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen SupportTreatment2Active Not RecruitingNCT04405102
2020-07-06OxygenHyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe HypoxemiaTreatment2Active Not RecruitingNCT04477954
2020-07-06RitonavirA Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last YearTreatment2Active Not RecruitingNCT04455958
2020-07-06LopinavirA Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir / Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last YearTreatment2Active Not RecruitingNCT04455958
2020-07-05AcalabrutinibA PHASE 2, OPEN LABEL, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ACALABRUTINIB WITH BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE IN SUBJECTS HOSPITALIZED WITH COVID-19Treatment2Active Not RecruitingPER-018-20
2020-07-05CurcuminEvaluation of the effect of nano micelles containing curcumin (Sina Ccurcumin) as a therapeutic supplement in patients with COVID-19 and investigating of immune responses balance changes following treatment : A randomized double blind clinical trial.TreatmentNot AvailableActive Not RecruitingIRCT20200611047735N1
2020-07-03TD-139Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19Treatment2, 3Active Not RecruitingNCT04473053
2020-07-03NafamostatRapid Experimental Medicine for COVID-19 - DEFINE COVID-19Treatment2, 3Active Not RecruitingNCT04473053
2020-07-03DapagliflozinmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Treatment2, 3Active Not RecruitingNCT04393246
2020-07-03AmbrisentanmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Treatment2, 3Active Not RecruitingNCT04393246
2020-07-02ABX-464A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).Treatment2Active Not RecruitingEUCTR2020-001673-75-GB
2020-07-02ABC-294640Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive PneumoniaTreatment2Active Not RecruitingNCT04414618
2020-07-02DutasterideAnti-Androgen Treatment for COVID-19TreatmentNot AvailableActive Not RecruitingNCT04446429
2020-07-01AlteplaseTissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS) : A Multicentral Randomized Trial (AtTAC-trial)Treatment3Active Not RecruitingNCT04453371
2020-07-01DiosminRandomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in EgyptTreatment1Active Not RecruitingNCT04452799
2020-07-01HesperidinRandomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in EgyptTreatment1Active Not RecruitingNCT04452799
2020-07-01AprepitantA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19Treatment2Active Not RecruitingNCT04470622
2020-07-01Povidone-iodineThe Efficacy of Topical Povidone-Iodine Rinses in the Management of the Coronavirus Disease 2019 (COVID-19)Treatment1Active Not RecruitingNCT04449965
2020-07-01Human interferon betaTreatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety StudyTreatment2Active Not RecruitingNCT04469491
2020-07-01PrasugrelPrasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised PatientsTreatment3Active Not RecruitingNCT04445623
2020-07-01ABC-294640Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia : a Randomized, Double-blind, Placebo-Controlled Phase 2 / 3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive PneumoniaTreatment2, 3Active Not RecruitingNCT04467840
2020-07-01FavipiravirAn Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 InfectionTreatment2Active Not RecruitingNCT04445467
2020-07-01SofosbuvirEfficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04443725
2020-07-01HydroxychloroquineEfficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04443725
2020-07-01DaclatasvirEfficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19Treatment2, 3Active Not RecruitingNCT04443725
2020-07-01NasoVAXPhase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04442230
2020-07-01NitazoxanideProspective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJTreatment2, 3Active Not RecruitingNCT04441398
2020-07-01IvermectinComparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir / Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 InfectionTreatment4Active Not RecruitingNCT04435587
2020-07-01OzoneRandomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated PatientsTreatment3Active Not RecruitingNCT04359303
2020-07-01HydroxychloroquinePost Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients : A Double-blind Randomized Clinical TrialPrevention3Active Not RecruitingNCT04437693
2020-07-01FavipiravirA Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19Treatment2, 3Active Not RecruitingNCT04464408
2020-07-01IvermectinPhase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)Treatment2Active Not RecruitingNCT04431466
2020-07-01Icosapent ethylPREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention TrialTreatment3Active Not RecruitingNCT04460651
2020-07-01Human Umbilical Cord Mesenchymal Stem CellsSafety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19Treatment2Active Not RecruitingNCT04429763
2020-07-01Covax-19™A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected PatientsTreatment1Active Not RecruitingNCT04428073
2020-07-01COVID-19 convalescent plasmaEffectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 : A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma)Treatment2, 3Active Not RecruitingNCT04425837
2020-07-01LopinavirA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01AzithromycinA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01HydroxychloroquineA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01RitonavirA Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04459702
2020-07-01COVID-19 convalescent plasmaConvalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients : A Feasibility StudyTreatment1Active Not RecruitingNCT04458363
2020-07-01Virus Specific T-CellPart Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19Treatment1, 2Active Not RecruitingNCT04457726
2020-07-01OseltamivirApplication of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 PatientsTreatment1Active Not RecruitingNCT04457609
2020-07-01Human Umbilical Cord Mesenchymal Stem CellsApplication of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 PatientsTreatment1Active Not RecruitingNCT04457609
2020-07-01AzithromycinApplication of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 PatientsTreatment1Active Not RecruitingNCT04457609
2020-07-01UlinastatinA Phase 3, Prospective, Randomized, Open Label, Comparative, Clinical Study To Evaluate Efficacy And Safety Of Ulinastatin Plus Standard-Of-Care Compared To Standard-Of-Care In Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized COVID-19 Infection PatientTreatment3Active Not RecruitingCTRI/2020/06/025704
2020-07-01NitazoxanideProof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day, Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical ConditionTreatment2Active Not RecruitingNCT04423861
2020-07-01Sodium chlorideInvestigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19Health Services Research1Active Not RecruitingNCT04419610
2020-07-01GaradacimabA Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)Treatment2Active Not RecruitingNCT04409509
2020-07-01AzithromycinHydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical TrialTreatment3Active Not RecruitingNCT04405921
2020-07-01HydroxychloroquineHydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia : A Randomized,Open-label,Controlled Clinical TrialTreatment3Active Not RecruitingNCT04405921
2020-07-01IC14Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)Treatment2Active Not RecruitingNCT04391309
2020-07-01Placental Mesenchymal Stem CellsA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19Treatment2Active Not RecruitingNCT04389450
2020-07-01MontelukastRepurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms : The COvid-19 Symptom MOntelukast (COSMO) TrialTreatment3Active Not RecruitingNCT04389411
2020-07-01Recombinant Bacterial ACE2 Receptors-like EnzymeCombination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2Treatment1Active Not RecruitingNCT04382950
2020-07-01IsotretinoinCombination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2Treatment1Active Not RecruitingNCT04382950
2020-07-01IsotretinoinIsotretinoin in Treatment of COVID-19 (Randomized)Treatment3Active Not RecruitingNCT04353180
2020-07-01TocilizumabA Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-PneumoniaTreatment2Active Not RecruitingNCT04335305
2020-07-01PembrolizumabA Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-PneumoniaTreatment2Active Not RecruitingNCT04335305
2020-07-01Gamolenic acidAnti-inflammatory / Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19 : A Randomized Controlled TrialSupportive Care4Active Not RecruitingNCT04323228
2020-07-01IcosapentAnti-inflammatory / Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19 : A Randomized Controlled TrialSupportive Care4Active Not RecruitingNCT04323228
2020-07-01Sodium bicarbonateSodium Bicarbonate for Treatment of COVID-19 Pneumonia : A Preliminary Prospective Controlled Crossover StudyTreatmentNot AvailableActive Not RecruitingNCT04374591
2020-07-01Nitric OxideRandomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental OxygenTreatment2Active Not RecruitingNCT04398290
2020-07-01AMY-101A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)Treatment2Active Not RecruitingNCT04395456
2020-07-01UlinastatinA Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized PatientsTreatment1, 2Active Not RecruitingNCT04393311
2020-07-01AV-COVID-19Adaptive Phase IB-II Randomized Clinical Trial Of Preventive Vaccine Consisting Of Autologous Dendritic Cells Loaded With Antigens From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), With Or Without GM-CSF, In Subjects Negative For COVID-19 Infection And Anti-SARS-CoV-2 AntibodiesPrevention1, 2Active Not RecruitingNCT04386252
2020-07-01Nitric OxideUse of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19Treatment1Active Not RecruitingNCT04383002
2020-07-01IfenprodilA Randomized Open Label Phase 2b / 3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 DiseaseTreatment2, 3Active Not RecruitingNCT04382924
2020-07-01BeractantPhase I / II Trial : Exogenous Surfactant Administration for Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04375735
2020-07-01TelmisartanRandomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 PatientsTreatment2Active Not RecruitingNCT04360551
2020-07-01AviptadilInhaled Aviptadil for the Treatment of Moderate and Severe COVID-19Treatment2, 3Active Not RecruitingNCT04360096
2020-07-01RuxolitinibRuxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept StudyTreatment2Active Not RecruitingNCT04359290
2020-07-01BacTRL-spikeA Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy AdultsPrevention1Active Not RecruitingNCT04334980
2020-07-01COVID-19 convalescent plasmaClinical-trial of COVID-19 Convalescent Plasma in OutpatientsTreatment3Active Not RecruitingNCT04355767
2020-07-01Acetylsalicylic acidAspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial TrialTreatment3Active Not RecruitingNCT04343001
2020-07-01SimvastatinAspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial TrialTreatment3Active Not RecruitingNCT04343001
2020-07-01LosartanAspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients : a Multinational Randomised Open-label Factorial TrialTreatment3Active Not RecruitingNCT04343001
2020-07-01DAS-181A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza InfectionTreatment2Active Not RecruitingNCT04298060
2020-07-01Alpha-1-proteinase inhibitorA Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (Prolastin®) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19Treatment2Active Not RecruitingNCT04495101
2020-07-01EnoxaparinEarly Thromboprophylaxis in COVID-19 (ETHIC Trial) : an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care in COVID-19 Positive PatientsTreatment3Active Not RecruitingNCT04492254
2020-07-01ThymalfasinA Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With LymphocytopeniaTreatment2Active Not RecruitingNCT04487444
2020-07-01COVID-19 convalescent plasmaTherapeutic effectiveness of COVID-19 convalescent plasma produced by HEMOPE : a multicenter, randomized and controlled clinical trial - PLAVID-TRIAL : Covid convalescent plasma - Clinical TrialTreatment3Active Not RecruitingRBR-7jqpnw
2020-07-01Rubella virus vaccineEffectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19Treatment3Active Not RecruitingPACTR202006883882711
2020-07-01Mumps virus strain B level jeryl lynn live antigenEffectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19Treatment3Active Not RecruitingPACTR202006883882711
2020-07-01Measles virus vaccine live attenuatedEffectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19Treatment3Active Not RecruitingPACTR202006883882711
2020-07-01FavipiravirJapanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trialTreatment2Active Not RecruitingJPRN-jRCTs041200025
2020-07-01MethylprednisoloneJapanese, multicenter, phase II trial of combination therapy with favipiravir and corticosteroids for coronavirus disease 2019 (COVID-19) patients with mild respiratory failure - J-CRITICAL trialTreatment2Active Not RecruitingJPRN-jRCTs041200025
2020-07-01CamostatMultiple-dose study of FOY-305 in Japanese healthy adult male subject(FOY-305-02)(COVID-19)Treatment1Active Not RecruitingJPRN-JapicCTI-205326
2020-07-01Human immunoglobulin GA Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care UnitTreatment2Active Not RecruitingNCT04480424
2020-07-01FavipiravirA Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Standard Therapy in Severe Adults With COVID-19Treatment2Active Not RecruitingNCT04475991
2020-07-01MaravirocA Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and / or Favipiravir vs Standard Therapy in Severe Adults With COVID-19Treatment2Active Not RecruitingNCT04475991
2020-07-01Bacillus calmette-guerin substrain connaught live antigenStudy to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in IndiaPrevention3Active Not RecruitingNCT04475302
2020-07-01PyronaridineA Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 PatientsTreatment2Active Not RecruitingNCT04475107
2020-07-01ArtesunateA Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 PatientsTreatment2Active Not RecruitingNCT04475107
2020-07-01MavrilimumabA Phase 2 / 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammationTreatment2, 3Active Not RecruitingNCT04447469
2020-07-01HydroxychloroquineHydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers : A Randomized-Controlled TrialPreventionNot AvailableActive Not RecruitingNCT04438837
2020-07-01CoronaVacDouble-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by SinovacPrevention3Active Not RecruitingNCT04456595
2020-07-01DiphenhydramineIntermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04456439
2020-07-01Remestemcel-LIntermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04456439
2020-07-01HydrocortisoneIntermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04456439
2020-07-01COVID-19 convalescent plasmaPhase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 InfectionTreatment2Active Not RecruitingNCT04456413
2020-07-01FisetinCovid-Fisetin : A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Hospitalized AdultsTreatment2Active Not RecruitingNCT04476953
2020-07-01EnzalutamideCOVID_ENZA Trial : Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1Treatment2Active Not RecruitingNCT04456049
2020-07-01TramadolSafety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients : A Randomized Double Blind Controlled Clinical TrialTreatment1, 2Active Not RecruitingNCT04454307
2020-06-30OlokizumabA Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19)Treatment2, 3Active Not RecruitingNCT04452474
2020-06-30Prednisolone acetateCombined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot StudyTreatmentNot AvailableActive Not RecruitingNCT04451239
2020-06-30CyclosporineCombined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis ; a Pilot StudyTreatmentNot AvailableActive Not RecruitingNCT04451239
2020-06-30VPM1002A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of the recombinant BCG VPM1002 on the Incidence or Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk Participants in AustraliaTreatment3Active Not RecruitingACTRN12620000707965
2020-06-30Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious CohortTreatment2Active Not RecruitingNCT04442178
2020-06-30GoldTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30Arsenic trioxideTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30SilverTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30CeleryTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30ZincTo Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients : A Double-Blind Randomized Controlled Trial - RNBTreatment3Active Not RecruitingCTRI/2020/06/025998
2020-06-30Povidone-iodinePovidone Iodine Gargle and Intranasal application : A Quasi-Experimental study to reduce the spread of coronavirus infection in community with Covid-19 positive clusters.TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/025928
2020-06-30COVID-19 convalescent plasmaInvestigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04420988
2020-06-30TofacitinibInvestigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC)Treatment2Active Not RecruitingNCT04415151
2020-06-30Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19Treatment2Active Not RecruitingNCT04362189
2020-06-30RuxolitinibA Pilot Study of Ruxolitinib to Combat COVID-19Treatment2Active Not RecruitingNCT04354714
2020-06-30Tranexamic acidA Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04390217
2020-06-30Stem-cell derived exosome vesicle productsEffect of stromal vascular fraction (SVF), blood and condition medium derived exosomes on treatment of covid-19 patients with Acute Respiratory Distress Syndrome(ARDS) / clinical TrialTreatment2, 3RecruitingIRCT20200510047385N1
2020-06-30Interferon beta-1aEfficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patientsTreatment3Active Not RecruitingIRCT20200511047396N1
2020-06-29Interferon beta-1aAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29RemdesivirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29LopinavirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29RitonavirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY - WHO-SOLIDARITY-GERMANYTreatment3Active Not RecruitingEUCTR2020-001549-38-DE
2020-06-29AG0301-COVID19A Non-randomized, Open-label, Non-controlled Phase I / II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg / 2mg) in Healthy AdultsPrevention1, 2Active Not RecruitingNCT04463472
2020-06-29Amniotic Epithelial CellsAllogeneic Amniotic Epithelial Cells for the Treatment of COVID-19 related respiratory failure, a pilot feasibility randomised controlled trialTreatment1, 2Active Not RecruitingACTRN12620000676910
2020-06-29Human immunoglobulin GA Phase II Safety and Efficacy Study on prognosis of Moderate Pneumonia in COVID-19 patients with Regular Intravenous Immunoglobulin TherapyTreatment2Active Not RecruitingCTRI/2020/06/026222
2020-06-29AcalabrutinibA Phase II, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19Treatment2Active Not RecruitingCTRI/2020/06/026228
2020-06-29UmifenovirA Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients.Treatment3Active Not RecruitingCTRI/2020/06/025957
2020-06-29FavipiravirA Randomized Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian COVID-19 Patients.Treatment3Active Not RecruitingCTRI/2020/06/025957
2020-06-29FenretinideRESOLUTION : A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 DiseaseTreatment2Active Not RecruitingNCT04417257
2020-06-29HeparinCoV-Hep Study : Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04487990
2020-06-29Sodium citrateCoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19TreatmentNot AvailableRecruitingRBR-45kf9p
2020-06-29HeparinCoV-Hep study : Randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID-19TreatmentNot AvailableRecruitingRBR-45kf9p
2020-06-27Indian frankincensePhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27ClovePhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27Azadirachta indica leafPhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27SpearmintPhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27OrangePhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27CinnamonPhase II, open label, randomized controlled trial to evaluate safety and efficacy of ShatPlus as an immunomodulator in adult Covid 19 positive patientsTreatment2Active Not RecruitingCTRI/2020/06/025999
2020-06-27COVID-19 convalescent plasmaA Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19Treatment1Active Not RecruitingNCT04353206
2020-06-26MaravirocBicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).Treatment2Active Not RecruitingNCT04441385
2020-06-26BCG vaccineA multi-centre, randomised, double-blind, placebo-controlled phase III study assessing the impact of BCG vaccination on the incidence and course of SARS-CoV-2 infection among healthcare workers in Poland during the COVID-19 pandemic.Treatment3Active Not RecruitingEUCTR2020-002111-22-PL
2020-06-26NitazoxanideEfficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group StudyTreatment2, 3Active Not RecruitingNCT04463264
2020-06-25EnoxaparinUtilização da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com síndrome respiratória Aguda Grave Por COVID-19Treatment3Active Not RecruitingNCT04444700
2020-06-25TocilizumabAn open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive decline in respiratory function and evolving systemic inflammation on time to intubation, non-invasive ventilation and / or all-cause mortalityTreatment2Active Not RecruitingEUCTR2020-001767-86-IE
2020-06-25SARS-CoV-2 mRNA vaccineA Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and abovePrevention1Active Not RecruitingChiCTR2000034112
2020-06-25CiclesonideCiclesonide Clinical Trial for COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04435795
2020-06-25COVID-19 convalescent plasmaA phase II, Open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19. - PLATINA TRIAL.Treatment2Active Not RecruitingCTRI/2020/06/026123
2020-06-25IvermectinRandomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 - RIVET-COVTreatment2, 3Active Not RecruitingCTRI/2020/06/026001
2020-06-25BCG vaccineStudy to Evaluate the Effectiveness of BCG vaccine in Reducing Morbidity and Mortality in Elderly individuals in COVID-19 Hotspots in India - BCG for COVID-19TreatmentNot AvailableActive Not RecruitingCTRI/2020/06/025854
2020-06-25COVID-19 convalescent plasmaTreatment of Critically Ill Patients With Covid-19 With Convalescent PlasmaTreatment2Active Not RecruitingNCT04468009
2020-06-25BrequinarThe CRISIS Study : A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)Treatment1, 2Active Not RecruitingNCT04425252
2020-06-25Plasma protein fraction (human)A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX) - PEX in severe COVID-19Treatment2Active Not RecruitingEUCTR2020-002668-29-GB
2020-06-25TocilizumabPHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVIDTreatment3Unknown StatusEUCTR2020-001707-16-ES
2020-06-25MethylprednisolonePHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVIDTreatment3Unknown StatusEUCTR2020-001707-16-ES
2020-06-24AZD1222An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIVPrevention1, 2Active Not RecruitingNCT04444674
2020-06-24COVID-19 convalescent plasmaCONCOR-1 : A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory IllnessTreatment3Active Not RecruitingNCT04418518
2020-06-24AZD1222COVID-19 : An Adaptive Phase I / II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARSCoV-2 Vaccine in South African Adults Living Without HIV ; and Safety and Immunogenicity in Adults Living With HIV.Treatment1Active Not RecruitingPACTR202006922165132
2020-06-23NafamostatRapid Experimental Medicine for COVID-19 - DEFINETreatment2Active Not RecruitingEUCTR2020-002230-32-GB
2020-06-23TD-139Rapid Experimental Medicine for COVID-19 - DEFINETreatment2Active Not RecruitingEUCTR2020-002230-32-GB
2020-06-23ChloroquineDoes Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19?Treatment3Active Not RecruitingNCT04447534
2020-06-23ZincDoes Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine / Hydroxychloroquine in Treatment of COVID-19?Treatment3Active Not RecruitingNCT04447534
2020-06-23PrednisoneEarly Use of Corticosteroids in Hospitalized Patients With Moderate COVID19 Pneumonia (PREDCOVID)Treatment3Active Not RecruitingNCT04451174
2020-06-23Sodium chlorideHypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19 : Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04382131
2020-06-22INO-4800A Phase I / IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04447781
2020-06-22DoxycyclineRepurpoSing Old Drugs TO SuppRess a Modern Threat : The STORM TrialTreatment2Active Not RecruitingNCT04433078
2020-06-22COVID-19 convalescent plasmaExperimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04445207
2020-06-22GlycineControlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical VentilationTreatmentNot AvailableActive Not RecruitingNCT04443673
2020-06-22RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingEUCTR2020-002060-31-CZ
2020-06-22Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology CohortTreatment2Active Not RecruitingNCT04426201
2020-06-22PentaglobinThe effect of pentaglobin in the treatment of critically ill patients with COVID-19Treatment2, 3Active Not RecruitingIRCT20151227025726N18
2020-06-22CyclosporinePhase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19Treatment1Active Not RecruitingNCT04412785
2020-06-22Povidone-iodineA Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 PatientsTreatment2Active Not RecruitingNCT04410159
2020-06-22WaterA Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 PatientsTreatment2Active Not RecruitingNCT04410159
2020-06-22IvermectinA double-blind clinical trial to repurpose and assess the efficacy and safety of ivermectin in COVID-19Treatment3CompletedISRCTN40302986
2020-06-22ZincA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22HydroxychloroquineA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22Vitamin DA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22Ascorbic acidA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 InfectionPrevention2Active Not RecruitingNCT04335084
2020-06-22AzithromycinA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22Ascorbic acidA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22ZincA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22Vitamin DA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22HydroxychloroquineA Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 InfectionTreatment2Active Not RecruitingNCT04334512
2020-06-22Peginterferon lambda-1aA Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19Treatment2Active Not RecruitingNCT04343976
2020-06-22BaricitinibA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2)Treatment3Active Not RecruitingJPRN-jRCT2031200035
2020-06-22RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT-2)Treatment3Active Not RecruitingJPRN-jRCT2031200035
2020-06-21Anakinra?Evaluation of Safety and efficacy of anakinra utilization in COVID-19, a randomized controlled clinical trialTreatment3Active Not RecruitingIRCT20120703010178N20
2020-06-21TranscrocetinateEvaluation of the effect of trans sodium crocetinate in respiratory distress caused by COVID-19Treatment2Active Not RecruitingIRCT20081019001369N6
2020-06-21RivaroxabanRandomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION TrialTreatment4Active Not RecruitingNCT04394377
2020-06-21TocilizumabA RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID-19 PNEUMONIATreatment3RecruitingPER-027-20
2020-06-21EdaravoneEffect of edaravone on clinical improvement and outcome of patients with respiratory distress syndrome caused by COVID-19Treatment3Active Not RecruitingIRCT20200317046797N6
2020-06-21Vitamin DEffect of vitamin D supplementation in diagnosed cases of 2019 Novel Coronavirus ; a randomized clinical trialTreatment3RecruitingIRCT20110726007117N11
2020-06-21HydroxychloroquineThe prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patientsTreatment3RecruitingIRCT20200513047426N1
2020-06-21COVID-19 convalescent plasmaPlasma exchange in patients with COVID-19 to reduce viral load and inflammatory moleculesTreatment2RecruitingIRCT20200416047099N2
2020-06-21Albumin humanPlasma exchange in patients with COVID-19 to reduce viral load and inflammatory moleculesTreatment2RecruitingIRCT20200416047099N2
2020-06-20PamrevlumabRandomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 DiseaseTreatment2Active Not RecruitingNCT04432298
2020-06-20QuercetinThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20ZincThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20BromelainsThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20Ascorbic acidThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19Treatment4Active Not RecruitingNCT04468139
2020-06-20RitonavirEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20LopinavirEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20HydroxychloroquineEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20AtazanavirEvaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200517047485N1
2020-06-20COVID-19 convalescent plasmaInactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19Treatment2Active Not RecruitingNCT04385186
2020-06-20SofosbuvirEfficacy & Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled studyTreatment2, 3Active Not RecruitingDRKS00022203
2020-06-20DaclatasvirEfficacy & Safety of Sofosbuvir / Daclatasvir treatment in COVID-19 : A randomized, controlled studyTreatment2, 3Active Not RecruitingDRKS00022203
2020-06-19COVID-19 convalescent plasmaTreatment of Severe and Critical COVID-19 Pneumonia With Convalescent PlasmaTreatment3Active Not RecruitingNCT04432103
2020-06-19Interferon beta-1bEvaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020Treatment3Active Not RecruitingIRCT20200412047042N1
2020-06-19RaltegravirEvaluation the effect of raltegravir, and raltegravir / interferon beta combination on covid 19 patients admitted in Peymanieh hospital of Jahrom in 2020Treatment3Active Not RecruitingIRCT20200412047042N1
2020-06-19SCB-2019A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.Prevention1Active Not RecruitingNCT04405908
2020-06-19ISS-1018A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.Prevention1Active Not RecruitingNCT04405908
2020-06-19LosartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19ValsartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19Angiotensin IIControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19CandesartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19EprosartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19TelmisartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19OlmesartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19IrbesartanControlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY DiseaseTreatment4Active Not RecruitingNCT04394117
2020-06-19CamostatThe Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients : An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa TrialTreatment2Active Not RecruitingNCT04353284
2020-06-18CVnCoVA Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy AdultsPrevention1Active Not RecruitingNCT04449276
2020-06-18CamostatSPIKE-1 TRIAL : A Randomised Phase II / III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. - SPIKE-1Treatment2Active Not RecruitingEUCTR2020-002110-41-GB
2020-06-18COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control TrialTreatment3Active Not RecruitingCTRI/2020/06/025803
2020-06-18Dornase alfaPulmozyme to Improve COVID-19 ARDS OutcomesTreatment2Active Not RecruitingNCT04402944
2020-06-18Human Umbilical Cord Mesenchymal Stem CellsPilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)Treatment1, 2Active Not RecruitingNCT04399889
2020-06-18VPM1002A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and / or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune SystemPrevention3Active Not RecruitingNCT04435379
2020-06-17MelatoninPHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) - MELCOVIDTreatment2Unknown StatusEUCTR2020-001808-42-ES
2020-06-17CamostatA randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”)Treatment2Active Not RecruitingEUCTR2020-002233-15-DE
2020-06-17NiclosamideA randomized, single blind, placebo-controlled, parallel-arm study to investigate the safety and preliminary efficacy of Niclosamide and Camostat alone and in combination to treat Covid-19 (“NICCAM”)Treatment2Active Not RecruitingEUCTR2020-002233-15-DE
2020-06-17Gam-COVID-VacAn Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac Lyo" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04437875
2020-06-17Gam-COVID-VacAn Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy VolunteersPrevention1, 2Active Not RecruitingNCT04436471
2020-06-17FavipiravirA Randomized, Open Label, Prospective, Comparative, Parallel Group, Multicentre Study To Evaluate Efficacy And Safety Of Favipiravir With Supportive Care Versus Supportive Care Alone In Subjects With Mild To Moderate Coronavirus Disease (COVID-19). - NATreatment3Active Not RecruitingCTRI/2020/06/025799
2020-06-17SofosbuvirEfficacy of Sofosbuvir in the management of hospitalized COVID 19 patients.Treatment3Active Not RecruitingCTRI/2020/06/025760
2020-06-17HeparinEvaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patientTreatment3RecruitingIRCT20200515047456N1
2020-06-17AlteplaseEvaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patientTreatment3RecruitingIRCT20200515047456N1
2020-06-17LY-CoV555A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 in Participants With Mild to Moderate COVID-19 IllnessTreatment2Active Not RecruitingNCT04427501
2020-06-16Nitrous acidAn open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with COVID-19 requiring supplemental oxygen (NOCoV2)Treatment2Active Not RecruitingEUCTR2020-002120-37-GB
2020-06-16MerimepodibA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04410354
2020-06-16RemdesivirA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04410354
2020-06-16TocilizumabA Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04409262
2020-06-16RemdesivirA Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04409262
2020-06-16IvermectinIvermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial.Treatment2Active Not RecruitingNCT04407130
2020-06-16DoxycyclineIvermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19 : a Randomised, Double-blind, Placebo-controlled Trial.Treatment2Active Not RecruitingNCT04407130
2020-06-16EIDD-2801A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19Treatment2Active Not RecruitingNCT04405570
2020-06-16TocilizumabPrognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)Basic ScienceNot AvailableActive Not RecruitingNCT04359667
2020-06-16LNP-nCoVsaRNA VaccineA first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19Treatment1Active Not RecruitingISRCTN17072692
2020-06-16FavipiravirThe Results of COVID 19 Treatment : A Real-life Experience on Patients With COVID 19Treatment2, 3Active Not RecruitingNCT04345419
2020-06-16OseltamivirThe Results of COVID 19 Treatment : A Real-life Experience on Patients With COVID 19Treatment2, 3Active Not RecruitingNCT04345419
2020-06-16IvermectinThe Results of COVID 19 Treatment : A Real-life Experience on Patients With COVID 19Treatment2, 3Active Not RecruitingNCT04345419
2020-06-16ChloroquineThe Results of COVID 19 Treatment : A Real-life Experience on Patients With COVID 19Treatment2, 3Active Not RecruitingNCT04345419
2020-06-16NiclosamideThe Results of COVID 19 Treatment : A Real-life Experience on Patients With COVID 19Treatment2, 3Active Not RecruitingNCT04345419
2020-06-16NitazoxanideThe Results of COVID 19 Treatment : A Real-life Experience on Patients With COVID 19Treatment2, 3Active Not RecruitingNCT04345419
2020-06-16NitazoxanideClinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04351347
2020-06-16IvermectinClinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04351347
2020-06-16Anti-SARS-CoV-2 REGN-COV2A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04425629
2020-06-16PioglitazoneControlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. - ESCORPIOTreatment4Unknown StatusEUCTR2020-001929-31-ES
2020-06-15Remestemcel-LDouble-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19Treatment2Unknown StatusEUCTR2020-002193-27-ES
2020-06-15COVID-19 convalescent plasmaEffectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 TrialTreatment2Active Not RecruitingNCT04428021
2020-06-15Vitamin DShort Term, High Dose Vitamin D Supplementation for COVID-19 Disease : Double Blind, Controlled, StudyTreatmentNot AvailableActive Not RecruitingNCT04459247
2020-06-15Sodium chlorideHomeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial - Homeopathy for Covid-19 in primary care : randomized, parallel-group, double-blind, placebo-controlled, clinical trial (Covid-Simile study)Treatment2Active Not RecruitingJPRN-UMIN000040602
2020-06-15NitazoxanideA Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 PatientsTreatment2Active Not RecruitingCTRI/2020/06/025849
2020-06-15HydroxychloroquineA Randomized, Open Label, 2-Treatment Groups Clinical Trial Evaluating the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in the Acute Treatment of Moderate COVID-19 PatientsTreatment2Active Not RecruitingCTRI/2020/06/025849
2020-06-15MelatoninMelatonin For COVID 19 pre exposure prophylaxis in High Risk population . (MELATONIN IMMUNE BOOST COVID 19 STUDY )Treatment4Active Not RecruitingCTRI/2020/06/025613
2020-06-15IloprostEfficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng) / Kilo(kg) / Minute(Min)) in Patients With COVID-19 Induced Pulmonary EndotheliopathyTreatment2Active Not RecruitingNCT04420741
2020-06-15SevofluraneSedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort StudyTreatment3Active Not RecruitingNCT04415060
2020-06-15IsofluraneSedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU : Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort StudyTreatment3Active Not RecruitingNCT04415060
2020-06-15NivolumabStudy of the Efficiency and Security of NIVOLUMAB Therapy, Used in Immuno-stimulation, in Hospitalized Obese Individuals at Risk to Evolve Towards Severe Forms of COVID-19 Infection. Multicentric, Paralleled, Randomized, Controlled TrialTreatment2Active Not RecruitingNCT04413838
2020-06-15CholecalciferolRandomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 PatientsTreatment4Active Not RecruitingNCT04411446
2020-06-15Vitamin DRandomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 PatientsTreatment4Active Not RecruitingNCT04411446
2020-06-15SulodexideSulodexide in the treatment of early stages of COVID-19TreatmentNot AvailableActive Not RecruitingISRCTN59048638
2020-06-15Angiotensin IIAngiotensin II Infusion in COVID-19-Associated Vasodilatory Shock : A multinational, multicentre registryBasic ScienceNot AvailableActive Not RecruitingACTRN12620000620921
2020-06-15CitrullineCACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress SyndromeTreatmentNot AvailableActive Not RecruitingNCT04404426
2020-06-15EnoxaparinEnoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus : The Multicenter Randomized Controlled Ovid TrialTreatment3Active Not RecruitingNCT04400799
2020-06-15HydroxychloroquineA randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19TreatmentNot AvailableActive Not RecruitingCTRI/2020/05/025067
2020-06-15AZD1222A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccineTreatment3Active Not RecruitingISRCTN89951424
2020-06-15HeparinNebulized heparin in patients with mainly moderate coronavirus disease 2019 : Randomized controlled trial. COVID-19TreatmentNot AvailableRecruitingPACTR202007606032743
2020-06-15HydroxychloroquinePilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis. - PRE-COVIDTreatment3Unknown StatusEUCTR2020-002449-41-ES
2020-06-15MetoprololIntravenous Metoprolol in Respiratory Distress Due to COVID-19 : Pilot Study "MADRID-COVID" - “MADRID-COVID”Treatment2Unknown StatusEUCTR2020-002310-41-ES
2020-06-14VPM1002A Randomized, Double-blind, Placebo-controlled Phase 3 Study : Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 SeverityPrevention3Active Not RecruitingNCT04439045
2020-06-14Human Umbilical Cord Mesenchymal Stem CellsEvolution of Allogenic Mesenchymal stem cell- derived Umbilical cord transplantation for ARDS patients infected with COVID19.Treatment2, 3Active Not RecruitingIRCT20160809029275N1
2020-06-14AtazanavirEvaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / RitonavirTreatment3Active Not RecruitingIRCT20200504047298N1
2020-06-14RitonavirEvaluation of Atazanavir / Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / RitonavirTreatment3Active Not RecruitingIRCT20200504047298N1
2020-06-14ResveratrolEvaluation of the effect of Resveratrol on the effectiveness of antiviral drug regimen in patients with COVID-19Treatment3RecruitingIRCT20200112046089N1
2020-06-14ValsartanTreatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial - CovidVal01TreatmentNot AvailableActive Not RecruitingDRKS00021732
2020-06-13Oral Polio VaccineShort-term Protection for COVID-19 by Oral Polio VaccineTreatment3Active Not RecruitingIRCT20140428017469N1
2020-06-13Nitric OxideInhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)TreatmentNot AvailableActive Not RecruitingNCT04397692
2020-06-13AcalabrutinibA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Treatment2Active Not RecruitingNCT04380688
2020-06-12Remestemcel-LMesenchymal Stromal Cell Therapy for Severe Covid-19 InfectionTreatment1, 2Active Not RecruitingNCT04445454
2020-06-12Hydroxychloroquineâ??Relative efficacy of hydroxy-chloroquine prophylaxis to healthcare-professionals for Covid-19 mitigation : a pragmatic prospective observational study (RE-HCP2 COVID study)â?? - RE-HCP2 COVID studyBasic ScienceNot AvailableActive Not RecruitingCTRI/2020/06/025593
2020-06-12BaricitinibA Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 InfectionTreatment3Active Not RecruitingNCT04421027
2020-06-12AcalabrutinibA Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Treatment2Active Not RecruitingNCT04346199
2020-06-11AnakinraA Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) StudyTreatment2Active Not RecruitingNCT04412291
2020-06-11TocilizumabA Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) StudyTreatment2Active Not RecruitingNCT04412291
2020-06-11Povidone-iodineEffect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal TitersTreatment1, 2Active Not RecruitingNCT04347954
2020-06-11VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19Treatment2, 3Active Not RecruitingNCT04379271
2020-06-11FavipiravirMulticenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 PneumoniaTreatment3Active Not RecruitingJPRN-jRCTs031200026
2020-06-11NafamostatMulticenter, Single blinded Randomized Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 PneumoniaTreatment3Active Not RecruitingJPRN-jRCTs031200026
2020-06-10TocilizumabA randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6Treatment3Active Not RecruitingEUCTR2020-001903-17-ES
2020-06-10CholecalciferolA randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complication. Assessment of IL-6. - Tocilizumab vs. its combination with Vitamin D. Variation in IL-6Treatment3Active Not RecruitingEUCTR2020-001903-17-ES
2020-06-10AcalabrutinibA Phase 2, Open-Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVITreatment2Active Not RecruitingEUCTR2020-001644-25-DE
2020-06-10NafamostatTreatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia : Open Labelled Randomized Controlled Clinical TrialTreatment2, 3Active Not RecruitingNCT04418128
2020-06-10COVID-19 convalescent plasmaConvalescent Plasma to Stem Coronavirus : A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19Treatment2Active Not RecruitingNCT04323800
2020-06-10IvermectinIn vivo use of ivermectin (IVR) for treatment for corona virus infected patients : a randomized controlled trialTreatment0Active Not RecruitingChiCTR2000033627
2020-06-10Anti-SARS-CoV-2 REGN-COV2A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04426695
2020-06-10SilibininPhase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection by COVID-19 positive. - SilCOVID19Treatment2Unknown StatusEUCTR2020-001794-77-ES
2020-06-10Human immunoglobulin GDouble-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19Treatment4Unknown StatusEUCTR2020-001890-56-ES
2020-06-09COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Patients With COVID-19 : A Randomized Control TrialTreatment3Active Not RecruitingNCT04425915
2020-06-09IvermectinThe Use of Ivermectin In the Treatment of COVID 19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04425707
2020-06-08COVID-19 convalescent plasmaA Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized PatientsTreatment2Active Not RecruitingNCT04421404
2020-06-08Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and BelgiumTreatment2Active Not RecruitingNCT04407689
2020-06-08CiclesonideA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 InfectionTreatment3Active Not RecruitingNCT04377711
2020-06-06PembrolizumabThe evaluation of safety and efficacy of Pembrolizumab (CinnaGen Co, Iran) in patients with COVID-19Treatment2Active Not RecruitingIRCT20150303021315N19
2020-06-06IbrutinibIbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)Treatment2Active Not RecruitingNCT04375397
2020-06-06AcetylcysteineComparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery processTreatment3Active Not RecruitingIRCT20200324046850N1
2020-06-06CholecalciferolComparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery processTreatment3Active Not RecruitingIRCT20200324046850N1
2020-06-05CurcuminEvaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19Treatment3Active Not RecruitingIRCT20200519047510N1
2020-06-05HydroxychloroquineLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05LopinavirLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05HeparinLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05AzithromycinLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05RitonavirLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05TocilizumabLow Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 : Multi-central Prospective StudySupportive CareNot AvailableActive Not RecruitingNCT04380818
2020-06-05SulodexideSulodexide in the Treatment of Early Stages of COVID-19Treatment2, 3Active Not RecruitingNCT04483830
2020-06-05ValsartanTreatment of Sars-CoV2 infections (COVID-19) with valsartan vs placebo, a three-armed randomized, partly blinded trialTreatment2Active Not RecruitingEUCTR2020-001431-27-DE
2020-06-04Omega-3 fatty acidsThe effect of omega-3 supplementation on inflammatory and biochemical markers in critical ill patients with COVID-19 a randomized clinical trialTreatmentNot AvailableActive Not RecruitingIRCT20151226025699N3
2020-06-04AcetylcysteineEvaluating the effect of intravenous N-acetyl cysteine versus placebo in the treatment of patients with mild and moderate acute respiratory distress syndrome caused by COVID-19 : A double-blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N355
2020-06-04BCG vaccineInvestigating the Effect of BCG Vaccine on Preventing COVID-19 Infection in Healthcare Staff Exposed to SARS-CoV-2Treatment3Active Not RecruitingIRCT20200411047019N1
2020-06-04BemiparinA Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19Treatment2Active Not RecruitingNCT04420299
2020-06-04DexamethasoneEvaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N354
2020-06-04MethylprednisoloneEvaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N354
2020-06-04HydrocortisoneEvaluating the effect of intravenous hydrocortisone, methylprednisolone, and dexamethasone in treatment of patients with moderate to severe acute respiratory distress syndrome caused by COVID-19 : A double blind randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N354
2020-06-04COVID-19 convalescent plasmaPrevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.PreventionNot AvailableActive Not RecruitingNCT04479163
2020-06-03HydroxychloroquineThe NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19Treatment3Active Not RecruitingEUCTR2020-000982-18-SE
2020-06-03RemdesivirThe NOR-SWE Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients. - S-ReCOVID 19Treatment3Active Not RecruitingEUCTR2020-000982-18-SE
2020-06-03RitonavirHydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition"Treatment3Active Not RecruitingNCT04403100
2020-06-03HydroxychloroquineHydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition"Treatment3Active Not RecruitingNCT04403100
2020-06-03LopinavirHydroxychloroquine and Lopinavir / Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms : "The Hope Coalition"Treatment3Active Not RecruitingNCT04403100
2020-06-03COVID-19 convalescent plasmaComparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19.Treatment2Active Not RecruitingNCT04373460
2020-06-03MethylprednisoloneEfficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS) in COVID-19Treatment4Unknown StatusEUCTR2020-002186-34-ES
2020-06-02BudesonideUse of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation - The STOIC Study (STerOids in COVID)Treatment2Active Not RecruitingEUCTR2020-001889-10-GB
2020-06-02ImatinibRandomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19Treatment3Active Not RecruitingNCT04394416
2020-06-02AzithromycinEVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRATreatment3Active Not RecruitingNCT04347512
2020-06-02HydroxychloroquineEVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRATreatment3Active Not RecruitingNCT04347512
2020-06-02SargramostimUsing GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated TrialTreatment2Active Not RecruitingNCT04400929
2020-06-02EnoxaparinCOVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) TrialPrevention2Active Not RecruitingNCT04354155
2020-06-02IvermectinPragmatic study "CORIVER" : Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) - CORIVERTreatment3Unknown StatusEUCTR2020-001971-33-ES
2020-06-01Vitamin DVitamin D Supplementation in Patients With COVID-19 : A Randomized, Double-blind, Placebo-controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04449718
2020-06-01FavipiravirControl of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)Prevention2Active Not RecruitingNCT04448119
2020-06-01IvermectinRandomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19Treatment2Active Not RecruitingNCT04438850
2020-06-01COVID-19 convalescent plasmaA Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19Treatment2Active Not RecruitingNCT04433910
2020-06-01COVID-19 convalescent plasmaUse of Convalescent Plasma for Treatment of Patients With COVID-19 InfectionTreatment1, 2Active Not RecruitingNCT04438694
2020-06-01Human Umbilical Cord Mesenchymal Stem CellsEfficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 PatientsTreatment2Active Not RecruitingNCT04437823
2020-06-01NitazoxanideProspective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable CommunitiesPrevention2Active Not RecruitingNCT04435314
2020-06-01ThymalfasinA Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Elderly Renal Dialysis PatientsPrevention2Active Not RecruitingNCT04428008
2020-06-01Human immunoglobulin GA Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19Treatment2Active Not RecruitingNCT04432324
2020-06-01InfliximabA Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).Treatment2Active Not RecruitingNCT04425538
2020-06-01FavipiravirA Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate TypeTreatment3Active Not RecruitingNCT04425460
2020-06-01Dornase alfaA Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19Treatment3Active Not RecruitingNCT04459325
2020-06-01COVID-19 convalescent plasmaRandomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04383548
2020-06-01HydroxychloroquineRandomized, placebo-controlled multiple dose study to evaluate the effect of hydroxychloroquine on the general immuno-competence in young and elderly healthy male volunteersTreatmentNot AvailableRecruitingNL8726
2020-06-01ImatinibImatinib for the Treatment of SARS-COV-2 Induced Pneumonia : A Pilot StudyTreatment3Active Not RecruitingNCT04422678
2020-06-01COVID-19 convalescent plasmaA Pilot Study to Explore the Efficacy and Safety of Rescue Therapy With Antibodies From Convalescent Patients Obtained With Double-filtration Plasmapheresis (DFPP) and Infused in Patients With Coronavirus Disease 2019 (COVID-19) and Need of Oxygen Support Without Mechanical VentilationTreatmentNot AvailableActive Not RecruitingNCT04418531
2020-06-01COVID-19 convalescent plasmaTreatment of Patients With COVID-19 With Convalescent Plasma Transfusion : a Multicenter, Open-labeled, Randomized and Controlled StudyTreatment2Active Not RecruitingNCT04415086
2020-06-01RuxolitinibSafety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2Treatment2Active Not RecruitingNCT04414098
2020-06-01TocilizumabA Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19Treatment3Active Not RecruitingNCT04412772
2020-06-01COVID-19 convalescent plasmaAn Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19Treatment1Active Not RecruitingNCT04412486
2020-06-01Talactoferrin alfaClinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory Therapy in Patients Diagnosed With COVID-19 DiseaseTreatment2Active Not RecruitingNCT04412395
2020-06-01Icosapent ethylAn Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)Treatment2Active Not RecruitingNCT04412018
2020-06-01SargramostimA Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute HypoxemiaTreatment2Active Not RecruitingNCT04411680
2020-06-01PrednisoneHome-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow upTreatmentNot AvailableActive Not RecruitingNCT04410536
2020-06-01IndomethacinHome-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency : Incidence of Relapses in Overuse and Changes in Impact at One Year Follow upTreatmentNot AvailableActive Not RecruitingNCT04410536
2020-06-01Dornase alfaPhase I Pilot Study Investigating the Safety and Tolerability of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected PatientsTreatment1Active Not RecruitingNCT04409925
2020-06-01ClopidogrelA Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsPrevention4Active Not RecruitingNCT04409834
2020-06-01EnoxaparinA Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsPrevention4Active Not RecruitingNCT04409834
2020-06-01HeparinA Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsPrevention4Active Not RecruitingNCT04409834
2020-06-01LopinavirEvaluation of Additional Treatments for COVID-19 : a Randomized Trial in NigerTreatment3Active Not RecruitingNCT04409483
2020-06-01RitonavirEvaluation of Additional Treatments for COVID-19 : a Randomized Trial in NigerTreatment3Active Not RecruitingNCT04409483
2020-06-01Angiotensin IIEfficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress SyndromeBasic ScienceNot AvailableActive Not RecruitingNCT04408326
2020-06-01Nicotinamide ribosideEffects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19Treatment2Active Not RecruitingNCT04407390
2020-06-01EIDD-2801A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults With PCR-Confirmed COVID-19Treatment2Active Not RecruitingNCT04405739
2020-06-01Remestemcel-LPhase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical VentilationTreatment1Active Not RecruitingNCT04397796
2020-06-01HeparinNebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung InjuryTreatment4Active Not RecruitingNCT04397510
2020-06-01TretinoinCombination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated VaccinesTreatment2Active Not RecruitingNCT04396067
2020-06-01TamoxifenCombination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome CoronavirusTreatment2Active Not RecruitingNCT04389580
2020-06-01IsotretinoinCombination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome CoronavirusTreatment2Active Not RecruitingNCT04389580
2020-06-01Vitamin DImproving Vitamin D Status in the Management of COVID-19Treatment3Active Not RecruitingNCT04385940
2020-06-01HydroxychloroquineCOVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers Involved In Suspected, or Confirmed Cases of COVID-19.PreventionNot AvailableActive Not RecruitingNCT04384458
2020-06-01ZanubrutinibA Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary DistressTreatment2Active Not RecruitingNCT04382586
2020-06-01HydroxychloroquineProphylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT)PreventionNot AvailableActive Not RecruitingNCT04371926
2020-06-01RuxolitinibInterleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and RuxolitinibTreatment2Active Not RecruitingNCT04366232
2020-06-01AnakinraInterleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation : Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and RuxolitinibTreatment2Active Not RecruitingNCT04366232
2020-06-01PrednisoneEfficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion FranceTreatment3Active Not RecruitingNCT04359511
2020-06-01HydrocortisoneEfficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion FranceTreatment3Active Not RecruitingNCT04359511
2020-06-01AldesleukinLow Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19Treatment2Active Not RecruitingNCT04357444
2020-06-01Remestemcel-LExploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04315987
2020-06-01ChloroquineAn international, multi-site, Bayesian platform adaptive, randomised, placebo-controlled trial assessing the effectiveness of varied doses of oral Chloroquine in preventing or reducing the severity of COVID-19 disease in healthcare workersTreatment3Active Not RecruitingISRCTN99916292
2020-06-01Stem-cell derived exosome vesicle productsRationale and investigational study for the treatment of COVID-19 with severe viral pneumonia with isolated, placental, mesenchymal stem cell exosomesTreatment2RecruitingISRCTN33578935
2020-06-01EnoxaparinRandomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical VentilationTreatment3Active Not RecruitingNCT04408235
2020-06-01IvermectinMulticenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without SymptomsTreatment2Active Not RecruitingNCT04407507
2020-06-01HeparinInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-06-01FondaparinuxInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-06-01ArgatrobanInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-06-01EnoxaparinInterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19 : A Prospective Randomized Study (The IMPACT Trial)Treatment4Active Not RecruitingNCT04406389
2020-06-01Lithium carbonateSARS-CoV-2 Specific Memory B and T- CD4+ CellsBasic ScienceNot AvailableActive Not RecruitingNCT04402892
2020-06-01DexamethasoneA Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Study Evaluating AVM0703 in Patients With COVID-19Treatment1, 2Active Not RecruitingNCT04366115
2020-06-01BudesonideARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)Treatment3Active Not RecruitingNCT04193878
2020-06-01FormoterolARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)Treatment3Active Not RecruitingNCT04193878
2020-06-01IvermectinThe Efficacy of Ivermectin and Doxycycline in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04403555
2020-06-01DoxycyclineThe Efficacy of Ivermectin and Doxycycline in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04403555
2020-06-01Angiotensin 1-7Randomized Controlled Trial of Angiotensin 1-7 / TXA127 for the Treatment of Moderate COVID-19Treatment2Active Not RecruitingNCT04401423
2020-06-01Ascorbic acidLessening Organ Dysfunction With VITamin C - COVIDTreatment3Active Not RecruitingNCT04401150
2020-06-01ResveratrolRandomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04400890
2020-06-01Human immunoglobulin GEfficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionPrevention3Active Not RecruitingNCT04400058
2020-06-01NiclosamideNiclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)Treatment2Active Not RecruitingNCT04399356
2020-06-01HydroxychloroquineMulticentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in SenegalTreatment3Active Not RecruitingNCT04390594
2020-06-01AzithromycinMulticentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in SenegalTreatment3Active Not RecruitingNCT04390594
2020-06-01Povidone-iodineA pilot study of virucidal activity of povidone-iodine (PVP-I) 0.5% aqueous solution oral / nasal spray and mouthwash in people with COVID-19 and confirmed oral / nasal shedding of SARS-CoV-2TreatmentNot AvailableCompletedISRCTN13447477
2020-06-01Mesenchymoangioblast-derived mesenchymal stem cellsA pilot, open-label, randomised controlled clinical trial to investigate early efficacy of CYP-001 in adults admitted to intensive care with COVID-19Treatment1, 2Active Not RecruitingACTRN12620000612910
2020-06-01HeparinHeparins for Thromboprophylaxis in COVID-19 Patients : HETHICO Study in VenetoBasic ScienceNot AvailableActive Not RecruitingNCT04393805
2020-06-01COVID-19 convalescent plasmaEfficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection : A Randomized, Open Label Clinical TrialTreatment3Active Not RecruitingNCT04391101
2020-06-01ArtesunateEvaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19Treatment2Active Not RecruitingNCT04387240
2020-06-01ArtemisininEvaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19Treatment2Active Not RecruitingNCT04387240
2020-06-01RitonavirTrial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19Treatment2Active Not RecruitingNCT04372628
2020-06-01LopinavirTrial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19Treatment2Active Not RecruitingNCT04372628
2020-06-01Tranexamic acidExploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in OutpatientsTreatment2Active Not RecruitingNCT04338074
2020-06-01TofacitinibTOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label TrialTreatment2Active Not RecruitingNCT04390061
2020-06-01HydroxychloroquineTOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia : a Multicenter Randomized Controlled Open Label TrialTreatment2Active Not RecruitingNCT04390061
2020-06-01DeferoxamineThe Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection : A Randomized Controlled TrialTreatment4Active Not RecruitingNCT04389801
2020-06-01DoxycyclineDoxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria : Prospective, Multicenter, Randomized, Double-blind StudyTreatment3Active Not RecruitingNCT04371952
2020-06-01LucinactantA Multicenter, Single-Treatment Study to Assess the Safety and Preliminary Efficacy of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung InjuryTreatment1, 2Active Not RecruitingNCT04389671
2020-06-01COVID-19 convalescent plasmaPhase 2b / 3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.Treatment2, 3Active Not RecruitingNCT04388410
2020-06-01ResiniferatoxinA Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin (RTX) Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed Due to the COVID-19-related Moratoria on Elective ProceduresTreatment3Active Not RecruitingNCT04386980
2020-06-01FavipiravirAn Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia â?? An open-label randomized controlled study â??Treatment2, 3Active Not RecruitingTCTR20200514001
2020-06-01COVID19 s-vax loaded autologous dendritic cell vaccineA safety and immune response study of novel coronavirus pneumonia (COVID-19) s-vax loaded autologous dendritic cellsPrevention0Active Not RecruitingChiCTR2000033003
2020-06-01RuxolitinibSafety and Efficacy of Ruxolitinib for COVID-19Treatment2, 3Active Not RecruitingNCT04348071
2020-06-01BaricitinibSafety and Efficacy of Baricitinib for COVID-19Treatment2, 3Active Not RecruitingNCT04340232
2020-06-01BCG vaccineCOVID-19 : BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin EnhancementTreatment4Active Not RecruitingNCT04369794
2020-06-01TocilizumabTreatment of Serious and Critical Patients With COVID-19 With TocilizumabTreatment2Active Not RecruitingNCT04363853
2020-06-01MRx-4DP0004A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)Treatment2Active Not RecruitingNCT04363372
2020-06-01COVID-19 convalescent plasmaExpanded Access Protocol For The Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)TreatmentNot AvailableActive Not RecruitingNCT04360486
2020-06-01Umbilical Cord Blood Hematopoietic Stem CellsCord Blood Therapy to prevent progression of COVID-19 related pneumoniaTreatmentNot AvailableActive Not RecruitingACTRN12620000478910
2020-06-01HydroxychloroquineEvaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 InfectionTreatment4Active Not RecruitingNCT04338906
2020-06-01CamostatEvaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 InfectionTreatment4Active Not RecruitingNCT04338906
2020-06-01COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.TreatmentNot AvailableActive Not RecruitingCTRI/2020/05/025346
2020-06-01ResveratrolA Phase-III, Open Label, Randomized Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Asymptomatic Or Mildly Symptomatic Patients With SARS-CoV-2 Infection (Covid-19)Treatment3Active Not RecruitingCTRI/2020/05/025336
2020-06-01COVID-19 convalescent plasmaTo Assess the Safety and Efficacy of Convalescent Plasma on outcome of COVID-19 Associated Complications - COVID PLASMA STUDYTreatment2Active Not RecruitingCTRI/2020/05/025328
2020-06-01LosartanAngiotensin Receptor Blocker Losartan for prevention of COVID 19 complications : a randomized placebo controlled trial - LICCITreatment3Active Not RecruitingCTRI/2020/05/025319
2020-06-01COVID-19 convalescent plasmaConvalescent Plasma to Limit Coronavirus Associated Complications : An Open label Clinical Study of Anti-SARS-CoV-2 Plasma in Hospitalized Patients with COVID-19Treatment2Active Not RecruitingCTRI/2020/05/025299
2020-06-01COVID-19 convalescent plasmaPERUCONPLASMA : RANDOMIZED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF THE USE OF CONVALESCENT PLASMA IN HOSPITALIZED PATIENTS WITH COVID-19Treatment2Active Not RecruitingPER-016-20
2020-06-01COVID-19 convalescent plasmaCONVALESCENT PLASMA USE AS TREATMENT FOR HOSPITALIZED PATIENTS WITH COVID-19 IN ESSALUDTreatment2Active Not RecruitingPER-013-20
2020-06-01AzithromycinA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01NaproxenA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01Clavulanic acidA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01AmoxicillinA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01LevofloxacinA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01OseltamivirA phase IIb, double-blind, randomized controlled trial to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicTreatment2RecruitingRBR-3rywwg
2020-06-01HydroxychloroquineEfficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19Treatment3Active Not RecruitingPACTR202005622389003
2020-06-01AzithromycinEfficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19Treatment3Active Not RecruitingPACTR202005622389003
2020-06-01ZincEfficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal : a dose ranging randomised trial. COVID-19Treatment3Active Not RecruitingPACTR202005622389003
2020-05-31IvermectinUse of Ivermectin as a Therapeutic Option for Patients With COVID-19Treatment2, 3Active Not RecruitingNCT04445311
2020-05-31IvermectinUse of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19Prevention2, 3Active Not RecruitingNCT04422561
2020-05-31DipyridamoleDipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19Treatment2Active Not RecruitingNCT04391179
2020-05-31AZD1222A phase Ib / II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in KenyaTreatment1Active Not RecruitingPACTR202005681895696
2020-05-31COVID-19 convalescent plasmaClinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)TreatmentNot AvailableActive Not RecruitingChiCTR2000030039
2020-05-31Mycobacterium w. VaccineObservational study to assess safety and efficacy of Inj Sepsivac in patients of Covid-19 at R D Gardi Medical College, Ujjain, IndiaTreatment2Active Not RecruitingCTRI/2020/05/025350
2020-05-31Mycobacterium w. VaccineA Randomized, Double-blind, Two arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in preventing COVID-19 in subjects at risk of getting infected with COVID-19.Treatment3Active Not RecruitingCTRI/2020/05/025277
2020-05-31Mycobacterium w. VaccineA Randomized, Double-blind, Two arm, controlled clinical trial to compare the Efficacy and Safety of Mycobacterium w (Mw) administered along with Standard of care versus Placebo administered along with Standard of care, in adult, COVID 19 positive patients hospitalized but not critically ill.Treatment3Active Not RecruitingCTRI/2020/05/025271
2020-05-31MetronidazoleEvaluation of therapeutic effects of Metronidazole In Inpatients with Pneuomonia Due to COVID-19Treatment2Active Not RecruitingIRCT20200608047686N1
2020-05-30IvermectinA randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19)Treatment2, 3Active Not RecruitingIRCT20200422047168N2
2020-05-30HoneyComparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trialTreatmentNot AvailableRecruitingIRCT20200209046427N1
2020-05-30Propolis waxComparison effect of N-Chromosome royal jelly, propolis, and mixed honey supplementation on clinical and laboratory findings of COVID-19 patients with standard treatment : a randomized clinical trialTreatmentNot AvailableRecruitingIRCT20200209046427N1
2020-05-30EnoxaparinFull versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19 : clinical, randomized, open and controlled study - HeSAcovid trialTreatment2Active Not RecruitingRBR-949z6v
2020-05-29Omega-3 fatty acidsResolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility studyTreatment2Active Not RecruitingEUCTR2020-002293-28-SE
2020-05-29AzithromycinA Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)Treatment3Active Not RecruitingNCT04381962
2020-05-29LiothyronineTriiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)Treatment2Active Not RecruitingNCT04348513
2020-05-29Peginterferon lambda-1aPeginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 InfectionPrevention2Active Not RecruitingNCT04344600
2020-05-29VPM1002A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and / or severe respiratory infectious diseases in elderly in the SARS-CoV-2 pandemic by modulating the immune systemTreatment3Active Not RecruitingEUCTR2020-001675-33-DE
2020-05-29MRx-4DP0004A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)Treatment2Active Not RecruitingEUCTR2020-001597-30-GB
2020-05-29mRNA-1273A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and OlderPrevention2Active Not RecruitingNCT04405076
2020-05-29RitonavirEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29HydroxychloroquineEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29AzithromycinEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29LopinavirEffectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir / ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectionTreatment4Unknown StatusEUCTR2020-001605-23-ES
2020-05-29Poractant alfaRandomized Controlled Phase II Trial of Poractant Alfa (Curosurf®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral PneumoniaTreatment2Active Not RecruitingNCT04384731
2020-05-28VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-DE
2020-05-28CiclesonideInhalation of Ciclesonide for patients with Covid-19 : A randomised open treatment study (HALT Covid-19).Treatment2Active Not RecruitingEUCTR2020-001928-34-SE
2020-05-28VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-HU
2020-05-28COVID-19 convalescent plasmaSafety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2Treatment1Active Not RecruitingNCT04377672
2020-05-28OtilimabA Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related DiseaseTreatment2Active Not RecruitingNCT04376684
2020-05-28TocilizumabTocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)Treatment2Active Not RecruitingNCT04370834
2020-05-28AZD1222A Phase 2 / 3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19Prevention2, 3Active Not RecruitingNCT04400838
2020-05-28CholecalciferolClinical trial, PHASE III, randomized, open-label, to evaluate the efficacy of administering high-dose cholecalciferol orally alongside standard therapy in patients with COVID-19 pneumonia (COVID-19 HUSO). - Efficacy of high dose vitamin D in COVID-19 pneumoniaTreatment3Unknown StatusEUCTR2020-002312-43-ES
2020-05-28RuxolitinibRuxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept studyTreatment2Active Not RecruitingEUCTR2020-001732-10-DE
2020-05-28Bacillus calmette-guerin substrain danish 1331 live antigenEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUSTreatment4Active Not RecruitingEUCTR2020-002456-21-NL
2020-05-28Alendronic acidEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS) - BCG-PLUSTreatment4Active Not RecruitingEUCTR2020-002456-21-NL
2020-05-27VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-BG
2020-05-27COVID-19 convalescent plasmaEarly transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.Prevention2, 3Active Not RecruitingNCT04374526
2020-05-27IvermectinA Phase IIB open label randomized controlled trial to evaluate the efficacy and safety of Ivermectin in reducing viral loads in patients with hematological disorders who are admitted with COVID 19 infection - Not applicableTreatment3Active Not RecruitingCTRI/2020/05/025068
2020-05-27TocilizumabA Multi-center, Randomized Controlled, Phase III Study to evaluate the Clinical Outcomes and Safety of Tocilizumab along with Standard of Care in Patients with Cytokine Release Syndrome associated with COVID-19 infection - NoneTreatment3Active Not RecruitingCTRI/2020/05/025369
2020-05-27EculizumabEculizumab for the treatment of Covid-19 severe cases - : Eculizumabe for COVIDTreatment1, 2RecruitingRBR-876qb5
2020-05-26BCG vaccineA Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19 : The ACTIVATE II TrialPrevention4Active Not RecruitingNCT04414267
2020-05-26ZilucoplanA prospective, randomized, open-label, interventional study to investigate the efficacy of complement C5 inhibition with Zilucoplan® in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - ZILU-COVTreatment2Active Not RecruitingEUCTR2020-002130-33-BE
2020-05-26IbuprofenLipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19 : a Multicentre, Randomised, Controlled TrialTreatment4Active Not RecruitingNCT04334629
2020-05-26BCG vaccineA RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ?? COVID-19 : THE ACTIVATE II TRIALTreatment4Active Not RecruitingEUCTR2020-002448-21-GR
2020-05-26TocilizumabTocilizumab for the treatment of COVID-19 in intensive care patients : effect on days free of ventilatory support.Treatment1, 2Active Not RecruitingACTRN12620000580976
2020-05-25Dornase alfaDetermination of Dornase Alpha Effectiveness in COVID-19 TreatmentTreatment2Active Not RecruitingNCT04432987
2020-05-25VPM1002A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune SystemPrevention3Active Not RecruitingNCT04387409
2020-05-25ColchicinePREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)Prevention3Active Not RecruitingNCT04416334
2020-05-25OzoneA Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 PneumoniaTreatment3Active Not RecruitingNCT04370223
2020-05-25NitazoxanideProof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.TreatmentNot AvailableActive Not RecruitingNCT04348409
2020-05-25NVX-CoV2373A 2-Part, Phase 1 / 2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy SubjectsPrevention1Active Not RecruitingNCT04368988
2020-05-25ColchicineColchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19Treatment3Unknown StatusEUCTR2020-001841-38-ES
2020-05-25Vitamin DEfficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19)Treatment4Unknown StatusEUCTR2020-001960-28-ES
2020-05-25SarilumabMulticenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsTreatment2Unknown StatusEUCTR2020-002037-15-ES
2020-05-25Ascorbic acidTherapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial : The International ALLIANCE StudyTreatment2Active Not RecruitingNCT04395768
2020-05-25Rubella virus vaccineEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25BCG vaccineEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25Alendronic acidEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25Measles virus vaccine live attenuatedEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25Mumps virus strain B level jeryl lynn live antigenEnhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine : a possible preventive approach against COVID-19 (BCG-PLUS)TreatmentNot AvailableActive Not RecruitingNL8609
2020-05-25DAS-181DAS181 for COVID-19 : A Phase II / III, Multicenter, Randomized, Placebo-Controlled, Double-Blind StudyTreatment2, 3Active Not RecruitingNCT04354389
2020-05-25TocilizumabA Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in JapanTreatment3Active Not RecruitingJPRN-JapicCTI-205270
2020-05-25NafamostatTreatment effect of Nafamostat mesilate in patients with COVID-19 pneumonia : open labelled randomized controlled clinical trialTreatment2Active Not RecruitingKCT0005003
2020-05-25GoldRapid Detection 2019-nCoV via Surface Plasamon ResonanceDiagnostic0Active Not RecruitingChiCTR2000032842
2020-05-25HydroxychloroquinePopulation pharmacokinetics of hydroxychloroquine sulphate in healthcare workers given for prophylaxis against Corona Virus Disease 2019 (COVID 19) pandemic in IndiaTreatmentNot AvailableActive Not RecruitingCTRI/2020/05/025242
2020-05-25Ascorbic acidA prospective, single centre, randomized open labelled comparative clinical study to evaluate the effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of asymptomatic COVID 19 patients.Treatment1, 2Active Not RecruitingCTRI/2020/05/025215
2020-05-25COVID-19 convalescent plasmaImmediate uses of convalescent covid-19 plasma in the treatment of new infected patients at the first day of hospitalization in a clinical trailTreatment3RecruitingIRCT20200525047562N1
2020-05-25OxygenA Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing ICU admission, Morbidity and Mortality in Adult Patients With COVID-19 - COVID-19-HBOTreatment2Active Not RecruitingDRKS00021626
2020-05-24RuxolitinibA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)Treatment3Active Not RecruitingNCT04377620
2020-05-24IvermectinInterventional study to assess the efficacy of Ivermectin with standard of care treatment versus standard of care in patients of COVID-19 at R D Gardi Medical College, Ujjain, IndiaTreatment2Active Not RecruitingCTRI/2020/05/025224
2020-05-23IloprostInhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory FailureTreatment2Active Not RecruitingNCT04445246
2020-05-23COVID19 s-vax loaded autologous dendritic cell vaccineA safety and immune response trial of novel coronavirus pneumonia (COVID-19) S-Vax loaded autologous dendritic cellsTreatment0RecruitingChiCTR2000034076
2020-05-23Interferon alfaEvaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19Treatment2, 3RecruitingIRCT20161206031256N3
2020-05-23Human interferon betaEvaluation and comparison of the effect of two interferon alpha and beta antiviral drugs on the prognosis of patients with COVID 19Treatment2, 3RecruitingIRCT20161206031256N3
2020-05-22TocilizumabA Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia : the BREATH-19 StudyTreatment2Active Not RecruitingNCT04445272
2020-05-22EnoxaparinIntermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19 : A Pilot Phase II Single-arm Study, INHIXACOVID19Treatment2Active Not RecruitingNCT04427098
2020-05-22PacritinibA Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without CancerTreatment3Active Not RecruitingNCT04404361
2020-05-22MavrilimumabA Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)Treatment2Active Not RecruitingNCT04397497
2020-05-22AzithromycinAzithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19Treatment3Active Not RecruitingNCT04332107
2020-05-22HydroxychloroquinePrevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped-wedge clinical trial by clusters. PREVICHARM Study - PREVICHARMTreatment3Unknown StatusEUCTR2020-002287-31-ES
2020-05-22ZilucoplanA Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory FailureTreatment2Active Not RecruitingNCT04382755
2020-05-21GingerThe effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19 : A randomized double-blind placebo-control clinical trialTreatment3RecruitingIRCT20200506047323N1
2020-05-21LicoriceEvaluation of the effects of Licorice on clinical symptoms and laboratory signs in patients with COVID-19 : An open-label randomized clinical trialTreatment3RecruitingIRCT20200506047323N2
2020-05-21CinnamonComparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19Treatment2, 3Active Not RecruitingIRCT20081011001323N25
2020-05-21Ginger oilComparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19Treatment2, 3Active Not RecruitingIRCT20081011001323N25
2020-05-21Vitamin AThe effect of supplementation with vitamin A on improvement of symptoms of acute respiratory syndrome in patients with COVID-19 : A randomized clinical trialTreatment3RecruitingIRCT20200405046951N1
2020-05-21FilgrastimEvaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000)Treatment1, 2Active Not RecruitingIRCT20200502047268N1
2020-05-21NitazoxanidePrevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With NitazoxanideTreatment4Active Not RecruitingNCT04406246
2020-05-21DexamethasoneHigh Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS : a Multicenter and Randomized Open-label Clinical TrialTreatment3Active Not RecruitingNCT04395105
2020-05-21HydroxychloroquineA Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19TreatmentNot AvailableActive Not RecruitingNCT04392973
2020-05-21FavipiravirA Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19TreatmentNot AvailableActive Not RecruitingNCT04392973
2020-05-21TocilizumabEvaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapyTreatment3Active Not RecruitingIRCT20200510047383N1
2020-05-21CoviGlobulinEvaluation of the efficacy and safety of Rabbit polyclonal antibody (CoviGlobulin) in patients with coronavirus COVID-19 virus moderate to severeTreatment3Active Not RecruitingIRCT20200508047346N1
2020-05-21Propolis waxThe effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19Treatment3Active Not RecruitingIRCT20200326046868N1
2020-05-21HeparinA randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on the duration of mechanical ventilation.Treatment3Active Not RecruitingACTRN12620000517976
2020-05-21IvermectinEffectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020Treatment3RecruitingIRCT20111224008507N3
2020-05-21COVID-19 convalescent plasmaCOVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients : Multicenter Interventional StudyTreatment1Active Not RecruitingNCT04474340
2020-05-20AnakinraSubcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics / Pharmacodynamics study - SCIL-COV19 PK / PD trialTreatment2Active Not RecruitingEUCTR2020-001636-95-GB
2020-05-20HeparinAntithrombotic Therapy to Ameliorate Complications of COVID-19Treatment2, 3Active Not RecruitingNCT04372589
2020-05-20COVID-19 convalescent plasmaDETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19Treatment1, 2Active Not RecruitingNCT04356482
2020-05-20FavipiravirGlasgow Early Treatment Arm FavIpiravir? : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients - GETAFIXTreatment2Active Not RecruitingEUCTR2020-001904-41-GB
2020-05-20COVID-19 convalescent plasmaPlasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind TrialTreatment2Active Not RecruitingNCT04405310
2020-05-20COVID-19 convalescent plasmaConvalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCTTreatment2Active Not RecruitingNCT04403477
2020-05-20MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04399980
2020-05-20OtilimabA randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease. - OSCARTreatment2Active Not RecruitingEUCTR2020-001759-42-GB
2020-05-20VidofludimusA Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care Therapy, in Patients with Coronavirus Disease 19 - CALVID-1Treatment2Active Not RecruitingEUCTR2020-001264-28-GR
2020-05-20LiothyronineTriiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) - Thy-Support STUDYTreatment2Active Not RecruitingEUCTR2020-001623-13-GR
2020-05-20AprotininA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20NadroparinA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20EnoxaparinA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20AnakinraA randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. - DAWN AntiCoTreatment2Active Not RecruitingEUCTR2020-001739-28-BE
2020-05-20AcetaminophenEvaluation of the effect of 0.002% sodium chloride saline (activated) administered intravenously and / or mists in patients with covid-19. (COVID-19) - TX-COVID19Treatment1, 2Active Not RecruitingRPCEC00000309
2020-05-20BrensocatibA randomised double-blind placebo-controlled trial of brensocatib (INS1007) in patients with severe COVID-19Treatment3Active Not RecruitingISRCTN30564012
2020-05-20BaricitinibBARICIVID-19 STUDY : MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard TherapyTreatment2Active Not RecruitingNCT04393051
2020-05-20AtorvastatinProspective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19Treatment2Active Not RecruitingNCT04380402
2020-05-20EthanolEvaluation of Shift, a smartphone application for New South Wales Junior Medical Officers, on depression and anxiety during the COVID-19 epidemic.Treatment1Active Not RecruitingACTRN12620000571976
2020-05-20CoronaVacA Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged =60 YearsPrevention1, 2Active Not RecruitingNCT04383574
2020-05-20FavipiravirA Randomized, Open-label, multicenter study to evaluate the efficacy and safety of Favipiravir combined with STANDARD supportive care in adult Indian patients with mild to moderate COVID-19Treatment3CompletedCTRI/2020/05/025114
2020-05-20SeleniumThe effect of addition of selenium to treatment regimen of hospitalized patients with COVID-19 on the outcome of disease compared with control groupTreatment2Active Not RecruitingIRCT20160706028815N5
2020-05-20COVID-19 convalescent plasmaExchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19Treatment2Active Not RecruitingNCT04376788
2020-05-20Methylene blueExchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19Treatment2Active Not RecruitingNCT04376788
2020-05-20LevamisoleImpact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19Prevention3Active Not RecruitingNCT04360122
2020-05-20Inosine pranobexImpact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19Prevention3Active Not RecruitingNCT04360122
2020-05-20HydroxychloroquineEffectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers : The COVID-SHIELD TrialTreatment2, 3Active Not RecruitingACTRN12620000501943
2020-05-20MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04492514
2020-05-20COVID-19 convalescent plasmaAN OPEN LABEL RANDOMISED CONTROL TRIAL ON PASSIVE IMMUNIZATION WITH CONVALESCENT PLASMA IN SEVERE COVID-19 DISEASE - PICP19Treatment2Active Not RecruitingCTRI/2020/05/025209
2020-05-20Dotatate gallium Ga-68[68Ga]Ga-DOTA-(RGD)2 PET / CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. - RDG-PET / CT imaging in COVID-19 patients.Treatment2Active Not RecruitingEUCTR2020-001325-31-NL
2020-05-19AzithromycinEvaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unitTreatment3RecruitingIRCT20200428047228N2
2020-05-19HydroxychloroquineEvaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unitTreatment3RecruitingIRCT20200428047228N2
2020-05-19TelmisartanTelmisartan for Treatment of COVID-19 Patients : an Open Label Randomized TrialTreatment2Active Not RecruitingNCT04355936
2020-05-19CholecalciferolVitamin D Testing and Treatment for Adults With COVID 19Treatment1Active Not RecruitingNCT04407286
2020-05-19AnakinraAn open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOVTreatment3Active Not RecruitingEUCTR2020-001754-21-FR
2020-05-19RuxolitinibAn open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOVTreatment3Active Not RecruitingEUCTR2020-001754-21-FR
2020-05-19TocilizumabAn open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOVTreatment3Active Not RecruitingEUCTR2020-001754-21-FR
2020-05-19HydroxychloroquineSafety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care : A Double-blind Randomized Control TrialPrevention3Active Not RecruitingNCT04397328
2020-05-19CholecalciferolUsefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias - Vitamin D and COVID-19Treatment4Unknown StatusEUCTR2020-002274-28-ES
2020-05-19PiperaquineA clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patientsTreatment4Active Not RecruitingChiCTR2000033049
2020-05-19ArtemisininA clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patientsTreatment4Active Not RecruitingChiCTR2000033049
2020-05-19HydroxychloroquineEvaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19Treatment3Active Not RecruitingIRCT20200428047228N1
2020-05-19FavipiravirEvaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19Treatment3Active Not RecruitingIRCT20200428047228N1
2020-05-19CurcuminEvaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19 : An open label non-randomized clinical trialTreatment3Active Not RecruitingIRCT20200408046990N1
2020-05-18BudesonideA Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of SeverityTreatment3Active Not RecruitingNCT04361474
2020-05-18Dornase alfaAerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trialTreatment2Active Not RecruitingEUCTR2020-001849-39-SE
2020-05-18IvermectinA Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19Treatment2Active Not RecruitingNCT04381884
2020-05-18Glycyrrhiza glabraObservational Study of YASHTIMADHU TABLET intake as a preventive measure in pandemic of COVID-19 â?? An open label, Randomized, Controlled, Prospective, interventional, Community-based Cclinical study on healthy subjectsTreatment2, 3Active Not RecruitingCTRI/2020/05/025093
2020-05-18Ascorbic acidTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-05-18CholecalciferolTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-05-18Zinc citrateTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-05-18MecobalaminTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-05-18AzithromycinTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-05-18HydroxychloroquineTherapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial : The International ALLIANCE StudyTreatmentNot AvailableActive Not RecruitingACTRN12620000557932
2020-05-18SelinexorA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 InfectionTreatment2Active Not RecruitingEUCTR2020-001411-25-DE
2020-05-16CurcuminEvaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19Treatment3RecruitingIRCT20080901001165N56
2020-05-16ResveratrolEvaluation efficacy of "Curcumin and Resveratrol" capsule in controlling symptoms in patients with COVID-19Treatment3RecruitingIRCT20080901001165N56
2020-05-16BromhexineOpen Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalizationTreatment3Active Not RecruitingNCT04424134
2020-05-16SpironolactoneOpen Label Randomized Clinical Trial BromhexIne And Spironolactone For Coron?VirUs Infection Requiring HospiTalizationTreatment3Active Not RecruitingNCT04424134
2020-05-16Gemtuzumab ozogamicinA randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.Treatment2Active Not RecruitingISRCTN40580903
2020-05-16TurmericEvaluation of the Immuno-stimulatory(Shareera Bala) potential of Ayurveda management protocol in Cohort of Delhi Police - An Exploratory clinical Study - EBAMDTreatment2Active Not RecruitingCTRI/2020/05/025171
2020-05-16BaricitinibBaricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19 : an Open-label, Pilot StudyTreatment2, 3Active Not RecruitingNCT04320277
2020-05-15COVID-19 convalescent plasmaEffectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress SyndromeTreatmentNot AvailableActive Not RecruitingNCT04442958
2020-05-15MethylprednisoloneTreatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled TrialTreatment3Active Not RecruitingNCT04438980
2020-05-15HydroxychloroquinePrevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. A Cluster Randomized Controlled Stepped-wedge Trial (PREVICHARM Study)Prevention2, 3Active Not RecruitingNCT04400019
2020-05-15Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)A Randomized, Double-blind, Placebo-controlled, Phase Ia / IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 YearsPrevention1, 2Active Not RecruitingNCT04412538
2020-05-15AviptadilIntravenous Aviptadil for Critical COVID-19 With Respiratory FailureTreatment2Active Not RecruitingNCT04311697
2020-05-15IvermectinMulticenter, randomized, double-blind, placebo-controlled study investigating efficacy, safety and tolerability of ivermectin HUVE-19 in patients with proven SARS-CoV-2 infection (COVID-19) and manifested clinical symptoms.Treatment2Active Not RecruitingEUCTR2020-002091-12-BG
2020-05-15BaricitinibA proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related PneumoniaTreatment2Active Not RecruitingNCT04399798
2020-05-15V-SARSClinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral PillTreatment1, 2Active Not RecruitingNCT04380532
2020-05-15Chloride ionHypernatremia in critically ill patients with Covid-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021611
2020-05-15UreaHypernatremia in critically ill patients with Covid-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021611
2020-05-15PotassiumHypernatremia in critically ill patients with Covid-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021611
2020-05-15LopinavirRetrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)Basic ScienceNot AvailableActive Not RecruitingNCT04275388
2020-05-15RitonavirRetrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)Basic ScienceNot AvailableActive Not RecruitingNCT04275388
2020-05-15HydroxychloroquineControlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-19). - Sanitarios sin COVID -SANsinCOVID-Treatment4Unknown StatusEUCTR2020-001704-42-ES
2020-05-15TocilizumabA multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia : the BREATH-19 StudyTreatment2Unknown StatusEUCTR2020-001995-13-ES
2020-05-15RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-IE
2020-05-15VidofludimusProspective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel CoronavirusTreatment2Active Not RecruitingEUCTR2020-001805-21-GB
2020-05-15OseltamivirProspective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 - IONIC study -IMU838 and Oseltamivir in treatment of Novel CoronavirusTreatment2Active Not RecruitingEUCTR2020-001805-21-GB
2020-05-15BrensocatibA randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 - STOP-COVID19 : Superiority Trial Of Protease inhibition in COVID-19Treatment3Active Not RecruitingEUCTR2020-001643-13-GB
2020-05-15HydroxychloroquinePreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Active Not RecruitingNCT04386070
2020-05-15LopinavirPreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Active Not RecruitingNCT04386070
2020-05-15RitonavirPreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Prevention3Active Not RecruitingNCT04386070
2020-05-15COVID-19 convalescent plasmaRandomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity CriteriaTreatmentNot AvailableActive Not RecruitingNCT04383535
2020-05-15CiclesonideInhalation of Ciclesonide for Patients With COVID-19 : A Randomised Open Treatment Study (HALT COVID-19)Treatment2Active Not RecruitingNCT04381364
2020-05-15NiclosamideEFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES : AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024949
2020-05-15CiclesonideEFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024948
2020-05-15HydroxychloroquineEFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024948
2020-05-15IvermectinEFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS : AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVIDTreatment2Active Not RecruitingCTRI/2020/04/024948
2020-05-15HeparinA Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-DimerTreatment2Active Not RecruitingNCT04377997
2020-05-15EnoxaparinA Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-DimerTreatment2Active Not RecruitingNCT04377997
2020-05-15HydroxychloroquineEfficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure : Randomised Control TrialPreventionNot AvailableActive Not RecruitingNCT04370015
2020-05-15LinagliptinEfficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19Treatment3Active Not RecruitingNCT04371978
2020-05-14MethylprednisoloneSteroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectioTreatment3Unknown StatusEUCTR2020-001921-30-IT
2020-05-14HeparinSteroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. - Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infectioTreatment3Unknown StatusEUCTR2020-001921-30-IT
2020-05-14HydroxychloroquineAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14FavipiravirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14DarunavirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14RitonavirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14LopinavirAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals - -Treatment3Unknown StatusEUCTR2020-001528-32-IT
2020-05-14HydroxychloroquineRandomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 InfectionPrevention3Active Not RecruitingNCT04372017
2020-05-14HydroxychloroquinePROTECT : A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04363827
2020-05-14AlteplaseFibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection : A Phase 2a Clinical TrialTreatment2Active Not RecruitingNCT04357730
2020-05-14COVID-19 convalescent plasmaA Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)Treatment3Active Not RecruitingNCT04348656
2020-05-14BromhexinePrevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease : a Randomised Controlled TrialPrevention4Active Not RecruitingNCT04405999
2020-05-14TocilizumabA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04372186
2020-05-14IvermectinPilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 TransmissionTreatment2Active Not RecruitingNCT04390022
2020-05-14EnoxaparinEnoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients : Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical TrialTreatment3Active Not RecruitingNCT04366960
2020-05-14FT516Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With HypoxiaTreatment1Active Not RecruitingNCT04363346
2020-05-14Interleukin-7A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UKTreatment2Active Not RecruitingNCT04379076
2020-05-14Interferon beta-1aInvestigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19Treatment3Active Not RecruitingIRCT20080901001165N53
2020-05-14COVID-19 convalescent plasmaEffect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19 : a randomized clinical trialTreatment2Active Not RecruitingIRCT20120215009014N353
2020-05-14COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Patients With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04372368
2020-05-14Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19Prevention2Active Not RecruitingNCT04348435
2020-05-13HydroxychloroquineA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of Covid-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13IvermectinA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of Covid-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13Ascorbic acidA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of Covid-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13ZincA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of Covid-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13Povidone-iodineA Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of Covid-19 (DORM Trial)Prevention3Active Not RecruitingNCT04446104
2020-05-13AcetylcysteineInvestigating the efficacy and safety of N-Acetyl Cysteine (NAC) inhalation spray in controlling the symptoms of patients with COVID-19Treatment3RecruitingIRCT20080901001165N55
2020-05-13BarleyInvestigating the effect of barely-based traditional remedy on controlling of clinical symptoms and paraclinical results in hospitalized patients with COVID-19Treatment3RecruitingIRCT20180923041093N6
2020-05-13HydroxychloroquineHydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During PregnancyTreatment3Active Not RecruitingNCT04410562
2020-05-13COVID-19 convalescent plasmaAn Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.Treatment1Active Not RecruitingNCT04397757
2020-05-13NitazoxanideA Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare WorkersPrevention3Active Not RecruitingNCT04359680
2020-05-13HydroxychloroquineAzithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled TrialTreatment3Active Not RecruitingNCT04339816
2020-05-13AzithromycinAzithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled TrialTreatment3Active Not RecruitingNCT04339816
2020-05-13CYNK-001A Phase I / II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19Treatment1, 2Active Not RecruitingNCT04365101
2020-05-13VPM1002A phase III, double-blind, randomized, placebo-controlled multicentre clinical trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals’ absenteeism in the SARS-CoV-2 pandemic by modulating the immune systemTreatment3Active Not RecruitingEUCTR2020-001376-15-DE
2020-05-13Human Umbilical Cord Mesenchymal Stem CellsA Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19Treatment1, 2Active Not RecruitingNCT04390139
2020-05-13EnoxaparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13NadroparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13DalteparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13HeparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13TinzaparinEffectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSEPrevention4Active Not RecruitingNCT04373707
2020-05-13PrazosinAlpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome : A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 InfectionTreatment2Active Not RecruitingNCT04365257
2020-05-13Peginterferon lambda-1aInterferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD) : A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19Treatment2Active Not RecruitingNCT04354259
2020-05-13Arsenic trioxideEFFECTIVENESS OF ARSENICUM ALBUM 30C IN PREVENTION OF COVID-19 IN INDIVIDUALS RESIDING IN HOSPOTS OF RED ZONES IN DELHIâ?? A PROSPECTIVE COHORT STUDYTreatmentNot AvailableActive Not RecruitingCTRI/2020/05/024986
2020-05-13COVID-19 convalescent plasmaConvalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infectionsTreatmentNot AvailableActive Not RecruitingNL8633
2020-05-12HydroxychloroquinePragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19Treatment4Active Not RecruitingNCT04466540
2020-05-12IvermectinIvermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04429711
2020-05-12MelatoninEvaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 PatientsTreatmentNot AvailableActive Not RecruitingNCT04409522
2020-05-12FamotidineFamotidine Use in Non-hospitalized Patients With COVID-19 : A Case SeriesBasic ScienceNot AvailableActive Not RecruitingNCT04389567
2020-05-12PlitidepsinMulticenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring HospitalizationTreatment1Active Not RecruitingNCT04382066
2020-05-12NitazoxanideA Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)Prevention3Active Not RecruitingNCT04343248
2020-05-12RavulizumabA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingEUCTR2020-001497-30-FR
2020-05-12AnakinraInterleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOVTreatment3Active Not RecruitingEUCTR2020-001963-10-FR
2020-05-12RuxolitinibInterleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation : Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib - JAKINCOVTreatment3Active Not RecruitingEUCTR2020-001963-10-FR
2020-05-12AzithromycinRandomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological MalignanciesTreatment2Active Not RecruitingNCT04392128
2020-05-12HydroxychloroquineRandomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological MalignanciesTreatment2Active Not RecruitingNCT04392128
2020-05-12Nitric OxidePrevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.Treatment2Active Not RecruitingNCT04388683
2020-05-12Hydroxychloroquine#StayHome : Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland : A Double-blind, Randomised, Placebo-controlled TrialTreatment2, 3Active Not RecruitingNCT04385264
2020-05-12Human Umbilical Cord Mesenchymal Stem CellsAssessment of safety, efficacy and effective dose determination of human umbilical cord Wharton’s jelly mesenchymal stem cell transplantation on treatment of COVID-19 (coronavirus) pneumonia and complications in humansTreatment2, 3RecruitingIRCT20200421047150N1
2020-05-12COVID-19 convalescent plasmaThe Effect of Convalescent Plasma Therapy on the Outcomes of Patients with 19-COVIDTreatment1, 2Active Not RecruitingIRCT20150808023559N21
2020-05-12NomacopanAGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILETreatment1Active Not RecruitingEUCTR2020-001860-27-GB
2020-05-12EIDD-2801AGILE : Seamless Phase I / IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment - AGILETreatment1Active Not RecruitingEUCTR2020-001860-27-GB
2020-05-11AZD1222A phase II / III study to determine the efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19Treatment2, 3Active Not RecruitingISRCTN90906759
2020-05-11Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem CellsTreatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem CellsTreatment1, 2Active Not RecruitingNCT04382547
2020-05-11COVID-19 convalescent plasmaSevere Reluctant COVID-19 Patients Responding to Convalescent Plasma ; A case seriesTreatmentNot AvailableActive Not RecruitingChiCTR2000033323
2020-05-11EnoxaparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11DalteparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11HeparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11TinzaparinCoagulopathy of COVID-19 : A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)Treatment3Active Not RecruitingNCT04362085
2020-05-11COVID-19 convalescent plasmaAn Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 InfectionTreatment2Active Not RecruitingNCT04354831
2020-05-11HydroxychloroquineChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)Prevention3Active Not RecruitingNCT04352933
2020-05-11BromhexineLow-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)Prevention1Active Not RecruitingNCT04340349
2020-05-11HydroxychloroquineLow-dose Hydroxychloroquine and Bromhexine : a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)Prevention1Active Not RecruitingNCT04340349
2020-05-11BCG vaccineRandomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care WorkersPrevention3Active Not RecruitingNCT04384549
2020-05-11COVID-19 convalescent plasmaEffectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in IndonesiaTreatment2, 3Active Not RecruitingNCT04380935
2020-05-11HydroxychloroquineRandomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZESTreatment3Active Not RecruitingCTRI/2020/04/024904
2020-05-11AzithromycinRandomised Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19 - HAZESTreatment3Active Not RecruitingCTRI/2020/04/024904
2020-05-11COVID-19 convalescent plasmaOpen Label, parallel arm, phase I / II clinical trial to evaluate Safety and efficacy of Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 DiseaseTreatment1, 2Active Not RecruitingCTRI/2020/04/024804
2020-05-11RavulizumabA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingNCT04369469
2020-05-11RamiprilA Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19Treatment2Active Not RecruitingNCT04366050
2020-05-11HydroxychloroquineEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-05-11LopinavirEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-05-11AzithromycinEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-05-11RitonavirEffectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia : A Pragmatic Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04359095
2020-05-10Angiotensin IIPrognosis of SARS-Cov 2 Positive Patients Receiving Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Antagonists (ARBs)Basic ScienceNot AvailableActive Not RecruitingNCT04357535
2020-05-10COVID-19 convalescent plasmaInvestigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration : IMPACTTreatment2, 3RecruitingISRCTN85216856
2020-05-09Human immunoglobulin GIntravenous immunoglubolin (IVIG) effect on improvement of severe pulmonary damage in COVID 19 diseaseTreatment3Active Not RecruitingIRCT20200501047259N1
2020-05-09COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated ComplicationsTreatment2Active Not RecruitingCTRI/2020/04/024915
2020-05-09DoxycyclineStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09Ascorbic acidStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09AzithromycinStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09MetforminStudy of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19Treatment3Active Not RecruitingIRCT20200418047121N1
2020-05-09Remestemcel-LInvestigation the adipose and placenta-derived mesenchymal stem cells effect on the respiratory distress syndrome in patients with COVID-19 : a pilot studyTreatment1, 2Active Not RecruitingIRCT20200418047121N2
2020-05-09COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated ComplicationsTreatment2Active Not RecruitingNCT04374487
2020-05-09ThalidomideEffectiveness and safety of thalidomide in moderate COVID-19 pneumonia : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200428047232N1
2020-05-08AnakinraClinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2 / 3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 InfectionTreatment2, 3Active Not RecruitingNCT04443881
2020-05-08ChloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare settingTreatment3Unknown StatusEUCTR2020-001441-39-IT
2020-05-08HydroxychloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV - Study of COVID-19 and Chloroquine / hydroxychloroquine in healthcare settingTreatment3Unknown StatusEUCTR2020-001441-39-IT
2020-05-08HydroxychloroquineAn Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19Treatment3Active Not RecruitingNCT04411433
2020-05-08AzithromycinAn Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19Treatment3Active Not RecruitingNCT04411433
2020-05-08FavipiravirAn Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19Treatment3Active Not RecruitingNCT04411433
2020-05-08BaricitinibA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)Treatment3Active Not RecruitingNCT04401579
2020-05-08RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-II)Treatment3Active Not RecruitingNCT04401579
2020-05-08ArtemisininA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08CurcuminA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08Ascorbic acidA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08Indian frankincenseA Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19Treatment2Active Not RecruitingNCT04382040
2020-05-08VerapamilAmiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIOTreatment3Active Not RecruitingEUCTR2020-001951-42-PL
2020-05-08AmiodaroneAmiodarone or Verapamil in COVID-19 hospitalized patients with symptoms : Randomized clinical trial - ReCOVery-SIRIOTreatment3Active Not RecruitingEUCTR2020-001951-42-PL
2020-05-08TocilizumabSafety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers : a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)Treatment3Active Not RecruitingNCT04403685
2020-05-08ColchicineCOLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialTreatment2Active Not RecruitingNCT04403243
2020-05-08SecukinumabCOLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialTreatment2Active Not RecruitingNCT04403243
2020-05-08RuxolitinibCOLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized TrialTreatment2Active Not RecruitingNCT04403243
2020-05-08BaricitinibmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Treatment4Active Not RecruitingNCT04390464
2020-05-08RavulizumabmulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)Treatment4Active Not RecruitingNCT04390464
2020-05-08IvermectinNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08NitazoxanideNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08ChloroquineNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08AzithromycinNovel Treatment Regimens in Treatment of COVID-19Treatment3Active Not RecruitingNCT04382846
2020-05-08EtoposideA Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 InfectionSupportive Care2Active Not RecruitingNCT04356690
2020-05-08Nitric OxideMulti-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of InfectionPrevention2Active Not RecruitingNCT04337918
2020-05-08IndomethacinEfficacy and safety of oral indomethacin for treatment of covid 19 induced pneumoniaTreatment2, 3Active Not RecruitingIRCT20200427047215N1
2020-05-08COVID-19 convalescent plasmaPhase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 InfectionTreatment1Active Not RecruitingNCT04333355
2020-05-08Alpha-1-proteinase inhibitorA Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19.Treatment2Active Not RecruitingEUCTR2020-001953-36-ES
2020-05-08Human immunoglobulin GA Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Patients with Mild / Moderate COVID19Treatment2Active Not RecruitingEUCTR2020-001696-32-ES
2020-05-08Washed Microbiota TransplantationClinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosisTreatment0Active Not RecruitingChiCTR2000032737
2020-05-07MavrilimumabA randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation : the COMBAT-19 trial - Mavrilimumab in COVID-19 pneumonia with hyperinflammationTreatment2Unknown StatusEUCTR2020-001795-15-IT
2020-05-07HydroxychloroquineHydroxychloroquine Use in Hospitalized Patients With COVID-19 : Impact on Progression to Severe or Critical DiseaseTreatment4Active Not RecruitingNCT04429867
2020-05-07RavulizumabCOVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingEUCTR2020-001497-30-GB
2020-05-07COVID-19 convalescent plasmaConvalescent Plasma for Treatment of COVID-19 : An Exploratory Dose Identifying StudyTreatment1, 2Active Not RecruitingNCT04384497
2020-05-07BaricitinibmulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R)Treatment4RecruitingISRCTN11188345
2020-05-07RavulizumabmulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R)Treatment4RecruitingISRCTN11188345
2020-05-07ClazakizumabA Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2Active Not RecruitingNCT04363502
2020-05-07HydroxychloroquineA Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)Prevention2Active Not RecruitingNCT04381988
2020-05-07Remestemcel-LPhase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19Treatment2Active Not RecruitingNCT04366271
2020-05-07PiperaquineA randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and AbidorTreatment4RecruitingChiCTR2000032915
2020-05-07ArtemisininA randomized controlled trial for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and AbidorTreatment4RecruitingChiCTR2000032915
2020-05-07IvermectinPilot study to evaluate the potential of ivermectin to reduce COVID-19 transmissionTreatment2Unknown StatusEUCTR2020-001474-29-ES
2020-05-07HydroxychloroquineRANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDYTreatment4Unknown StatusEUCTR2020-002123-11-ES
2020-05-07CyclosporineRANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDYTreatment4Unknown StatusEUCTR2020-002123-11-ES
2020-05-07MethylprednisoloneUSE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTIONTreatment4Unknown StatusEUCTR2020-001934-37-ES
2020-05-07ClarithromycinANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY : THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIALTreatment2Active Not RecruitingEUCTR2020-001882-36-GR
2020-05-07AzithromycinA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07LopinavirA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07RitonavirA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-07HydroxychloroquineA Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome : a Strategy to Prevent HospitalizationTreatment3Active Not RecruitingNCT04365582
2020-05-06HydroxychloroquinePRECOV : a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk - PRECOVTreatment3Unknown StatusEUCTR2020-001987-28-IT
2020-05-06DefibrotideUse of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia - Defibrotide in COVID19Treatment2Unknown StatusEUCTR2020-001513-20-IT
2020-05-06ClarithromycinAnti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early : The ACHIEVE Open-label Non-randomized Clinical TrialPrevention2Active Not RecruitingNCT04398004
2020-05-06IloprostEfficacy and safety of 72-hour infusion of Prostacyclin (1 ng / kg / min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initiated trialTreatment2Active Not RecruitingEUCTR2020-001296-33-DK
2020-05-06ABX-464A phase 2 / 3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure in patients aged = 65 and patients aged =18 with at least one additional risk factor who are infected with SARS-CoV-2. (the MiR-AGE study).Treatment2Active Not RecruitingEUCTR2020-001673-75-FR
2020-05-06AcalabrutinibA Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 - CALAVITreatment2Active Not RecruitingEUCTR2020-001644-25-FR
2020-05-06COVID-19 convalescent plasmaEfficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled TrialTreatment3Active Not RecruitingNCT04381858
2020-05-06Human immunoglobulin GEfficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia : A Randomized Controlled TrialTreatment3Active Not RecruitingNCT04381858
2020-05-06ClevudineA Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19Treatment2Active Not RecruitingNCT04347915
2020-05-06HydroxychloroquineAn open label randomised controlled trial to assess the efficacy of Hydroxychloroquine in patients with mild COVID -19 illness with risk factors for severe disease.Treatment2Active Not RecruitingCTRI/2020/05/025022
2020-05-06BCG vaccinePhase 2 Clinical Trial for the Evaluation of BCG as potential therapy for CoVID-I9 - COVID-19 BCGTreatment2Active Not RecruitingCTRI/2020/05/025013
2020-05-06EnoxaparinCOVID-19-associated Coagulopathy : Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19Treatment4Active Not RecruitingNCT04360824
2020-05-06IvermectinRamdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19Treatment3Unknown StatusEUCTR2020-001994-66-ES
2020-05-06ColchicineA RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) - COLCHI-COVIDTreatment3Unknown StatusEUCTR2020-001603-16-ES
2020-05-06RuxolitinibRuxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN - RAVENTreatment4Active Not RecruitingEUCTR2020-001777-71-GB
2020-05-06BCG vaccineREDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION - BACH (BCG Against COVID-19 in HungaTreatment3Active Not RecruitingEUCTR2020-001783-28-HU
2020-05-06Interleukin-7Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial” - ILIADTreatment2Active Not RecruitingEUCTR2020-001786-36-GB
2020-05-06CaptoprilEfficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia. A randomized phase II study - CAPTOCOVIDTreatment2Active Not RecruitingEUCTR2020-001700-42-FR
2020-05-05COVID-19 convalescent plasmaInfusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19) : A Double-blinded, Placebo-controlled, Proof-of-concept StudyTreatment2Active Not RecruitingNCT04442191
2020-05-05Inosine pranobexThe Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic TrialTreatment3Active Not RecruitingNCT04383717
2020-05-05LevamisoleThe Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19 : A Proposed Therapeutic TrialTreatment3Active Not RecruitingNCT04383717
2020-05-05HydroxychloroquineAssessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisiaTreatment4Active Not RecruitingNCT04351919
2020-05-05AzithromycinAssessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisiaTreatment4Active Not RecruitingNCT04351919
2020-05-05COVID-19 convalescent plasmaEfficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications : A Phase II TrialTreatment2Active Not RecruitingNCT04374565
2020-05-05TocilizumabA Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg / kg or 4mg / kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04363736
2020-05-05RuxolitinibPhase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) - RUXCOVIDTreatment3Active Not RecruitingEUCTR2020-001662-11-DE
2020-05-05Human immunoglobulin G"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19Treatment2Active Not RecruitingNCT04403269
2020-05-05NamilumabCATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19Treatment2Active Not RecruitingEUCTR2020-001684-89-GB
2020-05-05InfliximabCATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19Treatment2Active Not RecruitingEUCTR2020-001684-89-GB
2020-05-05Gemtuzumab ozogamicinCATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19Treatment2Active Not RecruitingEUCTR2020-001684-89-GB
2020-05-05COVID-19 convalescent plasmaA Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 InfectionTreatment2Active Not RecruitingNCT04392232
2020-05-05LeflunomideLeflunomide for the Treatment of Ambulatory Patients With Mild COVID-19Treatment1Active Not RecruitingNCT04361214
2020-05-05RemdesivirMulticenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.Basic ScienceNot AvailableActive Not RecruitingNCT04365725
2020-05-05HydroxychloroquineSingle-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) InfectionTreatment2Active Not RecruitingNCT04379492
2020-05-05LidocaineUsage of topical lignocaine to decrease the gag reflex while sampling for Covid-19 : Does it affect the yield of specimen?TreatmentNot AvailableActive Not RecruitingCTRI/2020/05/024983
2020-05-05Povidone-iodineEffectiveness of topical povidone iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic amongst COVID-19 positive patients in Andhra Pradesh, IndiaTreatmentNot AvailableActive Not RecruitingCTRI/2020/05/024962
2020-05-05HydroxychloroquineRCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without AntibioticsTreatment2Active Not RecruitingNCT04374552
2020-05-05AzithromycinRCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without AntibioticsTreatment2Active Not RecruitingNCT04374552
2020-05-05AzithromycinA multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) - ATOMIC2, Version 1.0Treatment2Active Not RecruitingEUCTR2020-001740-26-GB
2020-05-05CaptoprilEfficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II StudyTreatment2Active Not RecruitingNCT04355429
2020-05-05FilgrastimTreatment of lung lesions with autologous stem cells in patients recovered from COVID-19 (COVID-19)TreatmentNot AvailableRecruitingRPCEC00000322
2020-05-04TocilizumabUnicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19Treatment2Active Not RecruitingNCT04435717
2020-05-04Vitamin AAssessment of vitamin A effectiveness on COVID-19 patients and treatment outcomes referred to health centers of Qom provinceTreatment3Active Not RecruitingIRCT20200314046774N1
2020-05-04TranilastAssessment of the effect of Tranilast on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19Treatment3Active Not RecruitingIRCT20200419047128N1
2020-05-04HydroxychloroquineEfficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled TrialTreatment3Active Not RecruitingNCT04391127
2020-05-04IvermectinEfficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection : Randomized Controlled TrialTreatment3Active Not RecruitingNCT04391127
2020-05-04Interferon alfa-2bPharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19).Treatment1CompletedRPCEC00000308
2020-05-04Ascorbic acidEffect of high dose intravenous vitamin C on moderate novel coronavirus pneumonia (COVID-19) patients : a medical records based retrospective studyBasic ScienceNot AvailableRecruitingChiCTR2000033050
2020-05-04COVID-19 convalescent plasmaThe Use of Convalescent Plasma for Patients Hospitalized With COVID-19 DiseaseTreatment2Active Not RecruitingNCT04385199
2020-05-04CamphorProving the efficacy of Homeopathic treatment in prevention and cure of COVID-19.Treatment1, 2Active Not RecruitingCTRI/2020/04/024857
2020-05-04HydroxychloroquineHydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel : a placebo-controlled, randomized, clinical trialTreatment4Active Not RecruitingSLCTR/2020/011
2020-05-04ColchicineEvaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19Treatment3RecruitingIRCT20200418047126N1
2020-05-04COVID-19 convalescent plasmaInvestigation of the effects of COVID-19 convalescent plasma in acute respiratory distress syndrome due to COVID-19Treatment2, 3Active Not RecruitingIRCT20200501047258N1
2020-05-04CurcuminEffect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial studyTreatmentNot AvailableActive Not RecruitingIRCT20121216011763N46
2020-05-04PiperineEffect of curcumin-piperine supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus(COVID-19) : A randomized, double-blind, placebo-controlled clinical trial studyTreatmentNot AvailableActive Not RecruitingIRCT20121216011763N46
2020-05-04DeferiproneInvestigating the effect of Deferiprone on the improvement of symptoms of Coronavirus 2019 (COVID 19)Treatment3Active Not RecruitingIRCT20180114038350N3
2020-05-04SitagliptinEvaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19Treatment2, 3Active Not RecruitingIRCT20200420047147N1
2020-05-04TrifluoperazineEvaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 PatientsTreatment2, 3Active Not RecruitingIRCT20200329046892N1
2020-05-04SugarcaneEffect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of COVID-19 diseaseTreatment2, 3Active Not RecruitingIRCT20200415047082N1
2020-05-04COVID-19 convalescent plasmaEfficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patientsTreatment2, 3Active Not RecruitingIRCT20200406046968N2
2020-05-04IvermectinDose-Finding study of Ivermectin treatment on patients infected with Covid-19 : A clinical trialTreatment3Active Not RecruitingIRCT20200408046987N1
2020-05-04LevamisoleAssessment of effect of levamisole on pneumonia caused by COVID-19Treatment4Active Not RecruitingIRCT20131215015805N2
2020-05-04BCG vaccineReducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled TrialPrevention3Active Not RecruitingNCT04379336
2020-05-04HydroxychloroquineA Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)Prevention3Active Not RecruitingNCT04377646
2020-05-04ZincA Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)Prevention3Active Not RecruitingNCT04377646
2020-05-04COVID-19 convalescent plasmaEfficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection : a Randomized Phase II TrialTreatment2Active Not RecruitingNCT04375098
2020-05-04C-reactive proteinTriage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19 : A Prospective Cohort StudyBasic ScienceNot AvailableActive Not RecruitingNCT04373798
2020-05-04TocilizumabAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized StudyTreatment3Active Not RecruitingNCT04361032
2020-05-04DeferoxamineAssessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized StudyTreatment3Active Not RecruitingNCT04361032
2020-05-04TocilizumabSingle-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19Treatment2Unknown StatusEUCTR2020-002032-69-ES
2020-05-04EnoxaparinImpact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2Treatment2Unknown StatusEUCTR2020-001891-14-ES
2020-05-04AZD1222A phase 2 / 3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 - Investigating a Vaccine Against COVID-19 (COV002)Treatment2Active Not RecruitingEUCTR2020-001228-32-GB
2020-05-04COVID-19 convalescent plasmaA Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVERTreatment2Active Not RecruitingEUCTR2020-001632-10-DE
2020-05-04Poractant alfaPreliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1Treatment2Active Not RecruitingEUCTR2020-001598-66-FR
2020-05-04IsoquercetinA Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.Treatment2Active Not RecruitingEUCTR2020-001635-27-FR
2020-05-04HydroxychloroquineA Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.Treatment2Active Not RecruitingEUCTR2020-001635-27-FR
2020-05-04MasitinibA Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.Treatment2Active Not RecruitingEUCTR2020-001635-27-FR
2020-05-03DipyridamoleA Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 PatientsTreatment2Active Not RecruitingNCT04424901
2020-05-03Basic Fibroblast Growth FactorIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Interleukin-10Identification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Interleukin-1 alpha, human recombinantIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-03Human interferon betaIdentification of predictive biomarkers for severe progression of COVID-19Basic ScienceNot AvailableActive Not RecruitingDRKS00021591
2020-05-02Placental Mesenchymal Stem CellsTreatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical CordTreatment1, 2Active Not RecruitingNCT04461925
2020-05-02Human Umbilical Cord Mesenchymal Stem CellsTreatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical CordTreatment1, 2Active Not RecruitingNCT04461925
2020-05-02COVID-19 convalescent plasmaA Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19 : DAWN-PLASMATreatment2Active Not RecruitingNCT04429854
2020-05-02HeparinIntermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID)Treatment4Active Not RecruitingNCT04367831
2020-05-02EnoxaparinIntermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 : A Cluster Based Randomized Selection Trial (IMPROVE-COVID)Treatment4Active Not RecruitingNCT04367831
2020-05-02Lithium carbonateClinical trial of lithium in improving the clinical and laboratory symptoms of patients with COVID-19Treatment2Active Not RecruitingIRCT20081019001369N5
2020-05-02AzithromycinEfficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVIDTreatment3Active Not RecruitingNCT04371406
2020-05-02HydroxychloroquineEfficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients : Randomized Controlled Trial : MG-COVIDTreatment3Active Not RecruitingNCT04371406
2020-05-01Remestemcel-LProspective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)Treatment2Active Not RecruitingNCT04444271
2020-05-01Remestemcel-LMesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot StudyTreatment2Active Not RecruitingNCT04416139
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma Therapy in Patients With COVID-19Health Services Research1Active Not RecruitingNCT04407208
2020-05-01COVID-19 convalescent plasmaRandomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 DiseaseTreatment2Active Not RecruitingNCT04392414
2020-05-01IbuprofenExtended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.TreatmentNot AvailableActive Not RecruitingNCT04382768
2020-05-01CalciumEvaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia : A Single Center Experience in TurkeyBasic ScienceNot AvailableActive Not RecruitingNCT04379310
2020-05-01AcetylcysteinePhase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 InfectionTreatment2Active Not RecruitingNCT04374461
2020-05-01HydroxychloroquineA Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19Treatment2Active Not RecruitingNCT04373044
2020-05-01BaricitinibA Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19Treatment2Active Not RecruitingNCT04373044
2020-05-01RuxolitinibPhase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)Treatment3Active Not RecruitingNCT04362137
2020-05-01AzithromycinA Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19Treatment2Active Not RecruitingNCT04358068
2020-05-01HydroxychloroquineA Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19Treatment2Active Not RecruitingNCT04358068
2020-05-01TocilizumabA Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 InfectionTreatment2Active Not RecruitingNCT04377659
2020-05-01COVID-19 convalescent plasmaEfficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled TrialTreatment3Active Not RecruitingNCT04345289
2020-05-01FavipiravirStudy on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of BangladeshTreatment2, 3Active Not RecruitingNCT04402203
2020-05-01COVID-19 convalescent plasmaA pilot randomized clinical trial of therapeutic plasma exchange (TPE) in serious SARS CoV-2 disease (COVID-19)TreatmentNot AvailableRecruitingISRCTN21363594
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma To Limit COVID-19 Associated Complications : A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma To Placebo in COVID-19 Hospitalized PatientsTreatment2Active Not RecruitingNCT04404634
2020-05-01Remestemcel-LCellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard StudyTreatment1Active Not RecruitingNCT04400032
2020-05-01Human Umbilical Cord Mesenchymal Stem CellsA Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 PneumoniaTreatment1, 2Active Not RecruitingNCT04398303
2020-05-01Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned MediaA Phase 1 / 2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 PneumoniaTreatment1, 2Active Not RecruitingNCT04398303
2020-05-01Vitamin DDo Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?Basic ScienceNot AvailableActive Not RecruitingNCT04394390
2020-05-01Povidone-iodineCan a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?Treatment1Active Not RecruitingNCT04393792
2020-05-01COVID-19 convalescent plasmaTransfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2 : a Multicenter Open Label Randomized Control TrialTreatment2Active Not RecruitingNCT04393727
2020-05-01ABX-464A Phase 2 / 3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged = 65 and Patients Aged =18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.Treatment2, 3Active Not RecruitingNCT04393038
2020-05-01HydroxychloroquineA Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseTreatment3Active Not RecruitingNCT04358081
2020-05-01AzithromycinA Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 DiseaseTreatment3Active Not RecruitingNCT04358081
2020-05-01ColchicineRandomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)Treatment2Active Not RecruitingNCT04355143
2020-05-01ZincEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-05-01NitazoxanideEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-05-01RibavirinEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-05-01IvermectinEffect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 : a Pilot Sequential Clinical TrialTreatment3Active Not RecruitingNCT04392427
2020-05-01COVID-19 convalescent plasmaA Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 CasesTreatment2Active Not RecruitingNCT04390503
2020-05-01COVID-19 convalescent plasmaEvaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.Treatment3Active Not RecruitingNCT04372979
2020-05-01HydroxychloroquineComparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare PersonnelPrevention2Active Not RecruitingNCT04359537
2020-05-01SarilumabPilot Study on the Use of Sarilumab in Patients With COVID-19 InfectionTreatment1Active Not RecruitingNCT04386239
2020-05-01COVID-19 convalescent plasmaEfficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe InfectionTreatment2, 3Active Not RecruitingNCT04385043
2020-05-01AlmitrineEfficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia : a Randomized Controlled Double-blind Study From the Skip-icu ConsortiumTreatment3Active Not RecruitingNCT04357457
2020-05-01COVID-19 convalescent plasmaExperimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020TreatmentNot AvailableActive Not RecruitingNCT04352751
2020-05-01HydroxychloroquineHydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia TrialTreatment4Active Not RecruitingNCT04382625
2020-05-01ClazakizumabA Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2Active Not RecruitingNCT04381052
2020-05-01BCG vaccineEffect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers â?? a double blind randomized controlled trialTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024833
2020-05-01LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITY TRIALTreatment3Active Not RecruitingCTRI/2020/04/024773
2020-05-01AzithromycinEvaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trialTreatment2Active Not RecruitingRBR-3k4wxb
2020-05-01HydroxychloroquineEvaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19 : randomized clinical trialTreatment2Active Not RecruitingRBR-3k4wxb
2020-05-01HydroxychloroquineInvestigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19Treatment3Active Not RecruitingIRCT20080901001165N51
2020-05-01AzithromycinInvestigating the efficacy and safety of Azithromycin inhaled spray in controlling the symptoms of patients with COVID-19Treatment3Active Not RecruitingIRCT20080901001165N50
2020-05-01Methylprednisolone hemisuccinateComparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II TrialTreatment2Active Not RecruitingNCT04377503
2020-05-01TocilizumabComparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II TrialTreatment2Active Not RecruitingNCT04377503
2020-05-01FluoxetineFluoxetine to Reduce Intubation and Death After COVID19 InfectionTreatment4Active Not RecruitingNCT04377308
2020-05-01TridecactideAn Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 InfectionTreatment2, 3Active Not RecruitingNCT04374032
2020-05-01MetenkefalinAn Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 InfectionTreatment2, 3Active Not RecruitingNCT04374032
2020-05-01IvermectinRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01AzithromycinRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01WormwoodRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01CamostatRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01HydroxychloroquineRandomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive PatientsTreatment2Active Not RecruitingNCT04374019
2020-05-01SirolimusA Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)Treatment1Active Not RecruitingNCT04371640
2020-05-01Ascorbic acidPharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 TreatmentTreatment2Active Not RecruitingNCT04363216
2020-05-01St. John's WortUse of a Medical Device, Kerecis Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal MucosaTreatmentNot AvailableActive Not RecruitingNCT04357990
2020-05-01Azadirachta indica leafUse of a Medical Device, Kerecis Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal MucosaTreatmentNot AvailableActive Not RecruitingNCT04357990
2020-05-01ChloroquineAn International, Multi-site, Bayesian Platform Adaptive,Randomised, Double-blind, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare WorkersPrevention3Active Not RecruitingNCT04333732
2020-05-01HydroxychloroquineHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label TrialTreatmentNot AvailableActive Not RecruitingNCT04374903
2020-05-01AzithromycinHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label TrialTreatmentNot AvailableActive Not RecruitingNCT04374903
2020-05-01SirolimusHydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients : A Pilot, Multicenter Randomized Open-Label TrialTreatmentNot AvailableActive Not RecruitingNCT04374903
2020-05-01FavipiravirA Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19 : Favipiravir and StaNdard Care vErsEs Standard CaReTreatment3Active Not RecruitingNCT04373733
2020-05-01BCG vaccineUsing BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center TrialPrevention3Active Not RecruitingNCT04373291
2020-05-01NiclosamideEfficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled TrialTreatment3Active Not RecruitingNCT04372082
2020-05-01HydroxychloroquineEfficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled TrialTreatment3Active Not RecruitingNCT04372082
2020-05-01DiltiazemEfficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities : Multicenter, Randomized, Open-labeled Controlled TrialTreatment3Active Not RecruitingNCT04372082
2020-05-01HydroxychloroquineEfficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health : A Randomized, Double-blind, Placebo-controlled TrialPrevention3Active Not RecruitingNCT04364815
2020-05-01FondaparinuxIncreased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)Basic ScienceNot AvailableActive Not RecruitingNCT04359212
2020-05-01HeparinIncreased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)Basic ScienceNot AvailableActive Not RecruitingNCT04359212
2020-05-01HydroxychloroquineA Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 PatientsPreventionNot AvailableActive Not RecruitingNCT04354597
2020-05-01AzithromycinA Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 PatientsPreventionNot AvailableActive Not RecruitingNCT04354597
2020-05-01Povidone-iodineCan a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? - SINUS WASH pilot studyTreatment2Active Not RecruitingEUCTR2020-001721-31-GB
2020-05-01HydroxychloroquineHydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE) : A Parallel Randomized Controlled TrialPrevention3Active Not RecruitingNCT04371523
2020-05-01Dornase alfaA Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19Treatment2Active Not RecruitingNCT04359654
2020-05-01MethotrexateTreatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles : A Phase I / II StudyTreatment1, 2Active Not RecruitingNCT04352465
2020-05-01HydroxychloroquineA Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)Treatment4Active Not RecruitingNCT04363866
2020-05-01Acetylsalicylic acidThe LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 HospitalizationsTreatment2Active Not RecruitingNCT04363840
2020-05-01Vitamin DThe LEAD COVID-19 Trial : Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 HospitalizationsTreatment2Active Not RecruitingNCT04363840
2020-05-01AnakinraEarly Identification and Treatment of Cytokine Storm Syndrome in Covid-19Treatment3Active Not RecruitingNCT04362111
2020-05-01NitazoxanideClinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04361318
2020-05-01HydroxychloroquineClinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04361318
2020-05-01ChloroquineMulti-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South AfricaTreatment3Active Not RecruitingNCT04360759
2020-05-01HydroxychloroquineMulti-centre Randomised Controlled Trial of Chloroquine / Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South AfricaTreatment3Active Not RecruitingNCT04360759
2020-05-01IvermectinClinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04360356
2020-05-01NitazoxanideClinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients : A Tanta University HopeTreatment2, 3Active Not RecruitingNCT04360356
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04358211
2020-05-01ImatinibA RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.Treatment2Active Not RecruitingNCT04357613
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma for Patients With COVID-19 : A Randomized, Open Label, Parallel, Controlled Clinical StudyTreatment2, 3Active Not RecruitingNCT04332835
2020-05-01COVID-19 convalescent plasmaConvalescent Plasma for Patients With COVID-19 : A Pilot StudyTreatment2Active Not RecruitingNCT04332380
2020-05-01HydroxychloroquineRandomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection : HyPreC TrialTreatment2Active Not RecruitingNCT04354441
2020-05-01GoldNovel coronavirus pneumonia (COVID-19) Intelligent Assistant Analysis System : A Multi-center Clinical ResearchDiagnosticNot AvailableActive Not RecruitingChiCTR2000032010
2020-05-01MavrilimumabMavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammationTreatment2Active Not RecruitingNCT04337216
2020-04-30Dornase alfaA single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised participants with COVID-19 (The COVASE trial) - Dornase alfa to reduce hyperinflammation in COVID19 - The COVASE trialTreatment2Unknown StatusEUCTR2020-001937-11-GB
2020-04-30Remestemcel-LMesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress SyndromeTreatment3Active Not RecruitingNCT04371393
2020-04-30CanakinumabPhase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)Treatment3Active Not RecruitingNCT04362813
2020-04-30HoneyThe Role of Honey and Nigella Sativa in the Management of COVID-19 ; A Randomized Controlled, Open-label, Add-on Trial in Lahore, PakistanTreatment3Active Not RecruitingNCT04347382
2020-04-30COVID-19 convalescent plasmaAn Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2Treatment1Active Not RecruitingNCT04388527
2020-04-30LenzilumabA Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 PneumoniaPrevention3Active Not RecruitingNCT04351152
2020-04-30YohimbineImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1Active Not RecruitingDRKS00021573
2020-04-30MidazolamImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1Active Not RecruitingDRKS00021573
2020-04-30PantoprazoleImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1Active Not RecruitingDRKS00021573
2020-04-30HydroxychloroquineImpact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19 - K724_HCQ-PPITreatment1Active Not RecruitingDRKS00021573
2020-04-30COVID-19 convalescent plasmaUse of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and SafetyTreatmentNot AvailableActive Not RecruitingNCT04397523
2020-04-30COVID-19 convalescent plasmaA Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate SeverityTreatment3Active Not RecruitingNCT04361253
2020-04-30BCG vaccineUsing BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. - BCG-DENMARK-COVIDTreatment3Active Not RecruitingEUCTR2020-001888-90-DK
2020-04-30MelphalanSingle-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19Treatment2Active Not RecruitingNCT04380376
2020-04-30HydroxychloroquineVA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)Treatment3Active Not RecruitingNCT04363203
2020-04-30AzithromycinVA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)Treatment3Active Not RecruitingNCT04363203
2020-04-30Mycobacterium w. VaccineA Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04347174
2020-04-30Mycobacterium w. VaccineA clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infectionTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024846
2020-04-30HydroxychloroquineProtecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled Multi-Site Trial in Toronto, CanadaPrevention3Active Not RecruitingNCT04374942
2020-04-30Recombinant Human Angiotensin-Converting Enzyme 2Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19Treatment2Active Not RecruitingNCT04335136
2020-04-30COVID-19 convalescent plasmaInterventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)Treatment2Active Not RecruitingNCT04374149
2020-04-30RuxolitinibInterventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)Treatment2Active Not RecruitingNCT04374149
2020-04-30ColchicineAdministration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.Treatment3Active Not RecruitingNCT04350320
2020-04-30MethylprednisoloneEARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL - CORTIVIDTreatment3Unknown StatusEUCTR2020-001827-15-ES
2020-04-30AzithromycinAzithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled TrialTreatment3Active Not RecruitingNCT04363060
2020-04-30AmoxicillinAzithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled TrialTreatment3Active Not RecruitingNCT04363060
2020-04-30Clavulanic acidAzithromycin With Amoxicillin / Clavulanate Versus Amoxicillin / Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA) : a Superiority Open-label Randomized Controlled TrialTreatment3Active Not RecruitingNCT04363060
2020-04-30HydroxychloroquineHydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)Treatment3Active Not RecruitingNCT04361461
2020-04-30Mycobacterium w. VaccineA Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.Prevention3Active Not RecruitingNCT04353518
2020-04-30SelinexorA Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19Treatment2Active Not RecruitingNCT04355676
2020-04-30HydroxychloroquineHydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or DeathTreatment1Active Not RecruitingNCT04323631
2020-04-30LosartanAspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trialTreatment3Active Not RecruitingPACTR202006473370201
2020-04-30Acetylsalicylic acidAspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trialTreatment3Active Not RecruitingPACTR202006473370201
2020-04-30SimvastatinAspirin, losartan and simvastatin in hospitalised COVID-19 patients : a multinational randomised open-label factorial trialTreatment3Active Not RecruitingPACTR202006473370201
2020-04-29QuercetinEvaluation of the effect of quercetin on the effectiveness of antiviral drug regimen in patients with COVID19Treatment3Active Not RecruitingIRCT20200419047128N2
2020-04-29AzithromycinProactive Care of Ambulatory COVID19 Patients : Open-labeled Randomized TrialTreatment3Active Not RecruitingNCT04371107
2020-04-29BNT162b1 SARS-CoV-2 VaccineA PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTSPrevention2, 3Active Not RecruitingNCT04368728
2020-04-29BNT162b2 SARS-CoV-2 VaccineA PHASE 1 / 2 / 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTSPrevention2, 3Active Not RecruitingNCT04368728
2020-04-29RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-LT
2020-04-29HydroxychloroquineChloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)PreventionNot AvailableActive Not RecruitingNCT04303507
2020-04-29ChloroquineChloroquine / Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting ; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)PreventionNot AvailableActive Not RecruitingNCT04303507
2020-04-29Povidone-iodinePovidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 PandemicPrevention2Active Not RecruitingNCT04364802
2020-04-29Azoximer bromideA Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).Treatment2, 3Active Not RecruitingNCT04381377
2020-04-29KetamineStudy of Immunomodulation Using Naltrexone and Ketamine for COVID-19Treatment2Active Not RecruitingNCT04365985
2020-04-29NaltrexoneStudy of Immunomodulation Using Naltrexone and Ketamine for COVID-19Treatment2Active Not RecruitingNCT04365985
2020-04-29ColchicineEvaluation of colchicine tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad : A triple-blind randomized placebo controlled clinical trialTreatment3Active Not RecruitingIRCT20200408046990N2
2020-04-29HydroxychloroquineTherapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19Treatment3Active Not RecruitingIRCT20200421047155N1
2020-04-29TenofovirTherapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19Treatment3Active Not RecruitingIRCT20200421047155N1
2020-04-29Interferon beta-1beffect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospitalTreatment2RecruitingIRCT20200406046968N3
2020-04-29HydroxychloroquineEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29LopinavirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29RitonavirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29FavipiravirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19Treatment1, 2Active Not RecruitingIRCT20150808023559N20
2020-04-29UmifenovirEvaluation of the effect of Arbidol drug in the treatment of hospitalized patients with COVID-19Treatment3Active Not RecruitingIRCT20180725040596N2
2020-04-29Albumin humanPlasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled TrialTreatment2Active Not RecruitingNCT04374539
2020-04-29Human immunoglobulin GPlasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation : a Randomized Controlled TrialTreatment2Active Not RecruitingNCT04374539
2020-04-29FavipiravirA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29HydroxychloroquineA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29ZincA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29AzithromycinA Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19 : Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEERTreatment3Active Not RecruitingEUCTR2020-001449-38-GB
2020-04-29DalteparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29NadroparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29HeparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29EnoxaparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29TinzaparinEffectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSETreatment4Active Not RecruitingEUCTR2020-001709-21-FR
2020-04-29CanakinumabPhase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).Treatment3Active Not RecruitingEUCTR2020-001370-30-DE
2020-04-29LosartanLosartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCETreatment2Active Not RecruitingEUCTR2020-001766-11-FR
2020-04-29SpironolactoneLosartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCETreatment2Active Not RecruitingEUCTR2020-001766-11-FR
2020-04-29RemdesivirWHO SOLIDARITY Finland : The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY FinlandTreatment3Active Not RecruitingEUCTR2020-001784-88-FI
2020-04-29ChlorpromazineRepurposing of Chlorpromazine in Covid-19 TreatmentTreatment3Active Not RecruitingNCT04366739
2020-04-29BBIBP-CorVEvaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above : a randomized, double-blind, placebo parallel-controlled phase I / II clinical trialTreatment1, 2Active Not RecruitingChiCTR2000032459
2020-04-29ChloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis studyTreatment3RecruitingISRCTN10207947
2020-04-29HydroxychloroquineChloroquine / hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting ; a randomised, placebo-controlled prophylaxis studyTreatment3RecruitingISRCTN10207947
2020-04-29ArtesunateRandomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19Treatment2Active Not RecruitingPACTR202006899597082
2020-04-29Ascorbic acidRandomized clinical trial, phase 2, to evaluate the efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19Treatment2Active Not RecruitingPACTR202006899597082
2020-04-29TocilizumabStudy of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients : a ?crinical trial studyTreatment2RecruitingIRCT20081027001411N4
2020-04-29AdalimumabEvaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19Treatment3RecruitingIRCT20171105037262N4
2020-04-28Dornase alfaDouble Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory FailureTreatment2Active Not RecruitingNCT04445285
2020-04-28HydroxychloroquinePROTECT : A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). - PROTECTTreatment2Unknown StatusEUCTR2020-001501-24-IT
2020-04-28COVID-19 convalescent plasmaOpen, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19Prevention2Active Not RecruitingNCT04434131
2020-04-28HydroxychloroquineAssessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative StudyPrevention3Active Not RecruitingNCT04349228
2020-04-28Human immunoglobulin GRandomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 InfectionTreatment4Active Not RecruitingNCT04411667
2020-04-28ZilucoplanACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28HeparinACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28BemcentinibACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28AcalabrutinibACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28TD-139ACCORD 2 : A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised PatientsTreatment2Active Not RecruitingEUCTR2020-001736-95-GB
2020-04-28COVID-19 convalescent plasmaConvalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 DiseaseTreatment1Active Not RecruitingNCT04355897
2020-04-28HydroxychloroquineA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28Zinc sulfateA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28DoxycyclineA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28AzithromycinA Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient SettingTreatment4Active Not RecruitingNCT04370782
2020-04-28CholesterolMetabolic syndrome And Severity of Covid-19OtherNot AvailableActive Not RecruitingNL8580
2020-04-28MultiStemA Phase 2 / 3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)Treatment2, 3Active Not RecruitingNCT04367077
2020-04-28AnakinraCLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 - ANA-COVID-GEASTreatment2Unknown StatusEUCTR2020-001825-29-ES
2020-04-28CanakinumabPhase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).Treatment3Active Not RecruitingEUCTR2020-001370-30-GB
2020-04-28CalcifediolPrevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)Treatment2Active Not RecruitingNCT04366908
2020-04-28ThrombinAnalysis of the Coagulopathy Developed by COVID-19 Infected Patients : Thrombin Generation Potential in COVID-19 Infected PatientsBasic ScienceNot AvailableActive Not RecruitingNCT04356950
2020-04-28EnoxaparinPreventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation : a Randomized, Open-label Clinical TrialTreatment3Active Not RecruitingNCT04345848
2020-04-28BCG vaccineRandomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.” COVID-BCG - COVID BCGTreatment3Active Not RecruitingEUCTR2020-001678-31-FR
2020-04-28EnoxaparinEvaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOXTreatment4Active Not RecruitingEUCTR2020-001823-15-FR
2020-04-28IC14Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04346277
2020-04-27SiltuximabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27HydroxychloroquineCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27TocilizumabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27CanakinumabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27SarilumabCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27BaricitinibCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 - AMMURAVIDTreatment2Unknown StatusEUCTR2020-001854-23-IT
2020-04-27SarilumabA phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia - ESCAPETreatment3Unknown StatusEUCTR2020-001390-76-IT
2020-04-27Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsPhase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19Treatment1, 2Active Not RecruitingNCT04366323
2020-04-27COVID-19 convalescent plasmaPhase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 PneumoniaTreatment2Active Not RecruitingNCT04358783
2020-04-27AnakinraEfficacy and Safety of ANAkinra During Adult " COVID-19 " With Aggravating Respiratory Symptoms : a Multicenter Open-label Controlled Randomized TrialTreatment3Active Not RecruitingNCT04364009
2020-04-27ChloroquineComparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patientsTreatment4Active Not RecruitingTCTR20200404004
2020-04-27Ascorbic acidComparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patientsTreatment4Active Not RecruitingTCTR20200404004
2020-04-27ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SOLIDARITYTreatment3Active Not RecruitingLBCTR2020043495
2020-04-27Natural Killer CellEvaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trialTreatment1, 2Active Not RecruitingIRCT20200417047113N1
2020-04-27Human immunoglobulin G"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19 - GERONIMO19Treatment2Active Not RecruitingEUCTR2020-001768-27-FR
2020-04-27AzithromycinA Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) PandemicPrevention2Active Not RecruitingNCT04369365
2020-04-27HydroxychloroquineHydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)Prevention3Active Not RecruitingNCT04363450
2020-04-27COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Moderate-severe COVID-19 : A Proof-of-principle StudyTreatmentNot AvailableActive Not RecruitingNCT04365439
2020-04-27ProgesteroneA Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized MenTreatment1Active Not RecruitingNCT04365127
2020-04-27SarilumabClinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release SyndromeTreatment2Active Not RecruitingNCT04357860
2020-04-27AmiodaroneAmiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsTreatment2, 3Active Not RecruitingNCT04351763
2020-04-27VerapamilAmiodarone or Verapamil in COVID-19 Hospitalized Patients With SymptomsTreatment2, 3Active Not RecruitingNCT04351763
2020-04-27CIGB-258 peptideExpanded clinical use of CIGB-258 in the treatment of serious or critically ill patients by COVID-19 (COVID-19)TreatmentNot AvailableRecruitingRPCEC00000321
2020-04-26SeleniumInvestigating the effectiveness of selenium on recovery of hospitalized patients with COVID-19Treatment3RecruitingIRCT20190418043307N1
2020-04-26EnoxaparinSystemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)Treatment3Active Not RecruitingNCT04401293
2020-04-26IsofluraneVolatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome – a pilot studyTreatmentNot AvailableActive Not RecruitingNL8523
2020-04-26ImatinibEfficacy of Imatinib in mild SARS CoV2 infection : A randomized studyTreatment2Active Not RecruitingCTRI/2020/04/024806
2020-04-26PirfenidoneThe evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19Treatment3Active Not RecruitingIRCT20200314046764N1
2020-04-26ColchicineCOlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)Treatment2Active Not RecruitingNCT04363437
2020-04-26D-glucoseControl of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19Treatment4Unknown StatusEUCTR2020-000705-86-ES
2020-04-26Omega-3 fatty acidsControl of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19Treatment4Unknown StatusEUCTR2020-000705-86-ES
2020-04-26Amino acidsControl of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2 : randomized clinical trial COVID-19Treatment4Unknown StatusEUCTR2020-000705-86-ES
2020-04-26TocilizumabCORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)Treatment2Active Not RecruitingNCT04335071
2020-04-26COVID-19 convalescent plasmaConvalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in PakistanTreatmentNot AvailableActive Not RecruitingNCT04476888
2020-04-25OzoneInvestigation the effects medical Ozone Autohemotherapy on clinical and para clinical features of patients with Covid19Treatment2, 3RecruitingIRCT20190618043923N4
2020-04-25VazegepantBHV3500-203 : Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental OxygenTreatment2, 3Active Not RecruitingNCT04346615
2020-04-25Angiotensin 1-7Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19TreatmentNot AvailableActive Not RecruitingNCT04375124
2020-04-25Ivermectinâ??To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID 19 cases. A Pilot StudyTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024858
2020-04-25HydroxychloroquinePROTECT-SurgTreatment3Active Not RecruitingPACTR202004893013257
2020-04-25RitonavirPROTECT-SurgTreatment3Active Not RecruitingPACTR202004893013257
2020-04-25LopinavirPROTECT-SurgTreatment3Active Not RecruitingPACTR202004893013257
2020-04-25NiacinEvaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical TrialTreatment2, 3RecruitingIRCT20200418047122N1
2020-04-25ApocyninEvaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection : A Clinical TrialTreatment2, 3RecruitingIRCT20200418047122N1
2020-04-25IvermectinTo Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot StudyTreatmentNot AvailableActive Not RecruitingNCT04373824
2020-04-25Human Umbilical Cord Mesenchymal Stem CellsUmbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)Treatment1, 2Active Not RecruitingNCT04355728
2020-04-25HeparinUmbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)Treatment1, 2Active Not RecruitingNCT04355728
2020-04-25RuxolitinibCOVID-19 : Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE StudyBasic ScienceNot AvailableActive Not RecruitingNCT04361903
2020-04-25HydroxychloroquineEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative StudyTreatment3Active Not RecruitingNCT04359953
2020-04-25AzithromycinEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative StudyTreatment3Active Not RecruitingNCT04359953
2020-04-25TelmisartanEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 : a Randomized, Multicenter, Adaptative StudyTreatment3Active Not RecruitingNCT04359953
2020-04-24DexamethasoneEvolution of the efficacy and safety of Dexamethasone administration in patients with mild to moderate COVID-19 acute respiratory disease syndromeTreatment2, 3Active Not RecruitingIRCT20151227025726N17
2020-04-24DexmedetomidineImmunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19TreatmentNot AvailableActive Not RecruitingNCT04413864
2020-04-24ClazakizumabA Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 InfectionTreatment2Active Not RecruitingNCT04348500
2020-04-24VA-MENGOC-BC®Population impact of intervention based on the administration of a single dose of the Outer Membrane Vesicle (OMV) complex contained in VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 (COVID-19) - VME-CORONATreatmentNot AvailableCompletedRPCEC00000314
2020-04-24CanakinumabCanakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened InflammationTreatment2Active Not RecruitingNCT04365153
2020-04-24SirolimusSirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)Treatment2Active Not RecruitingNCT04341675
2020-04-24SelinexorA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection - Low Dose Oral Selinexor in Patients with Severe COVID-19 InfectionTreatment2Active Not RecruitingEUCTR2020-001411-25-GB
2020-04-24SirukumabPhase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 DiseaseTreatment2Active Not RecruitingNCT04380961
2020-04-24AzithromycinSafety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial studyTreatment3Active Not RecruitingIRCT20200415047092N1
2020-04-24Lactobacillus Coryniformis K8Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19PreventionNot AvailableActive Not RecruitingNCT04366180
2020-04-24COVID-19 convalescent plasmaA Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04362176
2020-04-24BevacizumabPilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19Treatment2Unknown StatusEUCTR2020-001541-39-ES
2020-04-24HydroxychloroquineProtecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis : A Randomized, Placebo-controlled TrialPrevention3Active Not RecruitingNCT04352946
2020-04-24Peginterferon lambda-1aA Phase 2 Randomized, Single Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19Treatment2Active Not RecruitingNCT04331899
2020-04-24Alpha-1-proteinase inhibitorA randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.Treatment2Active Not RecruitingEUCTR2020-001391-15-IE
2020-04-23SarilumabPILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION - COVID-SARI-001Treatment2Unknown StatusEUCTR2020-001745-40-IT
2020-04-23FavipiravirAn Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19Treatment2, 3Active Not RecruitingNCT04434248
2020-04-23AZD1222A Phase I / II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult VolunteersTreatment1, 2Active Not RecruitingNCT04324606
2020-04-23COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II TrialTreatmentNot AvailableActive Not RecruitingNCT04408209
2020-04-23COVID-19 convalescent plasmaPhase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 InfectionTreatment1, 2Active Not RecruitingNCT04366245
2020-04-23TocilizumabOutcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatmentBasic ScienceNot AvailableActive Not RecruitingNL8551
2020-04-23MethylprednisoloneOutcomes of patients with COVID-19 related cytokine release syndrome under immunosuppressive treatmentBasic ScienceNot AvailableActive Not RecruitingNL8551
2020-04-23OzoneComparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patientsTreatment2, 3Active Not RecruitingIRCT20191125045492N2
2020-04-23OxygenComparison of the effectiveness of Ozone therapy with conventional therapy in improving patient outcomes in Covid-19 patientsTreatment2, 3Active Not RecruitingIRCT20191125045492N2
2020-04-23OlokizumabAn International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)Treatment2, 3Active Not RecruitingNCT04380519
2020-04-23HydroxychloroquinePRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNATreatment3Unknown StatusEUCTR2020-001697-30-ES
2020-04-23Human Umbilical Cord Mesenchymal Stem CellsDouble-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 - COVIDMESTreatment1Unknown StatusEUCTR2020-001505-22-ES
2020-04-23Albumin humanPlasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVIDTreatment2Unknown StatusEUCTR2020-001722-66-ES
2020-04-23Human immunoglobulin GPlasma turnover in patients with COVID-19 disease and invasive mechanical ventilation : a randomized study - REP-COVIDTreatment2Unknown StatusEUCTR2020-001722-66-ES
2020-04-23SevofluraneSevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury : a Randomized Controlled TrialTreatment3Active Not RecruitingNCT04355962
2020-04-23AzithromycinOpen, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04329572
2020-04-23HydroxychloroquineOpen, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04329572
2020-04-23HydroxychloroquineCOVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial - COVID-19 PREVENTIONTreatment3Active Not RecruitingEUCTR2020-001363-85-DK
2020-04-22RuxolitinibFront line treatment with Ruxolitinib in stage II / III Covid-19 patients with defined Hyperinflammation - RuxCoFlamTreatment2Active Not RecruitingEUCTR2020-001481-11-DE
2020-04-22HydroxychloroquineHydroxychloroquine for the treatment of mild COVID-19 diseaseTreatment2Active Not RecruitingEUCTR2020-001512-26-DE
2020-04-22AzithromycinCovid-19 : A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19 DAWN AZITHROTreatment2Active Not RecruitingEUCTR2020-001614-38-BE
2020-04-22HydroxychloroquineHealthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)Prevention3Active Not RecruitingNCT04334148
2020-04-22HydroxychloroquineHydroxychloroquine for the Treatment of Mild COVID-19 DiseaseTreatment3Active Not RecruitingNCT04340544
2020-04-22COVID-19 convalescent plasmaA Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. - PLACIDTreatment2Active Not RecruitingCTRI/2020/04/024775
2020-04-22Hydroxychloroquineevaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad.Treatment2, 3RecruitingIRCT20200325046859N2
2020-04-22Umifenovirevaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections : A randomized interventional study in Imam Reza Hospital, Mashhad.Treatment2, 3RecruitingIRCT20200325046859N2
2020-04-22AlteplaseA Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)Treatment2Active Not RecruitingNCT04356833
2020-04-22Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsA Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus DiseasePrevention2Active Not RecruitingNCT04349631
2020-04-22RuxolitinibA Phase-II Clinical Trial for First Line Treatment of Stage II / III Covid-19 Patients to Treat HyperinflammationTreatment2Active Not RecruitingNCT04338958
2020-04-22UlinastatinEfficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)Treatment4Active Not RecruitingChiCTR2000032135
2020-04-22RuxolitinibRuxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study. - Ruxolitinib Treatment in Patients with Severe COVID-19 Infection.A Danish Safety and Efficacy StudyTreatment2Active Not RecruitingEUCTR2020-001459-42-DK
2020-04-22DapagliflozinAn International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19Treatment3Active Not RecruitingNCT04350593
2020-04-22OseltamivirPakistan Randomized and Observational Trial to Evaluate Coronavirus TreatmentTreatment3Active Not RecruitingNCT04338698
2020-04-22HydroxychloroquinePakistan Randomized and Observational Trial to Evaluate Coronavirus TreatmentTreatment3Active Not RecruitingNCT04338698
2020-04-22AzithromycinPakistan Randomized and Observational Trial to Evaluate Coronavirus TreatmentTreatment3Active Not RecruitingNCT04338698
2020-04-21Dornase alfaEfficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS)Treatment3Active Not RecruitingNCT04355364
2020-04-21HydroxychloroquineRandomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 PatientsTreatment2, 3Active Not RecruitingNCT04351516
2020-04-21HeparinLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21AzithromycinLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21LopinavirLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21RitonavirLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21PiperacillinLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21TazobactamLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21TocilizumabLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21HydroxychloroquineLow Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia : Prospective Multicentric Study in Radiation Oncology CentersSupportive CareNot AvailableActive Not RecruitingNCT04394182
2020-04-21TocilizumabCOVID 19 : Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia.Treatment2Active Not RecruitingEUCTR2020-001770-30-BE
2020-04-21VPM1002A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2 / COVID-19 Among High-Risk SubjectsTreatment3Active Not RecruitingCTRI/2020/04/024749
2020-04-21ChloroquineTopical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure ratesTreatment2Active Not RecruitingCTRI/2020/04/024729
2020-04-21TocilizumabThe effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failureTreatment2, 3Active Not RecruitingIRCT20200406046968N1
2020-04-21BudesonideTreatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 PneumoniaTreatment4Active Not RecruitingNCT04355637
2020-04-21COVID-19 convalescent plasmaA Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19Treatment2Active Not RecruitingNCT04359810
2020-04-21EnoxaparinA Randomized Trial of Anticoagulation Strategies in COVID-19Treatment3Active Not RecruitingNCT04359277
2020-04-21TocilizumabA prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia - TOC-COVIDTreatment2Active Not RecruitingEUCTR2020-001408-41-DE
2020-04-21IsotretinoinEvaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19 : Clinical StudyTreatment3Active Not RecruitingNCT04361422
2020-04-21Human interferon betaAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21Acetylsalicylic acidAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21ColchicineAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21RivaroxabanAnti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized TrialTreatment3Active Not RecruitingNCT04324463
2020-04-21ChloroquineCOVID-19 : addition of azithromycin to chloroquine treatment - CO VOR ITTreatment4Active Not RecruitingEUCTR2020-001527-14-NL
2020-04-21AzithromycinCOVID-19 : addition of azithromycin to chloroquine treatment - CO VOR ITTreatment4Active Not RecruitingEUCTR2020-001527-14-NL
2020-04-21SpironolactoneThe Effect of Spironolactone on Oxygenation in Covid-19 ARDS PatientsTreatment4Active Not RecruitingNCT04345887
2020-04-21PrednisoneCorticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 InfectionTreatment2Active Not RecruitingNCT04344288
2020-04-21GoldDevelopment and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagentDiagnosticNot AvailableActive Not RecruitingChiCTR2000031700
2020-04-21COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled Trial.Treatment2CompletedCTRI/2020/04/024706
2020-04-20ColchicineCOLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA - ColCOVID19Treatment2Active Not RecruitingEUCTR2020-001258-23-IT
2020-04-20UmifenovirEvaluating effectiveness and safety of Umifenovir in the treatment (COVID-19)infection In patients referred to Tehran Imam Khomeini Hospital ComplexTreatment3Active Not RecruitingIRCT20200523047550N1
2020-04-20BeractantThe effect of surfactant on clinical outcome of patients with COVID-19 under mechanical ventilationTreatment3RecruitingIRCT20091201002804N12
2020-04-20Remestemcel-LCell therapy in patients with coronavirus19 using mesenchymal stem cellsTreatment1RecruitingIRCT20190717044241N2
2020-04-20COVID-19 convalescent plasmaEfficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients : A Pilot Randomized Controlled TrialTreatment2Active Not RecruitingNCT04346446
2020-04-20AtovaquoneOpen-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 InfectionTreatment2Active Not RecruitingNCT04339426
2020-04-20AzithromycinOpen-Label, Non-Randomized Study to Evaluate Anti-Malarial / Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 InfectionTreatment2Active Not RecruitingNCT04339426
2020-04-20BNT162c2 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20BNT162a1 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20BNT162b2 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20BNT162b1 SARS-CoV-2 VaccineA Multi-site Phase I / II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults - Phase I / II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19Treatment1Active Not RecruitingEUCTR2020-001038-36-DE
2020-04-20CyanocobalaminZinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant WomenBasic ScienceNot AvailableActive Not RecruitingNCT04407572
2020-04-20Vitamin DZinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant WomenBasic ScienceNot AvailableActive Not RecruitingNCT04407572
2020-04-20ZincZinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant WomenBasic ScienceNot AvailableActive Not RecruitingNCT04407572
2020-04-20Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsAllogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled StudyTreatment1, 2Active Not RecruitingNCT04341610
2020-04-20BCG vaccineBacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2 : A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune ResponsesPrevention4Active Not RecruitingNCT04348370
2020-04-20AnakinraEfficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms : a multicenter open-label controlled randomized trial - ANACONDA-COVID-19Treatment3Active Not RecruitingEUCTR2020-001734-36-FR
2020-04-20ColchicineColchicine to Counteract Inflammatory Response in COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04322565
2020-04-20Folic acidThe host Epigenetic methylation repair in COVID-19 using Folic acid : A new suggested prevention and treatment.Treatment2Active Not RecruitingPACTR202005599385499
2020-04-20HydroxychloroquineA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20LopinavirA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20ChloroquineA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20RitonavirA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate, Hydroxychloroquine sulphate and Lopinavir / Ritonavir for the Treatment of COVID-19 in Lagos State.Treatment3Active Not RecruitingPACTR202004801273802
2020-04-20PrednisoloneInvestigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19Treatment3RecruitingIRCT20080901001165N52
2020-04-20MethylprednisoloneInvestigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19Treatment3RecruitingIRCT20080901001165N52
2020-04-20ZincThe effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)Treatment2, 3RecruitingIRCT20180425039414N2
2020-04-20Ascorbic acidComparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)Treatment2, 3RecruitingIRCT20140305016852N4
2020-04-20Vitamin DComparison of three methods of treatment in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with and without coronavirus positive test (Kovid-19)Treatment2, 3RecruitingIRCT20140305016852N4
2020-04-20PomegranateThe effect of pomegranate tea on symptom relief of COVID-19 patients : a double-blind randomized clinical trial studyTreatmentNot AvailableRecruitingIRCT20200416047104N1
2020-04-20HydroxychloroquinePrevention of COVID-19 disease after contact with an infected patient with coronavirus after taking hydroxychloroquine in the communityTreatment3Active Not RecruitingIRCT20190122042450N4
2020-04-20Human immunoglobulin GTo evaluate the effectiveness of intravenous immunoglobulin (IVIG) for the treatment of COVID-19-induced cytokine stormTreatment3Active Not RecruitingIRCT20200317046797N3
2020-04-20TranscrocetinateClinical trial of the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19Treatment2Active Not RecruitingIRCT20081019001369N3
2020-04-20MinocyclineClinical trial of minocycline against COVID-19Treatment2Active Not RecruitingIRCT20081019001369N4
2020-04-20HydroxychloroquineProspective post-exposure hydroxycloroquine prophylaxis for Covid 19 (PROSCLOROCOV 19)Treatment3Active Not RecruitingIRCT20130306012728N8
2020-04-20COVID-19 convalescent plasmaEvaluation of the therapeutic effects of Convalescent Plasma (CP) of recovered people from Covid-19 in improving clinical and laboratory symptoms of hospitalized patientsTreatment3Active Not RecruitingIRCT20151228025732N53
2020-04-20LicoriceEvaluation the effect of aqueous extract of licorice on coronavirus outpatients : A randomized, double-blind, placebo-controlled clinical trialTreatment2Active Not RecruitingIRCT20200404046933N1
2020-04-20BerberineClinical trial of berberine against COVID-19Treatment2Active Not RecruitingIRCT20081019001369N2
2020-04-20NaproxenThe effect of naproxen on the healing process of patients with COVID-19Treatment3Active Not RecruitingIRCT20200324046850N3
2020-04-20CalcifediolPrevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)Treatment2Unknown StatusEUCTR2020-001717-20-ES
2020-04-20Remestemcel-LPhase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumoniaTreatment1Unknown StatusEUCTR2020-001364-29-ES
2020-04-20Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsPhase I / II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumoniaTreatment1Unknown StatusEUCTR2020-001364-29-ES
2020-04-20BaricitinibClinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older AdultsBasic ScienceNot AvailableActive Not RecruitingNCT04362943
2020-04-20AnakinraClinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older AdultsBasic ScienceNot AvailableActive Not RecruitingNCT04362943
2020-04-20FavipiravirEfficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical TrialTreatment4Active Not RecruitingNCT04359615
2020-04-20EstradiolPhase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ PatientsTreatment2Active Not RecruitingNCT04359329
2020-04-20AzithromycinEfficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19 : A Randomized, Controlled, Double-Blind, Clinical TrialTreatment4Active Not RecruitingNCT04359316
2020-04-20MelatoninMulticenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.Prevention2, 3Active Not RecruitingNCT04353128
2020-04-20AzithromycinOpen Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04348474
2020-04-20HydroxychloroquineOpen Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 VirusTreatment1Active Not RecruitingNCT04348474
2020-04-20TocilizumabTocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19Treatment3Active Not RecruitingNCT04356937
2020-04-20BCG vaccineApplication of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19Prevention3Active Not RecruitingNCT04350931
2020-04-20DexmedetomidineProspective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 InfectionTreatment4Active Not RecruitingNCT04350086
2020-04-20COVID-19 convalescent plasmaPlasma Rich Antibodies From Recovered Patients From COVID19TreatmentNot AvailableActive Not RecruitingNCT04348877
2020-04-20Ascorbic acidProphylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCTPrevention2Active Not RecruitingNCT04347889
2020-04-20HydroxychloroquineProphylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19 : A RCTPrevention2Active Not RecruitingNCT04347889
2020-04-20HydroxychloroquineImmune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2Prevention3Active Not RecruitingNCT04346329
2020-04-20HeparinCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG TrialTreatment2Active Not RecruitingNCT04344756
2020-04-20TinzaparinCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG TrialTreatment2Active Not RecruitingNCT04344756
2020-04-20Human Umbilical Cord Mesenchymal Stem CellsClinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19TreatmentNot AvailableActive Not RecruitingNCT04273646
2020-04-20Povidone-iodineVirucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.Treatment0Active Not RecruitingACTRN12620000470998
2020-04-20RuxolitinibA Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 PneumoniaTreatmentNot AvailableActive Not RecruitingNCT04331665
2020-04-20BromelainsThe effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patientsTreatment3RecruitingIRCT20150725023332N3
2020-04-20MontelukastThe effect of Bromelain and Montelukast on Clinical and non-Clinical parameters in Covid-19 patientsTreatment3RecruitingIRCT20150725023332N3
2020-04-20Ascorbic acidThe effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)Treatment2, 3Active Not RecruitingIRCT20180425039414N3
2020-04-20Vitamin EThe effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19)Treatment2, 3Active Not RecruitingIRCT20180425039414N3
2020-04-19COVID-19 convalescent plasmaUse of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia : a Prospective Randomized TrialTreatmentNot AvailableActive Not RecruitingNCT04356534
2020-04-19COVID-19 convalescent plasmaUse of convalescent plasma submitted to pathogen inactivation for the treatment of patients with severe COVID-19TreatmentNot AvailableRecruitingRBR-4vm3yy
2020-04-19Ascorbic acidThe Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 PatientsTreatment1Active Not RecruitingNCT04370288
2020-04-19CysteineThe Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 PatientsTreatment1Active Not RecruitingNCT04370288
2020-04-19Methylene blueThe Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 PatientsTreatment1Active Not RecruitingNCT04370288
2020-04-19HydroxychloroquinePilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. - PrevenCOVID-19Treatment3Unknown StatusEUCTR2020-001440-26-ES
2020-04-19PrednisoneOUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASETreatment4Unknown StatusEUCTR2020-001622-64-ES
2020-04-19Ascorbic acidStudy of the effect of Vitamin C on duration of hospital stay in patients with Covid-19Treatment2Active Not RecruitingIRCT20200324046850N5
2020-04-18IvermectinEfficacy of Ivermectin as Add on Therapy in COVID19 Patients : A Pilot Randomized StudyTreatment1Active Not RecruitingNCT04343092
2020-04-18HydroxychloroquineProphylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection.Treatment3Active Not RecruitingEUCTR2020-001536-98-ES
2020-04-18COVID-19 convalescent plasmaA National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19Treatment2Active Not RecruitingNCT04347681
2020-04-18Nitric OxideNitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency DepartmentTreatment2Active Not RecruitingNCT04338828
2020-04-18ChloroquineComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18RitonavirComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18LopinavirComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18TenofovirComparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patientsTreatment2, 3RecruitingIRCT20200422047168N1
2020-04-18EchinaceaThe effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient casesTreatment3Active Not RecruitingIRCT20200415047089N1
2020-04-18GingerThe effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient casesTreatment3Active Not RecruitingIRCT20200415047089N1
2020-04-18Human immunoglobulin GComparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200413047056N1
2020-04-18COVID-19 convalescent plasmaComparison between the efficacy of intravenous immunoglobulin and convalescent plasma in improving the condition of patients with COVID-19 : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200413047056N1
2020-04-18FormoterolThe efficacy of inhaled formoterol on symptom improvement in covid 19 patientsTreatment3RecruitingIRCT20170210032478N3
2020-04-18Ascorbic acidEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18HydroxychloroquineEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18AtazanavirEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18RitonavirEvaluation of effectiveness? of Intravenous vitamin c in Patients with COVID-19 Referred to Imam ?Khomeini Hospital : a clinical trial ?Treatment2, 3Active Not RecruitingIRCT20200411047025N1
2020-04-18BromhexineEffect of Bromhexine Hydrochloride on clinical improvement and outcome of COVID-19-induced pneumoniaTreatment3Active Not RecruitingIRCT20200317046797N4
2020-04-18FennelEvaluation of the effect of herbal medicine containing Saatar, Hofarigon and Fennel on reduction of pulmonary complications of COVID-19 in patients : a clinical trialTreatment3RecruitingIRCT20200404046935N1
2020-04-18ColchicineTreatment With COLchicine of Patients Affected by COVID-19 : a Pilot StudyTreatment2Active Not RecruitingNCT04375202
2020-04-18MethylprednisoloneEfficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2) : a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.Treatment2Active Not RecruitingNCT04343729
2020-04-18SarilumabClinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndromeTreatment2Unknown StatusEUCTR2020-001531-27-ES
2020-04-18Antithrombin III humanPilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19Treatment2Unknown StatusEUCTR2020-001659-42-ES
2020-04-18FavipiravirEfficacy and Safety of Favipiravir in Management of COVID-19Treatment3Active Not RecruitingNCT04349241
2020-04-18Human interferon betaEfficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trialTreatment2, 3Active Not RecruitingIRCT20120225009124N4
2020-04-18Human immunoglobulin GEfficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trialTreatment2, 3Active Not RecruitingIRCT20120225009124N4
2020-04-18DexamethasoneEfficacy of different methods of administeration of combination regiemn including dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19 : a randomized controlled trialTreatment2, 3Active Not RecruitingIRCT20120225009124N4
2020-04-17COVID-19 convalescent plasmaConvalescent Plasma to Limit Coronavirus Associated Complications : a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized PatientsTreatment2Active Not RecruitingNCT04364737
2020-04-17ValsartanPRAETORIAN-COVID : A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection DiseaseTreatment4Active Not RecruitingNCT04335786
2020-04-17AlteplaseA pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS : The Plasminogen Activator COVID-19 ARDS (PACA) trial - Nebulised rtPA for ARDS due to COVID-19 – The PACA trialTreatment2Active Not RecruitingEUCTR2020-001640-26-GB
2020-04-17BaricitinibTreatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsTreatment2Active Not RecruitingNCT04321993
2020-04-17HydrocortisoneLow-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID TrialTreatment3Active Not RecruitingNCT04348305
2020-04-17SelinexorA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 InfectionTreatment2Active Not RecruitingNCT04349098
2020-04-17HydroxychloroquineA Randomized Phase 2 / 3 Trial of Hydroxychloroquine In Covid-19 KineticsTreatment2, 3Active Not RecruitingNCT04353271
2020-04-17ColchicineThe ECLA PHRI COLCOVID TrialTreatment3Active Not RecruitingNCT04328480
2020-04-17AzithromycinA randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOVTreatment3Active Not RecruitingEUCTR2020-001723-13-FR
2020-04-17LopinavirA randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOVTreatment3Active Not RecruitingEUCTR2020-001723-13-FR
2020-04-17RitonavirA randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOVTreatment3Active Not RecruitingEUCTR2020-001723-13-FR
2020-04-17HydroxychloroquineA randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study - OUTCOVTreatment3Active Not RecruitingEUCTR2020-001723-13-FR
2020-04-17Nitric OxideExpanded Access : Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Mild or Moderate Coronavirus Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04358588
2020-04-17FavipiravirOpen Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19Treatment2Active Not RecruitingNCT04358549
2020-04-17FavipiravirClinical Study Evaluating the Efficacy of Faviprevir in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04351295
2020-04-17LopinavirCOVID-19 Ring-based Prevention Trial With Lopinavir / RitonavirPrevention3Active Not RecruitingNCT04321174
2020-04-17RitonavirCOVID-19 Ring-based Prevention Trial With Lopinavir / RitonavirPrevention3Active Not RecruitingNCT04321174
2020-04-17OxygenEffecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)Treatment0Active Not RecruitingChiCTR2000032011
2020-04-16COVID-19 convalescent plasmaConvalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent PlasmaTreatment3Active Not RecruitingNCT04376034
2020-04-16SevofluraneSedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 InfectionTreatment4Active Not RecruitingNCT04359862
2020-04-16PropofolSedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 InfectionTreatment4Active Not RecruitingNCT04359862
2020-04-16HydroxychloroquineMulticentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19Treatment3Active Not RecruitingNCT04420247
2020-04-16ChloroquineMulticentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19Treatment3Active Not RecruitingNCT04420247
2020-04-16BCG vaccineReducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled TrialPrevention4Active Not RecruitingNCT04417335
2020-04-16AzithromycinEfficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform TrialTreatment2, 3Active Not RecruitingNCT04354428
2020-04-16Folic acidEfficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform TrialTreatment2, 3Active Not RecruitingNCT04354428
2020-04-16Ascorbic acidEfficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform TrialTreatment2, 3Active Not RecruitingNCT04354428
2020-04-16HydroxychloroquineEfficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults : An Adaptive Randomized Platform TrialTreatment2, 3Active Not RecruitingNCT04354428
2020-04-16ChloroquineMulticenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious ComplicationsTreatment4Active Not RecruitingNCT04331600
2020-04-16CyclosporineOpen, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 InfectionTreatment4Active Not RecruitingNCT04392531
2020-04-16BCG vaccineREDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIALTreatmentNot AvailableRecruitingNL8547
2020-04-16RibavirinEvaluation of the Effect of Trifluoperazin in Treatment of Patients with Confirmed 2019 Novel Coronavirus(COVID- 19) : An Open-Label Randomized Clinical TrialTreatment3Active Not RecruitingIRCT20200408046992N1
2020-04-16AzithromycinAn Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild SymptomsTreatment1, 2Active Not RecruitingNCT04344457
2020-04-16HydroxychloroquineAn Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild SymptomsTreatment1, 2Active Not RecruitingNCT04344457
2020-04-16IndomethacinAn Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild SymptomsTreatment1, 2Active Not RecruitingNCT04344457
2020-04-16Ascorbic acidAdministration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO) : A Phase I / II Safety, Tolerability, and Efficacy Clinical TrialTreatment1, 2Active Not RecruitingNCT04357782
2020-04-16CoronaVacA Randomized, Double-Blinded, Placebo-Controlled, Phase ? / ? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 YearsPrevention1, 2Active Not RecruitingNCT04352608
2020-04-16ClazakizumabA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16ChloroquineA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16RitonavirA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16CandesartanA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16HydroxychloroquineA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16LopinavirA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16RivaroxabanA Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)Treatment2, 3Active Not RecruitingNCT04351724
2020-04-16EculizumabCORIMUNO19-ECU : Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 CohortTreatment2Active Not RecruitingNCT04346797
2020-04-16SarilumabSarilumab Treatment In cytoKinE storm caused by infection with COVID-19.Treatment2Unknown StatusEUCTR2020-001255-40-ES
2020-04-16HemoglobinPredictive value of biological, physiological and analytical biomarkers with the use of personal protection equipment in COVID-19 : observational, prospective, analytical, intervention and multicenter studyBasic ScienceNot AvailableCompletedISRCTN18348009
2020-04-16UreaPredictive value of biological, physiological and analytical biomarkers with the use of personal protection equipment in COVID-19 : observational, prospective, analytical, intervention and multicenter studyBasic ScienceNot AvailableCompletedISRCTN18348009
2020-04-16CreatininePredictive value of biological, physiological and analytical biomarkers with the use of personal protection equipment in COVID-19 : observational, prospective, analytical, intervention and multicenter studyBasic ScienceNot AvailableCompletedISRCTN18348009
2020-04-16Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsTwo-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19.Treatment2Active Not RecruitingEUCTR2020-001266-11-ES
2020-04-16Human Umbilical Cord Mesenchymal Stem CellsA Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19Treatment1Active Not RecruitingNCT04456361
2020-04-15ThalidomideThe efficacy and safety of Thalidomide in severe Covid19 pneumonia : Arandomized controlled clinical trialTreatment3RecruitingIRCT20170207032444N3
2020-04-15LeronlimabA Phase 2b / 3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04347239
2020-04-15COVID-19 convalescent plasmaA Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04346589
2020-04-15ChloroquineA Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.Treatment2Active Not RecruitingNCT04333914
2020-04-15TocilizumabA Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.Treatment2Active Not RecruitingNCT04333914
2020-04-15MonalizumabA Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.Treatment2Active Not RecruitingNCT04333914
2020-04-15NivolumabA Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti-PD-1 (Nivolumab), an Anti-NKG2A (Monalizumab), an Anti-interleukine-6 Receptor (Tocilizumab) and an Anti-C5aR (Avdoralimab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.Treatment2Active Not RecruitingNCT04333914
2020-04-15COVID-19 convalescent plasmaCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTSTreatment2Active Not RecruitingNCT04345991
2020-04-15IvermectinEfficacy of Ivermectin in COVID-19 : A Randomized Controlled TrialTreatmentNot AvailableActive Not RecruitingNCT04392713
2020-04-15COVID-19 convalescent plasmaConvalescent Plasma for the Treatment of Patients With COVID-19Treatment2Active Not RecruitingNCT04389710
2020-04-15Mumps virus strain B level jeryl lynn live antigenEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)TreatmentNot AvailableActive Not RecruitingPACTR202004693933092
2020-04-15Rubella virus vaccineEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)TreatmentNot AvailableActive Not RecruitingPACTR202004693933092
2020-04-15Measles virus vaccine live attenuatedEffectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)TreatmentNot AvailableActive Not RecruitingPACTR202004693933092
2020-04-15CalcifediolThe efficacy of oral 25-hydroxyvitamin D3 on COVID-19 treatment in adults : A Randomized, Controlled Double-Blind Clinical Trial.Treatment3Active Not RecruitingIRCT20200401046909N1
2020-04-15CholecalciferolCOvid-19 and Vitamin D Supplementation : a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)Treatment3Active Not RecruitingNCT04344041
2020-04-15TocilizumabA multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)Treatment2Active Not RecruitingEUCTR2020-001302-30-AT
2020-04-15LopinavirA multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)Treatment2Active Not RecruitingEUCTR2020-001302-30-AT
2020-04-15AsunerceptA multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)Treatment2Active Not RecruitingEUCTR2020-001302-30-AT
2020-04-15RivaroxabanA multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)Treatment2Active Not RecruitingEUCTR2020-001302-30-AT
2020-04-15RitonavirA multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)Treatment2Active Not RecruitingEUCTR2020-001302-30-AT
2020-04-15Candesartan cilexetilA multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2) ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)Treatment2Active Not RecruitingEUCTR2020-001302-30-AT
2020-04-15HydroxychloroquineTreating COVID-19 With Hydroxychloroquine : A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized AdultsTreatment2Active Not RecruitingNCT04369742
2020-04-15HydroxychloroquineUse and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization RateTreatment4Active Not RecruitingNCT04351191
2020-04-15ChloroquineUse and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization RateTreatment4Active Not RecruitingNCT04351191
2020-04-15EmtricitabinePrevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial Controlled With PlaceboPrevention3Active Not RecruitingNCT04334928
2020-04-15Tenofovir disoproxilPrevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial Controlled With PlaceboPrevention3Active Not RecruitingNCT04334928
2020-04-15HydroxychloroquinePrevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial Controlled With PlaceboPrevention3Active Not RecruitingNCT04334928
2020-04-15AldesleukinLow dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID - LILIADE-COVIDTreatment2Active Not RecruitingEUCTR2020-001571-32-FR
2020-04-15DexmedetomidineImpact of Dexmedetomidine Infusion on the Time Course and Outcomes of Acute Respiratory Distress Syndrome (ARDS) in Patients Affected by the SARS-CoV-2 (COVID-19) Admitted to Critical Care UnitBasic ScienceNot AvailableActive Not RecruitingNCT04358627
2020-04-15SulfamethoxazolesuPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19 : The SAVE Open-label, Non-randomized Single-arm TrialPrevention2Active Not RecruitingNCT04357366
2020-04-15AnakinrasuPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19 : The SAVE Open-label, Non-randomized Single-arm TrialPrevention2Active Not RecruitingNCT04357366
2020-04-15TrimethoprimsuPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19 : The SAVE Open-label, Non-randomized Single-arm TrialPrevention2Active Not RecruitingNCT04357366
2020-04-15RuxolitinibAn Open-Label Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04355793
2020-04-15Schisandra chinensis fruitA multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumoniaTreatmentNot AvailableActive Not RecruitingChiCTR2000032205
2020-04-15GinsengA multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumoniaTreatmentNot AvailableActive Not RecruitingChiCTR2000032205
2020-04-15ImatinibOutpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)Treatment3Active Not RecruitingNCT04356495
2020-04-15TelmisartanOutpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)Treatment3Active Not RecruitingNCT04356495
2020-04-15HydroxychloroquineOutpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)Treatment3Active Not RecruitingNCT04356495
2020-04-15FavipiravirOutpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19) : a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)Treatment3Active Not RecruitingNCT04356495
2020-04-15UmifenovirEfficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19 : A Randomized, Double-Blind, Placebo-Controlled, Clinical TrialTreatment4Active Not RecruitingNCT04350684
2020-04-15Interferon beta-1aAn Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized, Double-Blind, Placebo-Controlled, Clinical TrialTreatment4Active Not RecruitingNCT04350671
2020-04-15TocilizumabAn Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of ProgressionTreatment3Active Not RecruitingNCT04345445
2020-04-15MethylprednisoloneAn Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of ProgressionTreatment3Active Not RecruitingNCT04345445
2020-04-15CaptoprilRandomized Trial of ACEIs in Treatment of COVID-19Treatment3Active Not RecruitingNCT04345406
2020-04-15EnalaprilRandomized Trial of ACEIs in Treatment of COVID-19Treatment3Active Not RecruitingNCT04345406
2020-04-15BevacizumabCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA TrialTreatment2Active Not RecruitingNCT04344782
2020-04-15NivolumabCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab TrialTreatment2Active Not RecruitingNCT04343144
2020-04-15RuxolitinibTreatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With RuxolitinibTreatment1, 2Active Not RecruitingNCT04334044
2020-04-15SiltuximabPhase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 PneumoniaTreatment2Active Not RecruitingNCT04329650
2020-04-15MethylprednisolonePhase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 PneumoniaTreatment2Active Not RecruitingNCT04329650
2020-04-15HoneyThe Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center TrialTreatment3Active Not RecruitingNCT04323345
2020-04-15HydroxychloroquinePreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 - COVIDSurgRCT_v1.0_20200330Treatment3Unknown StatusEUCTR2020-001448-24-GB
2020-04-15RitonavirPreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 - COVIDSurgRCT_v1.0_20200330Treatment3Unknown StatusEUCTR2020-001448-24-GB
2020-04-15LopinavirPreventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 - COVIDSurgRCT_v1.0_20200330Treatment3Unknown StatusEUCTR2020-001448-24-GB
2020-04-15AnakinrasuPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19 : THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIALTreatment2Active Not RecruitingEUCTR2020-001466-11-GR
2020-04-15TrimethoprimsuPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19 : THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIALTreatment2Active Not RecruitingEUCTR2020-001466-11-GR
2020-04-15SulfamethoxazolesuPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19 : THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIALTreatment2Active Not RecruitingEUCTR2020-001466-11-GR
2020-04-15HydroxychloroquineThe Danish Pre-HCQ Dialysis Study : Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical trial - The Danish Pre-HCQ COVID19 Dialysis StudyTreatment3Active Not RecruitingEUCTR2020-001257-51-DK
2020-04-14HydroxychloroquineOff Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2Prevention1, 2Active Not RecruitingNCT04435808
2020-04-14HydroxychloroquineFeasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care ProvidersPrevention2Active Not RecruitingNCT04345653
2020-04-14LopinavirChemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical TrialPrevention3Active Not RecruitingNCT04328285
2020-04-14HydroxychloroquineChemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical TrialPrevention3Active Not RecruitingNCT04328285
2020-04-14RitonavirChemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical TrialPrevention3Active Not RecruitingNCT04328285
2020-04-14SelinexorA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 InfectionTreatment2Active Not RecruitingEUCTR2020-001411-25-AT
2020-04-14SenicapocSenicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial - COVIPOCTreatment2Active Not RecruitingEUCTR2020-001420-34-DK
2020-04-14CalcifediolPreventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in AdultsPrevention2, 3Active Not RecruitingNCT04386850
2020-04-14TranscrocetinateA Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 DiseaseTreatment1, 2Active Not RecruitingNCT04378920
2020-04-14AcetylcysteineClinical Trial using N-acetylcysteine for treatment of 2019-nCoV PneumoniaTreatmentNot AvailableActive Not RecruitingRBR-8969zg
2020-04-14COVID-19 convalescent plasmaExperimental Use of COVID-19 Convalescent Plasma for the Purpose Of Passive Immunization in Current COVID-19 PandemicTreatmentNot AvailableRecruitingIRCT20200414047072N1
2020-04-14MelatoninEvaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings : A double-blind randomized and placebo controlled trialTreatment2, 3RecruitingIRCT20200408046988N1
2020-04-14MelatoninEvaluation of adding melatonin to routine treatment on outcomes and quality of sleep in COVID-19 patientsTreatment3RecruitingIRCT20200411047030N1
2020-04-14CalcifediolInvestigating preventive effects of oral 25-hydroxyvitamin D3 on COVID-19 in adults : A Randomized, Controlled Double-Blind Clinical Trial.Treatment3Active Not RecruitingIRCT20200401046909N2
2020-04-14MethylprednisoloneEvaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19) : A Non-Randomized Controlled StudyTreatment2, 3Active Not RecruitingIRCT20200204046369N1
2020-04-14PrednisoloneEvaluation of Methylprednisolone Administration as a Therapeutic Option in the 2019 Novel Coronavirus (COVID-19) : A Non-Randomized Controlled StudyTreatment2, 3Active Not RecruitingIRCT20200204046369N1
2020-04-14ChloroquineUse and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization RateTreatment4Active Not RecruitingNCT04346667
2020-04-14HydroxychloroquineUse and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization RateTreatment4Active Not RecruitingNCT04346667
2020-04-14BaricitinibEfficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCTTreatment3Active Not RecruitingEUCTR2020-001367-88-DK
2020-04-14SarilumabEfficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCTTreatment3Active Not RecruitingEUCTR2020-001367-88-DK
2020-04-14HydroxychloroquineEfficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCTTreatment3Active Not RecruitingEUCTR2020-001367-88-DK
2020-04-14ChloroquineAn Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19Treatment4Active Not RecruitingNCT04362332
2020-04-14HydroxychloroquineAn Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19Treatment4Active Not RecruitingNCT04362332
2020-04-14COVID-19 convalescent plasmaAnti COVID-19 Convalescent Plasma TherapyTreatment1Active Not RecruitingNCT04345679
2020-04-14AzithromycinA SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMICTreatment2Active Not RecruitingEUCTR2020-001327-13-AT
2020-04-14HydroxychloroquineA Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19Treatment2Active Not RecruitingACTRN12620000457943
2020-04-14NivolumabCOVID-19 : A Pilot Study of Adaptive Immunity and Anti-PD1Treatment2Active Not RecruitingNCT04356508
2020-04-14MethylprednisoloneProphylactic Corticosteroid to Prevent COVID-19 Cytokine StormPrevention2Active Not RecruitingNCT04355247
2020-04-14HydroxychloroquineHydroxychloroquine for Outpatients With Confirmed COVID-19Treatment2Active Not RecruitingNCT04342169
2020-04-14HydroxychloroquineChemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients : A Randomized Controlled Trial (PHYDRA Trial)Prevention3Active Not RecruitingNCT04318015
2020-04-14HydroxychloroquineHydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease : Randomised Clinical Trial (HYDRA Trial)Treatment3Active Not RecruitingNCT04315896
2020-04-14ColchicineRandomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVIDTreatment3Unknown StatusEUCTR2020-001511-25-ES
2020-04-14SevofluraneSedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infectionTreatment4Active Not RecruitingEUCTR2020-001379-34-ES
2020-04-14PropofolSedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infectionTreatment4Active Not RecruitingEUCTR2020-001379-34-ES
2020-04-14HydroxychloroquineChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) - PROLIFIC Trial (COVID-19)Treatment3Active Not RecruitingEUCTR2020-001331-26-GB
2020-04-14HydroxychloroquineRandomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19TreatmentNot AvailableActive Not RecruitingNCT04349592
2020-04-14AzithromycinRandomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19TreatmentNot AvailableActive Not RecruitingNCT04349592
2020-04-13DexamethasoneCOVID-19-associated ARDS Treated With DEXamethasone : an Open-label, Randomized, Controlled Trial : CoDEX (Alliance Covid-19 Brasil III)Treatment3Active Not RecruitingNCT04327401
2020-04-13LosartanRandomized Controlled Trial of Losartan for Patients With COVID-19 Requiring HospitalizationTreatment2Active Not RecruitingNCT04312009
2020-04-13HydroxychloroquineA Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.Treatment3Active Not RecruitingNCT04329611
2020-04-13ImatinibProspective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 PneumoniaTreatment2Active Not RecruitingNCT04346147
2020-04-13BaricitinibProspective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 PneumoniaTreatment2Active Not RecruitingNCT04346147
2020-04-13RitonavirProspective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 PneumoniaTreatment2Active Not RecruitingNCT04346147
2020-04-13LopinavirProspective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 PneumoniaTreatment2Active Not RecruitingNCT04346147
2020-04-13HydroxychloroquineProspective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 PneumoniaTreatment2Active Not RecruitingNCT04346147
2020-04-13ChloroquineOpen labelled Randomised controlled trial to study the effect of Chloroquine in addition to standard therapy in COVID-19 patientsTreatmentNot AvailableActive Not RecruitingCTRI/2020/04/024479
2020-04-13HydroxychloroquineThe prophylactic effect of Hydroxychloroquine on Novel Corona virus (COVID-19) in health care providersTreatment3RecruitingIRCT20151222025660N2
2020-04-13AtorvastatinEvaluating the efficacy of Atorvastatin in clinical improvement, prognosis and hospitalization course in patients with COVID-19 infectionTreatment3Active Not RecruitingIRCT20200413047062N1
2020-04-13COVID-19 convalescent plasmaThe effect of plasma administration of COVID-19 survivors in patients with acute respiratory distress syndrome due to COVID-19TreatmentNot AvailableActive Not RecruitingIRCT20200409047007N1
2020-04-13NaproxenEvaluation of the role of naproxen as adjunctive therapy with standard therapies and its efficacy in the early improvement and reduced mortality rate of COVID-19 patientsTreatment4RecruitingIRCT20200410047009N1
2020-04-13COVID-19 convalescent plasmaRandomized, parallel-controlled and multi-center clinical study evaluating the efficacy and safety of convalescent plasma, in the treatment of patients with severe SARS-CoV-2 infection (COVID-19)Treatment3RecruitingIRCT20200404046948N1
2020-04-13HydroxychloroquineEffect of Hydroxychloroquine on Novel Coronavirus Disease (COVID-19) prevention in cancer patients under treatmentTreatment2, 3RecruitingIRCT20200405046958N1
2020-04-13SarilumabRandomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 InfectionTreatment2Active Not RecruitingNCT04357808
2020-04-13COVID-19 convalescent plasmaCOPLA Study : Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsmaTreatment2Active Not RecruitingNCT04357106
2020-04-13IcosapentA Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2Treatment3Active Not RecruitingNCT04335032
2020-04-13HydroxychloroquineProtecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis : a randomized, placebo-controlled multi-site trial in Toronto, CanadaTreatment3RecruitingISRCTN14326006
2020-04-13BudesonideProtective Role of Inhaled Steroids for Covid-19 InfectionTreatment3Active Not RecruitingNCT04331054
2020-04-13FormoterolProtective Role of Inhaled Steroids for Covid-19 InfectionTreatment3Active Not RecruitingNCT04331054
2020-04-13TradipitantODYSSEY : A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 InfectionTreatment3Active Not RecruitingNCT04326426
2020-04-13NaproxenEfficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 InfectionTreatment3Active Not RecruitingNCT04325633
2020-04-13Remestemcel-LDouble-blind, placebo-controlled phase I / II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV®-allo) in acute respiratory failure in patients with COVID-19 pneumonia. - Treatment of COVID.19 with allogeneic mesenchymal cells (MSV®).Treatment2Unknown StatusEUCTR2020-001682-36-ES
2020-04-13PrednisoneCorticoïdes au cours de la pneumonie virale Covid-19 liée à l’infection par le SARS-Cov-2 - CORTI-CovidTreatment2Active Not RecruitingEUCTR2020-001553-48-FR
2020-04-13HydroxychloroquineA questionnaire investigation of hydroxychloroquine for its potential protective effect against Severe Acute Respiratory Syndromes-coronavirus-2 infectionBasic ScienceNot AvailableActive Not RecruitingChiCTR2000031782
2020-04-12GimsilumabA Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)Treatment2Active Not RecruitingNCT04351243
2020-04-12HydroxychloroquineA Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19Treatment1Active Not RecruitingNCT04333654
2020-04-12Ad5-nCoVA Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 YearsPrevention2Active Not RecruitingNCT04341389
2020-04-12ChloroquineAn open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19TreatmentNot AvailableActive Not RecruitingNL8490
2020-04-12HydroxychloroquineAn open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19TreatmentNot AvailableActive Not RecruitingNL8490
2020-04-12HydroxychloroquineAn open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 - COVIDAMTreatment2Active Not RecruitingEUCTR2020-001417-21-BE
2020-04-12SimvastatinRandomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.Treatment2Active Not RecruitingNCT04348695
2020-04-12RuxolitinibRandomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.Treatment2Active Not RecruitingNCT04348695
2020-04-12GoldAI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)DiagnosticNot AvailableActive Not RecruitingChiCTR2000031336
2020-04-11AzithromycinEfficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19 : a Multicenter Open-label 1 : 1 Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04341870
2020-04-11HydroxychloroquineEfficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19 : a Multicenter Open-label 1 : 1 Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04341870
2020-04-11SarilumabEfficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19 : a Multicenter Open-label 1 : 1 Randomized Controlled TrialTreatment2, 3Active Not RecruitingNCT04341870
2020-04-11HydroxychloroquineAn Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 VirusTreatment3Active Not RecruitingNCT04355052
2020-04-11AzithromycinAn Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 VirusTreatment3Active Not RecruitingNCT04355052
2020-04-11CamostatAn Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 VirusTreatment3Active Not RecruitingNCT04355052
2020-04-11Human immunoglobulin GValue of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 InfectionsTreatment3Active Not RecruitingNCT04350580
2020-04-11HydroxychloroquineRandomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 PneumoniaTreatment2, 3Active Not RecruitingNCT04345861
2020-04-11AzithromycinRandomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 PneumoniaTreatment2, 3Active Not RecruitingNCT04345861
2020-04-11SolnatideCOVID-19 : Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.Treatment2Active Not RecruitingEUCTR2020-001244-26-AT
2020-04-11RemdesivirThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11LosartanThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11COVID-19 convalescent plasmaThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11AzithromycinThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11DoxycyclineThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11Interferon alfa-2bThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11PrimaquineThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11MethylprednisoloneThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11TocilizumabThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11HydroxychloroquineThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11ClindamycinThe Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolTreatment2, 3Active Not RecruitingNCT04349410
2020-04-11HydroxychloroquinePragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts : patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alterationTreatment2Active Not RecruitingEUCTR2020-001765-37-ES
2020-04-11ColchicineCOLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)Treatment3Unknown StatusEUCTR2020-001689-12-ES
2020-04-11RitonavirProspective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUFTreatment2Unknown StatusEUCTR2020-001321-31-ES
2020-04-11HydroxychloroquineProspective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUFTreatment2Unknown StatusEUCTR2020-001321-31-ES
2020-04-11LopinavirProspective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUFTreatment2Unknown StatusEUCTR2020-001321-31-ES
2020-04-11BaricitinibProspective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUFTreatment2Unknown StatusEUCTR2020-001321-31-ES
2020-04-11ImatinibProspective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUFTreatment2Unknown StatusEUCTR2020-001321-31-ES
2020-04-11SarilumabEfficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care - SARICOVIDTreatment3Unknown StatusEUCTR2020-001290-74-ES
2020-04-11HydroxychloroquineEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-AgingTreatment3Active Not RecruitingEUCTR2020-001303-16-FR
2020-04-11TelmisartanEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-AgingTreatment3Active Not RecruitingEUCTR2020-001303-16-FR
2020-04-11AzithromycinEfficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-AgingTreatment3Active Not RecruitingEUCTR2020-001303-16-FR
2020-04-10SarilumabSarilumab for Patients With Moderate COVID-19 Disease : A Randomized Controlled Trial With a Play-The-Winner DesignTreatment2Active Not RecruitingNCT04359901
2020-04-10Interferon alfa-2bEvaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19).Treatment2CompletedRPCEC00000307
2020-04-10Interferon GammaEvaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19).Treatment2CompletedRPCEC00000307
2020-04-10EIDD-2801A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy VolunteersTreatment1Active Not RecruitingNCT04392219
2020-04-10FluvoxamineA Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 InfectionTreatment2Active Not RecruitingNCT04342663
2020-04-10LopinavirAustralasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir / ritonavir and / or hydroxychloroquine compared to standard of careTreatment3Active Not RecruitingACTRN12620000445976
2020-04-10RitonavirAustralasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir / ritonavir and / or hydroxychloroquine compared to standard of careTreatment3Active Not RecruitingACTRN12620000445976
2020-04-10HydroxychloroquineAustralasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir / ritonavir and / or hydroxychloroquine compared to standard of careTreatment3Active Not RecruitingACTRN12620000445976
2020-04-10COVID-19 convalescent plasmaPlasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 DiseaseTreatment1, 2Active Not RecruitingNCT04390178
2020-04-10COVID-19 convalescent plasmaConvalescent Plasma in the Treatment of COVID 19Treatment2Active Not RecruitingNCT04343261
2020-04-10COVID-19 convalescent plasmaPilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical CenterTreatment1Active Not RecruitingNCT04340050
2020-04-10HydroxychloroquineRandomized, pragmatic, open study evaluating Hydroxychloroquine for prevention of Hospitalization and Respiratory Complications in outpatients with confirmed or presumptive diagnosis of Infection by (COVID-19)Treatment3Active Not RecruitingRBR-3cbs3w
2020-04-10HydroxychloroquineSafety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N2
2020-04-10PrednisoloneSafety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N2
2020-04-10NaproxenSafety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N2
2020-04-10AzithromycinSafety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N2
2020-04-10BromhexineUse of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 PneumoniaTreatment4Active Not RecruitingNCT04355026
2020-04-10HydroxychloroquineUse of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 PneumoniaTreatment4Active Not RecruitingNCT04355026
2020-04-10DexamethasoneDexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUSTreatmentNot AvailableActive Not RecruitingNCT04344730
2020-04-10AzithromycinTreatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease : A Randomized Clinical TrialTreatment3Active Not RecruitingNCT04344444
2020-04-10HydroxychloroquineTreatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease : A Randomized Clinical TrialTreatment3Active Not RecruitingNCT04344444
2020-04-10Vitamin DCOvid-19 and Vitamin D supplementation : a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients - CoVitTrialTreatment3Active Not RecruitingEUCTR2020-001602-34-FR
2020-04-10ValsartanA double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (COVID-19) - PRAETORIAN-COVIDTreatment2Active Not RecruitingEUCTR2020-001320-34-NL
2020-04-10Vitamin DEffect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19TreatmentNot AvailableActive Not RecruitingNCT04334005
2020-04-10Dornase alfaInterest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornaseTreatment3Active Not RecruitingEUCTR2020-001492-33-FR
2020-04-10OxygenDexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUSTreatment3Active Not RecruitingEUCTR2020-001457-43-FR
2020-04-10DexamethasoneDexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUSTreatment3Active Not RecruitingEUCTR2020-001457-43-FR
2020-04-10FavipiravirHome treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) - COVERAGETreatment3Active Not RecruitingEUCTR2020-001435-27-FR
2020-04-10TelmisartanHome treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) - COVERAGETreatment3Active Not RecruitingEUCTR2020-001435-27-FR
2020-04-10ImatinibHome treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatments to reduce the risk of hospitalization or death (COVERAGE trial) - COVERAGETreatment3Active Not RecruitingEUCTR2020-001435-27-FR
2020-04-10NaproxenEfficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVIDTreatment3Active Not RecruitingEUCTR2020-001301-23-FR
2020-04-10HydroxychloroquineClearing the Fog : Is HCQ Effective in Reducing COVID-19 ProgressionTreatmentNot AvailableActive Not RecruitingNCT04491994
2020-04-09HydroxychloroquineHydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial - Hydro-STOP-COVID19 TrialTreatment3Unknown StatusEUCTR2020-001558-23-IT
2020-04-09Glycyrrhiza glabraEvaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19Treatment1, 2Active Not RecruitingIRCT20200405046960N1
2020-04-09FennelEvaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19Treatment1, 2Active Not RecruitingIRCT20200405046960N1
2020-04-09LicoriceEvaluating the therapeutic effect of a mixed herbal drink of Marshmallow and Licorice on COVID 19 patients, A double blind clinical trialTreatment3Active Not RecruitingIRCT20200404046937N1
2020-04-09Interferon beta-1aAn Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized Clinical TrialTreatment2Active Not RecruitingNCT04343768
2020-04-09Interferon beta-1bAn Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19 : A Randomized Clinical TrialTreatment2Active Not RecruitingNCT04343768
2020-04-09HydroxychloroquineThe PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)Treatment2Active Not RecruitingNCT04329923
2020-04-09LosartanRandomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring HospitalizationTreatment2Active Not RecruitingNCT04311177
2020-04-09RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment3Unknown StatusEUCTR2020-001366-11-IT
2020-04-09HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment3Unknown StatusEUCTR2020-001366-11-IT
2020-04-09LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment3Unknown StatusEUCTR2020-001366-11-IT
2020-04-09RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment3Unknown StatusEUCTR2020-001366-11-IT
2020-04-09ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment3Unknown StatusEUCTR2020-001366-11-IT
2020-04-09Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment3Unknown StatusEUCTR2020-001366-11-IT
2020-04-09Nitric OxideInhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 - NOSARSCOVID19Treatment4Active Not RecruitingEUCTR2020-001329-30-AT
2020-04-09HydroxychloroquineAn Open-label Randomized Controlled Trial on Interferon ß-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 InfectionTreatment2Active Not RecruitingNCT04350281
2020-04-09Interferon beta-1bAn Open-label Randomized Controlled Trial on Interferon ß-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 InfectionTreatment2Active Not RecruitingNCT04350281
2020-04-09IodineA Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19Treatment2Active Not RecruitingNCT04344236
2020-04-09ChlorhexidineA Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19Treatment2Active Not RecruitingNCT04344236
2020-04-09PovidoneA Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19Treatment2Active Not RecruitingNCT04344236
2020-04-09COVID-19 convalescent plasmaPhase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 InfectionTreatment2Active Not RecruitingNCT04343755
2020-04-09GalidesivirA Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19Treatment1Active Not RecruitingNCT03891420
2020-04-09SarilumabRandomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.Treatment2Unknown StatusEUCTR2020-001634-36-ES
2020-04-09MelatoninRandomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19Treatment4Unknown StatusEUCTR2020-001530-35-ES
2020-04-09TocilizumabRandom, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugsTreatment4Unknown StatusEUCTR2020-001437-12-ES
2020-04-09CyclosporineRandom, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugsTreatment4Unknown StatusEUCTR2020-001437-12-ES
2020-04-09ChloroquineRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09LopinavirRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09RitonavirRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09CyclosporineRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09TocilizumabRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09SpironolactoneRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09DarunavirRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09Interferon beta-1bRandomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01Treatment4Unknown StatusEUCTR2020-001262-11-ES
2020-04-09TocilizumabA Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19 (COPERNICO Study)Treatment2Unknown StatusEUCTR2020-001160-28-ES
2020-04-09PembrolizumabA Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19 (COPERNICO Study)Treatment2Unknown StatusEUCTR2020-001160-28-ES
2020-04-09HydroxychloroquineDexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCOTreatment3Active Not RecruitingEUCTR2020-001333-13-FR
2020-04-09DexamethasoneDexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCOTreatment3Active Not RecruitingEUCTR2020-001333-13-FR
2020-04-09Ad5-nCoVA randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 yearsTreatment2Active Not RecruitingChiCTR2000031781
2020-04-09Zinc chlorideHigh-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients : A pilot randomized controlled trialTreatment1, 2Active Not RecruitingACTRN12620000454976
2020-04-08Recombinant Human Angiotensin-Converting Enzyme 2Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19Treatment2Active Not RecruitingEUCTR2020-001172-15-DE
2020-04-08CiclesonideA Trial of Ciclesonide in Adults with Mild COVID-19Treatment2RecruitingKCT0005105
2020-04-08Ascorbic acidInterventional study of intravenous vitamin C in definitive patients with covid 19 and its effect on changes in lung CT scan and clinical and laboratory symptoms of patientsTreatment2, 3Active Not RecruitingIRCT20200516047468N1
2020-04-08UmifenovirEvaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patientsTreatment3RecruitingIRCT20151227025726N15
2020-04-08MefloquineAn Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19Treatment2, 3Active Not RecruitingNCT04347031
2020-04-08COVID-19 convalescent plasmaConvalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19Treatment2, 3Active Not RecruitingNCT04342182
2020-04-08Ascorbic acidCoronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center StudySupportive CareNot AvailableActive Not RecruitingNCT04342728
2020-04-08Zinc gluconateCoronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center StudySupportive CareNot AvailableActive Not RecruitingNCT04342728
2020-04-08HydroxychloroquineHydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study - CORONA studyTreatment3Active Not RecruitingCTRI/2020/03/024402
2020-04-08HydroxychloroquineRandomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trialTreatment3Active Not RecruitingIRCT20200405046953N1
2020-04-08Interferon beta-1aRandomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trialTreatment3Active Not RecruitingIRCT20200405046953N1
2020-04-08LopinavirRandomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trialTreatment3Active Not RecruitingIRCT20200405046953N1
2020-04-08RitonavirRandomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trialTreatment3Active Not RecruitingIRCT20200405046953N1
2020-04-08RemdesivirRandomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trialTreatment3Active Not RecruitingIRCT20200405046953N1
2020-04-08ChloroquineRandomzied trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care- Iranian SOLIDARITY multicentre trialTreatment3Active Not RecruitingIRCT20200405046953N1
2020-04-08SofosbuvirThe effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients : A Clinical Trial StudyTreatment3RecruitingIRCT20200403046926N1
2020-04-08DaclatasvirThe effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients : A Clinical Trial StudyTreatment3RecruitingIRCT20200403046926N1
2020-04-08SofosbuvirComparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19Treatment3RecruitingIRCT20130812014333N147
2020-04-08DaclatasvirComparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19Treatment3RecruitingIRCT20130812014333N147
2020-04-08Lithium carbonateComparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19Treatment3RecruitingIRCT20130812014333N147
2020-04-08TrifluoperazineComparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19Treatment3RecruitingIRCT20130812014333N147
2020-04-08VelpatasvirComparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir” to “standard of care therapeutic regimen” in patients with COVID-19Treatment3Active Not RecruitingIRCT20130812014333N145
2020-04-08SofosbuvirComparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir” to “standard of care therapeutic regimen” in patients with COVID-19Treatment3Active Not RecruitingIRCT20130812014333N145
2020-04-08TocilizumabThe Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary HyperinflammationTreatment4Active Not RecruitingNCT04377750
2020-04-08AT-001A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 InfectionTreatment2Active Not RecruitingNCT04365699
2020-04-08ChloroquineA multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.Treatment4Active Not RecruitingEUCTR2020-001469-35-PL
2020-04-08DefibrotidePhase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release SyndromeTreatment2Active Not RecruitingNCT04348383
2020-04-08COVID-19 convalescent plasmaConvalescent Plasma to Reduce Complications Associated With COVID-19 Infection : A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 InfectionTreatment1, 2Active Not RecruitingNCT04344535
2020-04-08ChloroquinePhase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2) : a Double-blind, Randomized, Placebo-controlled Clinical TrialTreatment2Active Not RecruitingNCT04342650
2020-04-08FingolimodEffect of Fingolimod for treatment of COVID-19-induced cytokine stormTreatment3Active Not RecruitingIRCT20200317046797N2
2020-04-08HydroxychloroquineHydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancyTreatment4Unknown StatusEUCTR2020-001587-29-ES
2020-04-07Ascorbic acidA study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar HopsitalTreatment2Active Not RecruitingIRCT20151228025732N52
2020-04-07MelatoninA study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar HopsitalTreatment2Active Not RecruitingIRCT20151228025732N52
2020-04-07Zinc sulfateA study on melatonin and Vitamin C and zinc efficacy in patients with COVID19 hospitalized in intensive care unit of Semnan Kowsar HopsitalTreatment2Active Not RecruitingIRCT20151228025732N52
2020-04-07COVID-19 convalescent plasmaConvalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications : A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Patients With Severe Respiratory Distress Due to COVID-19Treatment1Active Not RecruitingNCT04411602
2020-04-07ChloroquineA Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in VietnamTreatment2Active Not RecruitingNCT04328493
2020-04-07NicotinamideImprovement of the nutritional status regarding nicotinamide (vitamin B3) and the course of COVID-19 disease - COVitTreatmentNot AvailableActive Not RecruitingDRKS00021214
2020-04-07FamotidineA Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04370262
2020-04-07COVID-19 convalescent plasmaInvestigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria : FALP 001-2020 Trial (FALP-COVID)Treatment2, 3Active Not RecruitingNCT04384588
2020-04-07Vitamin AComparison of the effectiveness of standard treatment with stand treatment plus Vitamin A in treatment in covid19 patientsTreatment3Active Not RecruitingIRCT20180520039738N2
2020-04-07HydroxychloroquineEvaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxisTreatment3RecruitingIRCT20130917014693N10
2020-04-07HydroxychloroquineWill Hydroxychloroquine Impede or Prevent COVID-19 : WHIP COVID-19 StudyPrevention3Active Not RecruitingNCT04341441
2020-04-07TocilizumabTociluzumab for Cytokine Release Syndrome With SARS-CoV-2 : An Open-Labeled, Randomized Phase 3 TrialTreatment3Active Not RecruitingNCT04361552
2020-04-07HydroxychloroquinePATCH 2 & 3 : (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19Treatment2Active Not RecruitingNCT04353037
2020-04-07SiltuximabPhase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumoniaTreatment2Active Not RecruitingEUCTR2020-001413-20-ES
2020-04-07MethylprednisolonePhase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumoniaTreatment2Active Not RecruitingEUCTR2020-001413-20-ES
2020-04-07HydroxychloroquineRandomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19Treatment3Active Not RecruitingEUCTR2020-001406-27-FR
2020-04-07AzithromycinRandomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19Treatment3Active Not RecruitingEUCTR2020-001406-27-FR
2020-04-07AzithromycinRandomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infectionTreatment3Active Not RecruitingEUCTR2020-001606-33-ES
2020-04-07HydroxychloroquineRandomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infectionTreatment3Active Not RecruitingEUCTR2020-001606-33-ES
2020-04-07RitonavirChemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers : a randomized double-blind placebo-controlled clinical trial - COVIDAXISTreatment3Active Not RecruitingEUCTR2020-001188-96-FR
2020-04-07HydroxychloroquineChemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers : a randomized double-blind placebo-controlled clinical trial - COVIDAXISTreatment3Active Not RecruitingEUCTR2020-001188-96-FR
2020-04-07LopinavirChemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers : a randomized double-blind placebo-controlled clinical trial - COVIDAXISTreatment3Active Not RecruitingEUCTR2020-001188-96-FR
2020-04-07Nitric OxideNitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare ProvidersPrevention2Active Not RecruitingNCT04312243
2020-04-06ChloroquineChloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19) : The HOPE Open-Label, Non Randomized Clinical TrialPrevention2Active Not RecruitingNCT04344951
2020-04-06COVID-19 convalescent plasmaA randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19Treatment2Active Not RecruitingEUCTR2020-001310-38-DE
2020-04-06CyanocobalaminA cohort study to evaluate the effect of combination vitamin D, magnesium and vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patientsBasic ScienceNot AvailableCompletedISRCTN15324611
2020-04-06CholecalciferolA cohort study to evaluate the effect of combination vitamin D, magnesium and vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patientsBasic ScienceNot AvailableCompletedISRCTN15324611
2020-04-06HydroxychloroquinePre-exposure Prophylaxis for SARS-Coronavirus-2 : A Pragmatic Randomized Clinical TrialTreatment3Active Not RecruitingNCT04328467
2020-04-06GoldEvaluation of Novel Diagnostic Tests for 2019-nCOVBasic ScienceNot AvailableActive Not RecruitingNCT04326387
2020-04-06TocilizumabPre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trialTreatmentNot AvailableActive Not RecruitingNL8504
2020-04-06AzithromycinProactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID : A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19Treatment2Active Not RecruitingNCT04322396
2020-04-06HydroxychloroquineProactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID : A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19Treatment2Active Not RecruitingNCT04322396
2020-04-06Hydrocortisone succinateLow dose hydrocortisone in patients with COVID-19 and severe hypoxia – the COVID STEROID trial - COVID-STEROID trialTreatment3Active Not RecruitingEUCTR2020-001395-15-DK
2020-04-06Acetylsalicylic acidPlatelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use ProtocolTreatment2Active Not RecruitingNCT04368377
2020-04-06ClopidogrelPlatelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use ProtocolTreatment2Active Not RecruitingNCT04368377
2020-04-06FondaparinuxPlatelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use ProtocolTreatment2Active Not RecruitingNCT04368377
2020-04-06TirofibanPlatelet Inhibition With GP IIb / IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use ProtocolTreatment2Active Not RecruitingNCT04368377
2020-04-06HydroxychloroquineTreatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor OutcomeTreatment4Active Not RecruitingNCT04341493
2020-04-06NitazoxanideTreatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor OutcomeTreatment4Active Not RecruitingNCT04341493
2020-04-06Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsTwo-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19Treatment2Active Not RecruitingNCT04348461
2020-04-06Dental Mesenchymal Pulp Stem CellsSafety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19 : a Single-center, Prospective, Randomised Clinical TrialTreatment1, 2Active Not RecruitingNCT04336254
2020-04-06HydroxychloroquineRandomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 InfectionPrevention4Active Not RecruitingNCT04330495
2020-04-06LopinavirComparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)Treatment2, 3Active Not RecruitingNCT04328012
2020-04-06HydroxychloroquineComparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)Treatment2, 3Active Not RecruitingNCT04328012
2020-04-06LosartanComparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)Treatment2, 3Active Not RecruitingNCT04328012
2020-04-06RitonavirComparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)Treatment2, 3Active Not RecruitingNCT04328012
2020-04-06HydroxychloroquineClinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.Treatment4Unknown StatusEUCTR2020-001421-31-ES
2020-04-06DefibrotideUse of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04335201
2020-04-05FennelEvaluating efficacy and safety of Stopcivir (Zataria multiflora Boiss+ Alium Sativum+ Heracleum persicum+ Satureja hortensis+ Dianthus+ Foeniculum vulgare+ opium) syrup on length of hospitalization in patients with COVID-19Treatment3Active Not RecruitingIRCT20200411047016N1
2020-04-05OpiumEvaluating efficacy and safety of Stopcivir (Zataria multiflora Boiss+ Alium Sativum+ Heracleum persicum+ Satureja hortensis+ Dianthus+ Foeniculum vulgare+ opium) syrup on length of hospitalization in patients with COVID-19Treatment3Active Not RecruitingIRCT20200411047016N1
2020-04-05COVID-19 convalescent plasmaUse of convalescent plasma in the treatment of patients with severe COVID-19 pneumoniaTreatmentNot AvailableRecruitingIRCT20200416047099N1
2020-04-05Remestemcel-LMesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 2-3 Clinical TrialTreatment2, 3RecruitingIRCT20200217046526N2
2020-04-05RitonavirEvaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patientsTreatment3RecruitingIRCT20151227025726N14
2020-04-05LopinavirEvaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patientsTreatment3RecruitingIRCT20151227025726N14
2020-04-05FavipiravirEvaluation the efficacy and safety of Favipiravir made by Shahid Beheshti University of Medical Sciences in comparison with Lopinavir-ritonavir in COVID-19 patientsTreatment3RecruitingIRCT20151227025726N14
2020-04-05AtorvastatinAtorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State : A Randomized Clinical TrialTreatment2, 3Active Not RecruitingIRCT20190727044343N2
2020-04-05Remestemcel-LMesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 2-3 Clinical TrialTreatment2, 3Active Not RecruitingNCT04366063
2020-04-05SarilumabEffectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia : An Open-Label, Multicenter Sequential and Cluster Randomized TrialTreatment2Active Not RecruitingNCT04322773
2020-04-05TocilizumabEffectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia : An Open-Label, Multicenter Sequential and Cluster Randomized TrialTreatment2Active Not RecruitingNCT04322773
2020-04-04Autologous Non-Hematopoietic Peripheral Blood Stem CellsAdaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)Treatment1, 2Active Not RecruitingNCT04473170
2020-04-04ColchicineInvestigation of the efficacy and safety of colchicine In combination with standard treatment on covid-19 patients : A clinical trialTreatment3RecruitingIRCT20190810044500N5
2020-04-04TocilizumabEarly Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 PneumonitisTreatment2Active Not RecruitingNCT04331795
2020-04-04ThymeEvaluation of the effect of herbal oral product (thyme syrup) in patients with COVID-19Treatment3RecruitingIRCT20131129015584N2
2020-04-04Human immunoglobulin GEvaluation of the efficacy of intravenous immunoglobulin (IVIg) in patients with severe COVID-19 (Before intubation phase) who have not responded to treatment with the standard three-drug protocol (hydroxychloroquine / chloroquine + lupinavir / ritonavir + ribavirin)Treatment2Active Not RecruitingIRCT20200325046859N1
2020-04-04CamostatThe Impact of Camostat Mesilate on COVID-19 Infection : An Investigator-initiated Randomized, Placebo-controlled, Phase IIa TrialTreatment1, 2Active Not RecruitingNCT04321096
2020-04-04PyridostigminePyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 InfectionTreatment2, 3Active Not RecruitingNCT04343963
2020-04-04Dental Mesenchymal Pulp Stem CellsStudy the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumoniaTreatment2Active Not RecruitingIRCT20140911019125N6
2020-04-04FormoterolEvaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the DiseaseTreatment2, 3Active Not RecruitingNCT04331470
2020-04-04LevamisoleEvaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the DiseaseTreatment2, 3Active Not RecruitingNCT04331470
2020-04-04BudesonideEvaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the DiseaseTreatment2, 3Active Not RecruitingNCT04331470
2020-04-03COVID-19 convalescent plasmaThe Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, IraqTreatmentNot AvailableActive Not RecruitingNCT04441424
2020-04-03INO-4800Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy VolunteersPrevention1Active Not RecruitingNCT04336410
2020-04-03TocilizumabA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 PneumoniaTreatment3Active Not RecruitingNCT04320615
2020-04-03HydrocortisoneNeuroendocrine mechanisms Social isolation and psychobiological stress during the Covid-19 pandemic - SoDi StudyBasic ScienceNot AvailableRecruitingDRKS00021671
2020-04-03OxytocinNeuroendocrine mechanisms Social isolation and psychobiological stress during the Covid-19 pandemic - SoDi StudyBasic ScienceNot AvailableRecruitingDRKS00021671
2020-04-03RemdesivirSOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTSTreatment0RecruitingPER-010-20
2020-04-03LopinavirSOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTSTreatment0RecruitingPER-010-20
2020-04-03HydroxychloroquineSOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTSTreatment0RecruitingPER-010-20
2020-04-03RitonavirSOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTSTreatment0RecruitingPER-010-20
2020-04-03Interferon beta-1aSOLIDARITY : AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTSTreatment0RecruitingPER-010-20
2020-04-03CiclesonideA multicenter, open-label, randomized controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 - RACCO trialTreatment2Active Not RecruitingJPRN-jRCTs031190269
2020-04-03HydroxychloroquineA Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk ExposuresPrevention2Active Not RecruitingNCT04333225
2020-04-03ColchicineThe GReek Study in the Effects of Colchicine in Covid-19 cOmplications PreventionTreatment2Active Not RecruitingNCT04326790
2020-04-03TocilizumabPre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial - PreToVidTreatment2Active Not RecruitingEUCTR2020-001375-32-NL
2020-04-03SarilumabEffectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia : An Open-Label Multicenter Sequential Randomized Controlled TrialTreatment2Active Not RecruitingEUCTR2020-001275-32-DK
2020-04-03TocilizumabEffectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia : An Open-Label Multicenter Sequential Randomized Controlled TrialTreatment2Active Not RecruitingEUCTR2020-001275-32-DK
2020-04-03AzithromycinProactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID - ProPAC-COVIDTreatment2Active Not RecruitingEUCTR2020-001198-55-DK
2020-04-03HydroxychloroquineProactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID - ProPAC-COVIDTreatment2Active Not RecruitingEUCTR2020-001198-55-DK
2020-04-03HydroxychloroquineOff Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2Treatment2Active Not RecruitingNCT04354870
2020-04-03TocilizumabA Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release SyndromeTreatment3Active Not RecruitingNCT04330638
2020-04-03SiltuximabA Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release SyndromeTreatment3Active Not RecruitingNCT04330638
2020-04-03AnakinraA Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release SyndromeTreatment3Active Not RecruitingNCT04330638
2020-04-03SiltuximabA prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AIDTreatment3Unknown StatusEUCTR2020-001500-41-BE
2020-04-03TocilizumabA prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AIDTreatment3Unknown StatusEUCTR2020-001500-41-BE
2020-04-03AnakinraA prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AIDTreatment3Unknown StatusEUCTR2020-001500-41-BE
2020-04-03COVID-19 convalescent plasmaMulti-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized PatientsTreatment2Active Not RecruitingNCT04345523
2020-04-03DexamethasoneEfficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19Treatment4Active Not RecruitingNCT04325061
2020-04-03Ascorbic acidEffects of High-dose Vitamin C on Treatment, Clinical Symptoms and Laboratory Signs of Iranian COVID-19 Patients : A Double Blind Randomized Clinical TrialTreatment2, 3Active Not RecruitingIRCT20190917044805N2
2020-04-03IpecacDouble blind clinical trial study on Evaluation of the effectiveness of Ipecac homeopathic remedy in control of Clinical manifestations of COVID-19Treatment3Active Not RecruitingIRCT20140907019073N4
2020-04-03PomegranateThe Effect of Persian Medicine Products on the Clinical and Laboratory Symptoms of Patients With or Suspected of Covid-19Treatment3Active Not RecruitingIRCT20140617018126N2
2020-04-03Vitamin Aevaluation the effect of vitamin A on respiratory signs and hospitalization in patients with COVID-19TreatmentNot AvailableActive Not RecruitingIRCT20170117032004N3
2020-04-03HydroxychloroquineCOVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer PatientsTreatment2Active Not RecruitingNCT04341207
2020-04-03AzithromycinCOVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer PatientsTreatment2Active Not RecruitingNCT04341207
2020-04-03OmeprazolePreventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.TreatmentNot AvailableActive Not RecruitingNCT04333407
2020-04-03ClopidogrelPreventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.TreatmentNot AvailableActive Not RecruitingNCT04333407
2020-04-03AtorvastatinPreventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.TreatmentNot AvailableActive Not RecruitingNCT04333407
2020-04-03RivaroxabanPreventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.TreatmentNot AvailableActive Not RecruitingNCT04333407
2020-04-03Acetylsalicylic acidPreventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy : A Randomised Controlled Trial.TreatmentNot AvailableActive Not RecruitingNCT04333407
2020-04-03HydroxychloroquinePre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic : A Multicentre, Double-Blinded Randomized Controlled TrialPrevention3Active Not RecruitingNCT04331834
2020-04-03HydroxychloroquinePRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID) : A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVIDTreatment3Unknown StatusEUCTR2020-001565-37-ES
2020-04-03AzithromycinCOVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVIDTreatment2Active Not RecruitingEUCTR2020-001250-21-FR
2020-04-03HydroxychloroquineCOVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVIDTreatment2Active Not RecruitingEUCTR2020-001250-21-FR
2020-04-02HydroxychloroquineOutcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic DiseaseTreatment3Active Not RecruitingNCT04332991
2020-04-02Medium-chain triglyceridesEvaluation of the effect of oral intermediate chain triglyceride on prognosis and course of disease in suspected outpatients with COVID-19TreatmentNot AvailableActive Not RecruitingIRCT20160313027033N2
2020-04-02ChloroquineCHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19) : THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPETreatment2Active Not RecruitingEUCTR2020-001345-38-GR
2020-04-02TocilizumabEfficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach : the ESCAPE Clinical TrialTreatment2Active Not RecruitingNCT04339712
2020-04-02AnakinraEfficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach : the ESCAPE Clinical TrialTreatment2Active Not RecruitingNCT04339712
2020-04-02HydroxychloroquineAn adaptive Phase 2 / 3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19Treatment2Active Not RecruitingEUCTR2020-001270-29-GB
2020-04-02Vitamin AImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02BiotinImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02PyridoxineImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02Pantothenic acidImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02Vitamin EImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02ThiamineImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02Ascorbic acidImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02Vitamin DImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02RiboflavinImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02NicotinamideImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02Folic acidImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02CyanocobalaminImpact of vitamin B, A, D, E, C supplementation on improvement and mortality rate in patients with COVID-19 admitted in intensive care unitTreatment3RecruitingIRCT20200319046819N1
2020-04-02NintedanibEfficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled StudyTreatment2Active Not RecruitingNCT04338802
2020-04-02HydroxychloroquineHydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT) : A Prospective Pragmatic TrialTreatment3Active Not RecruitingNCT04334382
2020-04-02AzithromycinHydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT) : A Prospective Pragmatic TrialTreatment3Active Not RecruitingNCT04334382
2020-04-02HydroxychloroquinePilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)Treatment2Active Not RecruitingNCT04332094
2020-04-02TocilizumabPilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)Treatment2Active Not RecruitingNCT04332094
2020-04-02AzithromycinPilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)Treatment2Active Not RecruitingNCT04332094
2020-04-02AnakinraA Phase 2 / 3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.Treatment2, 3Active Not RecruitingNCT04324021
2020-04-02EmapalumabA Phase 2 / 3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.Treatment2, 3Active Not RecruitingNCT04324021
2020-04-02TocilizumabPilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVIDTreatment2Unknown StatusEUCTR2020-001442-19-ES
2020-04-01HydroxychloroquineLow-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled TrialPrevention3Active Not RecruitingNCT04336748
2020-04-01LeronlimabA Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)Treatment2Active Not RecruitingNCT04343651
2020-04-01AzithromycinAn Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical PatientsTreatment3Active Not RecruitingNCT04322123
2020-04-01HydroxychloroquineAn Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical PatientsTreatment3Active Not RecruitingNCT04322123
2020-04-01HydroxychloroquineHydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore : a Review of Process Feasibility, Safety, and Clinical OutcomesTreatment2Active Not RecruitingNCT04350450
2020-04-01Chlorine DioxideDetermination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19Basic ScienceNot AvailableActive Not RecruitingNCT04343742
2020-04-01Remestemcel-LWhat is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study)Treatment1, 2Active Not RecruitingNCT04392778
2020-04-01ColchicineApplication of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19Treatment1, 2Active Not RecruitingNCT04392141
2020-04-01HydroxychloroquineHydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication : a Prospective, Multicentre, Randomised, Double-blind StudyTreatment3Active Not RecruitingNCT04325893
2020-04-01HydroxychloroquineA Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care TreatmentTreatment4Active Not RecruitingNCT04384380
2020-04-01HydroxychloroquineEvaluation of patients treated by telemedicine in the Covid-19 pandemic in Brazil in a medical clinic in the supplementary health sector in São Paulo, Brazil - : MAZZEI MEDICAL CENTERTreatmentNot AvailableRecruitingRBR-658khm
2020-04-01AzithromycinEvaluation of patients treated by telemedicine in the Covid-19 pandemic in Brazil in a medical clinic in the supplementary health sector in São Paulo, Brazil - : MAZZEI MEDICAL CENTERTreatmentNot AvailableRecruitingRBR-658khm
2020-04-01FavipiravirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N1
2020-04-01RitonavirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N1
2020-04-01LopinavirEvaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19 ; a randomized, multicenter, parallel groups, open label studyTreatment3Active Not RecruitingIRCT20200318046812N1
2020-04-01HydroxychloroquineRandomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19Treatment2Active Not RecruitingNCT04336332
2020-04-01AzithromycinRandomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19Treatment2Active Not RecruitingNCT04336332
2020-04-01DeferoxamineApplication of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 ManifestationsTreatment1, 2Active Not RecruitingNCT04333550
2020-04-01HydroxychloroquineEfficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women : an Open-label Randomized Clinical TrialTreatment3Active Not RecruitingNCT04365231
2020-04-01AzithromycinEfficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women : an Open-label Randomized Clinical TrialTreatment3Active Not RecruitingNCT04365231
2020-04-01Remestemcel-LDouble Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)Treatment2Active Not RecruitingNCT04361942
2020-04-01Remestemcel-LIntermediate-size Expanded Access of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome Due to COVID-19 InfectionTreatmentNot AvailableActive Not RecruitingNCT04366830
2020-04-01Angiotensin IIARB, ACEi, DRi Usage in COVID-19Basic ScienceNot AvailableActive Not RecruitingNCT04364984
2020-04-01RitonavirEfficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized TrialPrevention3Active Not RecruitingNCT04364022
2020-04-01HydroxychloroquineEfficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized TrialPrevention3Active Not RecruitingNCT04364022
2020-04-01LopinavirEfficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland : an Open-label Cluster Randomized TrialPrevention3Active Not RecruitingNCT04364022
2020-04-01FavipiravirThe Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to PositiveTreatmentNot AvailableActive Not RecruitingNCT04333589
2020-04-01EculizumabSOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency TreatmentTreatmentNot AvailableActive Not RecruitingNCT04355494
2020-04-01Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic OriginsIV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)Treatment1Active Not RecruitingNCT04352803
2020-04-01NafamostatRAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)Treatment2, 3Active Not RecruitingNCT04352400
2020-04-01HydroxychloroquineHigh-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19Treatment1Active Not RecruitingNCT04351620
2020-04-01Zinc gluconateImpact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04351490
2020-04-01CholecalciferolImpact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19TreatmentNot AvailableActive Not RecruitingNCT04351490
2020-04-01ChloroquineChloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVIDPrevention2Active Not RecruitingNCT04349371
2020-04-01CanakinumabObservational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 PneumoniaBasic ScienceNot AvailableActive Not RecruitingNCT04348448
2020-04-01DexamethasoneDexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19) : a Multicentre, Randomised Controlled TrialTreatment3Active Not RecruitingNCT04347980
2020-04-01HydroxychloroquineDexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19) : a Multicentre, Randomised Controlled TrialTreatment3Active Not RecruitingNCT04347980
2020-04-01Remestemcel-LSafety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19) : A Phase 1 / 2 Randomized Controlled TrialTreatment1, 2Active Not RecruitingNCT04346368
2020-04-01HydroxychloroquineSafety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT)Prevention3Active Not RecruitingNCT04342156
2020-04-01AnakinraCORIMUNO-ANA : Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19Treatment2Active Not RecruitingNCT04341584
2020-04-01ChloroquineChloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized TrialTreatment2, 3Active Not RecruitingNCT04333628
2020-04-01OseltamivirA prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.Treatment2Active Not RecruitingJPRN-jRCTs031190227
2020-04-01HydroxychloroquineA prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.Treatment2Active Not RecruitingJPRN-jRCTs031190227
2020-04-01LopinavirA prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.Treatment2Active Not RecruitingJPRN-jRCTs031190227
2020-04-01RitonavirA prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.Treatment2Active Not RecruitingJPRN-jRCTs031190227
2020-04-01LopinavirEvaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the diseaseTreatment2, 3Active Not RecruitingIRCT20200324046852N1
2020-04-01RitonavirEvaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the diseaseTreatment2, 3Active Not RecruitingIRCT20200324046852N1
2020-04-01BudesonideEvaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the diseaseTreatment2, 3Active Not RecruitingIRCT20200324046852N1
2020-04-01FormoterolEvaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the diseaseTreatment2, 3Active Not RecruitingIRCT20200324046852N1
2020-04-01LevamisoleEvaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the diseaseTreatment2, 3Active Not RecruitingIRCT20200324046852N1
2020-04-01HydroxychloroquineEvaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the diseaseTreatment2, 3Active Not RecruitingIRCT20200324046852N1
2020-04-01ThymalfasinObservation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)Basic ScienceNot AvailableRecruitingChiCTR2000032040
2020-04-01HydroxychloroquineMilitary COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis StudyPrevention2Active Not RecruitingNCT04343677
2020-04-01MethylprednisoloneOpen Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19Treatment3Active Not RecruitingNCT04341038
2020-04-01TacrolimusOpen Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19Treatment3Active Not RecruitingNCT04341038
2020-04-01TocilizumabEfficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19 : a Proof of Concept StudyBasic ScienceNot AvailableActive Not RecruitingNCT04332913
2020-04-01RemdesivirIntermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV ; GS-5734™)Treatment1Active Not RecruitingNCT04302766
2020-04-01TocilizumabEFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH : THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTIONTreatment2Active Not RecruitingEUCTR2020-001039-29-GR
2020-04-01AnakinraEFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH : THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTIONTreatment2Active Not RecruitingEUCTR2020-001039-29-GR
2020-04-01MethylprednisoloneEfficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)Treatment3Unknown StatusEUCTR2020-001307-16-ES
2020-04-01DefibrotideA prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVIDTreatment2Unknown StatusEUCTR2020-001409-21-ES
2020-04-01NivolumabIMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection - IMMUNONCOVID-20Treatment2Active Not RecruitingEUCTR2020-001373-70-FR
2020-04-01TocilizumabIMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection - IMMUNONCOVID-20Treatment2Active Not RecruitingEUCTR2020-001373-70-FR
2020-04-01COVID-19 convalescent plasmaEvaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19Treatment1Active Not RecruitingNCT04333251
2020-04-01CiclesonideA Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19Treatment2Active Not RecruitingNCT04330586
2020-04-01HydroxychloroquineA Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19Treatment2Active Not RecruitingNCT04330586
2020-04-01HydroxychloroquineA Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)Prevention3Active Not RecruitingNCT04330144
2020-04-01NintedanibEfficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19) : a single-center, randomized, placebo-controlled trialTreatment4Active Not RecruitingChiCTR2000031453
2020-04-01Dental Mesenchymal Pulp Stem CellsSafety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19 : a Single-center, Prospective, Randomised Clinical TrialTreatmentNot AvailableActive Not RecruitingChiCTR2000031319
2020-04-01COVID-19 convalescent plasmaRole of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19TreatmentNot AvailableActive Not RecruitingNCT04492501
2020-04-01TocilizumabRole of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19TreatmentNot AvailableActive Not RecruitingNCT04492501
2020-04-01Remestemcel-LRole of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19TreatmentNot AvailableActive Not RecruitingNCT04492501
2020-04-01RemdesivirRole of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19TreatmentNot AvailableActive Not RecruitingNCT04492501
2020-03-31TocilizumabAn Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04346355
2020-03-31CIGB-258 peptideAdministration of the CIGB-258 peptide in patients with COVID-19 under intensive therapy regimen (COVID-19)TreatmentNot AvailableCompletedRPCEC00000313
2020-03-31COVID-19 convalescent plasmaAmotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19)TreatmentNot AvailableActive Not RecruitingNCT04389944
2020-03-31ImatinibCountering Lung Damage in COVID-19 infection (CounterCovid) studyTreatmentNot AvailableActive Not RecruitingNL8491
2020-03-31Dornase alfaNebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients : A Case SeriesBasic ScienceNot AvailableActive Not RecruitingNCT04387786
2020-03-31HydroxychloroquineEfficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19) : a Blinded, Randomized StudyPrevention2, 3Active Not RecruitingNCT04328961
2020-03-31ClazakizumabA Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionTreatment2Active Not RecruitingNCT04343989
2020-03-31FavipiravirMulticenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe PneumoniaTreatment3Active Not RecruitingJPRN-JapicCTI-205238
2020-03-31LosartanEvaluation of the effects of Losartan in patients with corona virus disease 2019Treatment3RecruitingIRCT20180802040678N4
2020-03-31AmlodipineEvaluation of the effects of Losartan in patients with corona virus disease 2019Treatment3RecruitingIRCT20180802040678N4
2020-03-31MethylprednisolonePRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)Treatment2Active Not RecruitingEUCTR2020-001445-39-ES
2020-03-31TacrolimusPRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)Treatment2Active Not RecruitingEUCTR2020-001445-39-ES
2020-03-31HydroxychloroquineUse of therapeutic drug monitoring (TDM) to optimise oral / enteral hydroxychloroquine dosing in critically ill patients with COVID-19TreatmentNot AvailableRecruitingACTRN12620000447954
2020-03-31Angiotensin 1-7Angiotensin-(1,7) Treatment in COVID-19 : the ATCO TrialTreatment2, 3Active Not RecruitingNCT04332666
2020-03-31ImatinibCOUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19 – a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid StudyTreatment2Active Not RecruitingEUCTR2020-001236-10-NL
2020-03-31HydroxychloroquineHYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d’aggravation secondaire : étude prospective multicentrique randomisée en double aveugle - HYCOVIDTreatment3Active Not RecruitingEUCTR2020-001271-33-FR
2020-03-30HydroxychloroquineRandomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care TreatmentTreatment4Active Not RecruitingNCT04334967
2020-03-30HydroxychloroquineHydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS) : A Prospective Pragmatic TrialTreatment2Active Not RecruitingNCT04329832
2020-03-30AzithromycinHydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS) : A Prospective Pragmatic TrialTreatment2Active Not RecruitingNCT04329832
2020-03-30BCG vaccineBCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers Following Coronavirus Exposure (BRACE) TrialPrevention3Active Not RecruitingNCT04327206
2020-03-30HydroxychloroquineOpen and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19) : a randomized controlled trial - Brazil COVID Coalition I TrialTreatment3Active Not RecruitingRBR-9d8z6m
2020-03-30AzithromycinOpen and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19) : a randomized controlled trial - Brazil COVID Coalition I TrialTreatment3Active Not RecruitingRBR-9d8z6m
2020-03-30Mentha arvensis topEvaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19TreatmentNot AvailableRecruitingIRCT20080901001165N49
2020-03-30Urtica dioica pollenEvaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19TreatmentNot AvailableRecruitingIRCT20080901001165N49
2020-03-30Glycyrrhiza glabraEvaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19TreatmentNot AvailableRecruitingIRCT20080901001165N49
2020-03-30MethylprednisoloneEvaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDSTreatment3RecruitingIRCT20200406046963N1
2020-03-30UmifenovirInvestigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19Treatment3RecruitingIRCT20080901001165N46
2020-03-30TeicoplaninStudy of the Efficacy of Teicoplanin on mortality rate of patients with COVID-19 Infection : A randomized clinical trialTreatment3RecruitingIRCT20161204031229N3
2020-03-30COVID-19 convalescent plasmaArkansas Expanded Access COVID-19 Convalescent Plasma Treatment ProgramTreatmentNot AvailableActive Not RecruitingNCT04363034
2020-03-30TocilizumabCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)Treatment2Active Not RecruitingNCT04331808
2020-03-30ChloroquineMulti-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2 / COVID-19 in Healthcare Workers at High-Risk of ExposureTreatment4Active Not RecruitingACTRN12620000417987
2020-03-30MefloquinePilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19Treatment3Unknown StatusEUCTR2020-001194-69-ES
2020-03-30HydroxychloroquineEvaluation of the concentration / viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.Treatment4Active Not RecruitingEUCTR2020-001281-11-FR
2020-03-30Human interferon betaA randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectionTreatment2RecruitingISRCTN14241621
2020-03-29PrednisoloneStudy of Prednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients : a clinical trial studyTreatment2RecruitingIRCT20081027001411N3
2020-03-29HydroxychloroquineThe Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir / Ritonavir Plus Hydroxychloroquine Regimen : an Open-label, Non-randomized Clinical Trial StudyTreatmentNot AvailableActive Not RecruitingNCT04376814
2020-03-29FavipiravirThe Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir / Ritonavir Plus Hydroxychloroquine Regimen : an Open-label, Non-randomized Clinical Trial StudyTreatmentNot AvailableActive Not RecruitingNCT04376814
2020-03-29HydroxychloroquineHydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients : A NYC Community-Based Randomized Clinical TrialPrevention2, 3Active Not RecruitingNCT04318444
2020-03-29HydroxychloroquineEffect of hydroxychloroquine on prevention of covid-19 virus infection among treatment staff in Arash hospital-A double-blind clinical trialTreatmentNot AvailableRecruitingIRCT20120826010664N6
2020-03-29HydroxychloroquineRandomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19Treatment3Active Not RecruitingNCT04342221
2020-03-29EthanolInvestigating the effect of Medical Beer on the fever of patients with COVID-19Treatment3RecruitingIRCT20200428047229N1
2020-03-28SarilumabAn Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19Treatment3Active Not RecruitingNCT04327388
2020-03-28HydroxychloroquineEvaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - PatientsTreatment3Active Not RecruitingNCT04321278
2020-03-28AzithromycinEvaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - PatientsTreatment3Active Not RecruitingNCT04321278
2020-03-28MethylprednisoloneStudy of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian ?COVID-19 patients : a clinical trial studyTreatment2Active Not RecruitingIRCT20200404046947N1
2020-03-28UmifenovirEvaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19 : A randomized clinical trialTreatment3Active Not RecruitingIRCT20200322046833N1
2020-03-28PurslaneEfficacy evaluation of an herbal compound “Fluherb” on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.Treatment2, 3Active Not RecruitingIRCT20200323046841N1
2020-03-28LicoriceEfficacy evaluation of an herbal compound “Fluherb” on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.Treatment2, 3Active Not RecruitingIRCT20200323046841N1
2020-03-28Plantago ovata seedEfficacy evaluation of an herbal compound “Fluherb” on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.Treatment2, 3Active Not RecruitingIRCT20200323046841N1
2020-03-28Centella asiaticaEfficacy evaluation of an herbal compound “Fluherb” on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.Treatment2, 3Active Not RecruitingIRCT20200323046841N1
2020-03-28TurmericEfficacy evaluation of an herbal compound “Fluherb” on clinical symptoms and paraclinical parameters in highly suspected COVID-19 patients : a controlled randomized clinical trial.Treatment2, 3Active Not RecruitingIRCT20200323046841N1
2020-03-28HydroxychloroquineThe (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected PatientsTreatment2, 3Active Not RecruitingNCT04321616
2020-03-28RemdesivirThe (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected PatientsTreatment2, 3Active Not RecruitingNCT04321616
2020-03-28Remestemcel-LMesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing in patients infected with 2019-nCoV (phase I clinical trial)Treatment1Active Not RecruitingIRCT20200325046860N2
2020-03-28HydroxychloroquinePrevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial controlled with placebo - EPICOSTreatment3Unknown StatusEUCTR2020-001385-11-ES
2020-03-28Tenofovir disoproxilPrevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial controlled with placebo - EPICOSTreatment3Unknown StatusEUCTR2020-001385-11-ES
2020-03-28EmtricitabinePrevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil / Emtricitabine and Hydroxychloroquine in Healthcare Personnel : Randomized Clinical Trial controlled with placebo - EPICOSTreatment3Unknown StatusEUCTR2020-001385-11-ES
2020-03-28HydroxychloroquineEffectiveness of Hydroxychloroquine in Covid-19 Patients : A Single Centred Single-blind RCT StudyTreatment3Active Not RecruitingNCT04328272
2020-03-28AzithromycinEffectiveness of Hydroxychloroquine in Covid-19 Patients : A Single Centred Single-blind RCT StudyTreatment3Active Not RecruitingNCT04328272
2020-03-28COVID-19 convalescent plasmaInvestigating Effect of Convalescent Plasma on COVID-19 Patients Outcome : A Clinical TrialTreatmentNot AvailableActive Not RecruitingNCT04327349
2020-03-27CIGB 2020 VaccineRandomized control clinical trial of CIGB 2020 in contacts and SARS-CoV-2 infection suspects (COVID-19)Treatment1, 2CompletedRPCEC00000306
2020-03-27EtanerceptEvaluation the efficacy of Tumor Necrosis Factor alpha inhibitor in COVID-19 outcomes : a prospective clinical trial study.Treatment2, 3RecruitingIRCT20200312046749N1
2020-03-27SarilumabCohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARITreatment2, 3Active Not RecruitingNCT04324073
2020-03-27Interferon beta-1athe efficacy of Interferon beta 1 a (ReciGen) in treatment of patients with Covid-19 in Sina Hospital Emergency DepartmentTreatment3RecruitingIRCT20150914024017N1
2020-03-27HydroxychloroquineRandomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19Treatment3Unknown StatusEUCTR2020-001156-18-ES
2020-03-27LopinavirRandomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19Treatment3Unknown StatusEUCTR2020-001156-18-ES
2020-03-27AzithromycinRandomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19Treatment3Unknown StatusEUCTR2020-001156-18-ES
2020-03-27RitonavirRandomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19Treatment3Unknown StatusEUCTR2020-001156-18-ES
2020-03-27Interferon beta-1aAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-ES
2020-03-27HydroxychloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-ES
2020-03-27ChloroquineAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-ES
2020-03-27LopinavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-ES
2020-03-27RemdesivirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-ES
2020-03-27RitonavirAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - SolidarityTreatment4Active Not RecruitingEUCTR2020-001366-11-ES
2020-03-27TocilizumabUno studio randomizzato multicentrico in aperto per valutare l’efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RETreatment2Unknown StatusEUCTR2020-001386-37-IT
2020-03-26HydroxychloroquineA Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized PatientsTreatment3Active Not RecruitingNCT04345692
2020-03-26AZD1222A phase I / II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers - A phase I / II trial of a candidate COVID-19 vaccine (COV001)Treatment2Active Not RecruitingEUCTR2020-001072-15-GB
2020-03-26RemdesivirA Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT)Treatment3Active Not RecruitingJPRN-jRCT2031190264
2020-03-26OzoneOxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial FloraTreatment2Active Not RecruitingNCT04366089
2020-03-26OxygenOxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial FloraTreatment2Active Not RecruitingNCT04366089
2020-03-26HydroxychloroquineThe NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19Treatment3Active Not RecruitingEUCTR2020-000982-18-NO
2020-03-26RemdesivirThe NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19Treatment3Active Not RecruitingEUCTR2020-000982-18-NO
2020-03-26HydroxychloroquineStudy for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communitiesTreatment4Active Not RecruitingChiCTR2000032487
2020-03-26RemdesivirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careTreatment3Active Not RecruitingISRCTN83971151
2020-03-26RitonavirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careTreatment3Active Not RecruitingISRCTN83971151
2020-03-26ChloroquineAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careTreatment3Active Not RecruitingISRCTN83971151
2020-03-26HydroxychloroquineAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careTreatment3Active Not RecruitingISRCTN83971151
2020-03-26Human interferon betaAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careTreatment3Active Not RecruitingISRCTN83971151
2020-03-26LopinavirAn international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of careTreatment3Active Not RecruitingISRCTN83971151
2020-03-26SofosbuvirA prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatmentTreatment3Active Not RecruitingIRCT20200128046294N2
2020-03-26DaclatasvirA prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatmentTreatment3Active Not RecruitingIRCT20200128046294N2
2020-03-26ItraconazoleCovid-19 : A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19Treatment2Active Not RecruitingEUCTR2020-001243-15-BE
2020-03-26SarilumabAn adaptive phase 2 / 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19Treatment2Active Not RecruitingEUCTR2020-001162-12-FR
2020-03-26AZD1222A phase I / II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteersTreatment1, 2RecruitingISRCTN15281137
2020-03-25HydroxychloroquinePreemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)Treatment3Active Not RecruitingNCT04421664
2020-03-25HydroxychloroquineNorwegian Coronavirus Disease 2019 Study : An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 InfectionTreatment4Active Not RecruitingNCT04316377
2020-03-25HydroxychloroquineRandomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19Treatment2Active Not RecruitingEUCTR2020-001224-33-DE
2020-03-25AzithromycinPlatform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)Treatment3Active Not RecruitingISRCTN86534580
2020-03-25Interferon beta-1bEfficacy and safety evaluation of therapeutic regimen of lopinavir / ritonavir and interferon beta 1b in patients with COVID-19Treatment2, 3RecruitingIRCT20190804044429N1
2020-03-25BCG vaccineReducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial.Prevention3Active Not RecruitingNCT04328441
2020-03-25LosartanAn Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19Treatment1Active Not RecruitingNCT04335123
2020-03-25FavipiravirA Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate TypeTreatment3Active Not RecruitingNCT04336904
2020-03-25GoldNovel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trialDiagnostic0Active Not RecruitingChiCTR2000031427
2020-03-25GoldNovel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trialDiagnostic0Active Not RecruitingChiCTR2000031465
2020-03-24SargramostimA Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.Treatment4Active Not RecruitingNCT04326920
2020-03-24TragacanthEvaluation of the effect of Traditional medicine product incorporated in the base of Astragalus gossypinus with food spice on improvement of clinical menifestation of COVID -19 patients with conventional protocolTreatment3RecruitingIRCT20101219005416N2
2020-03-24Human Umbilical Cord Mesenchymal Stem CellsEvaluation of the efficacy and safety of cord-derived mesenchymal stem cell transplantation in the treatment of COVID-19Treatment3Active Not RecruitingIRCT20140528017891N8
2020-03-24COVID-19 convalescent plasmaComparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients : A Clinical Trial StudyTreatment2, 3Active Not RecruitingIRCT20200310046736N1
2020-03-24SargramostimA prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPACTreatment4Active Not RecruitingEUCTR2020-001254-22-BE
2020-03-24LV-SMENP VaccinePhase I / II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 CoronavirusTreatment1, 2Active Not RecruitingNCT04276896
2020-03-24AzithromycinOpen Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 InfectionTreatment2Active Not RecruitingNCT04458948
2020-03-24HydroxychloroquineOpen Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 InfectionTreatment2Active Not RecruitingNCT04458948
2020-03-23MethylprednisoloneProlonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory SyndromeBasic ScienceNot AvailableActive Not RecruitingNCT04323592
2020-03-23Althea rootFormulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.Treatment3RecruitingIRCT20180712040449N2
2020-03-23Urtica dioica pollenFormulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.Treatment3RecruitingIRCT20180712040449N2
2020-03-23Centella asiaticaFormulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.Treatment3RecruitingIRCT20180712040449N2
2020-03-23Glycyrrhiza glabraFormulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.Treatment3RecruitingIRCT20180712040449N2
2020-03-23ChamomileFormulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.Treatment3RecruitingIRCT20180712040449N2
2020-03-23PomegranateFormulation and evaluation of their efficacy of herbal capsule and decoction in patients with COVID-19 via a randomized clinical trial.Treatment3RecruitingIRCT20180712040449N2
2020-03-23HydroxychloroquineEffectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)TreatmentNot AvailableActive Not RecruitingChiCTR2000031174
2020-03-23ColchicineColchicine Coronavirus SARS-CoV2 Trial (COLCORONA)Treatment3Active Not RecruitingNCT04322682
2020-03-23ChloroquineClinical Study Evaluating the Efficacy of Chloroquine in COVID-19 TreatmentTreatment2, 3Active Not RecruitingNCT04353336
2020-03-23LicoriceComparison of the Effectiveness of Standard Treatment with Standard Treatment plus licorice extract in Improving Respiratory Symptoms and Survival Rate in COVID-19 PatientsTreatment3Active Not RecruitingIRCT20160316027081N1
2020-03-23HydroxychloroquineNORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY : AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19Treatment4Active Not RecruitingEUCTR2020-001010-38-NO
2020-03-23Nitric OxideNitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.Treatment2Active Not RecruitingNCT04290871
2020-03-22RemdesivirMulti-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04315948
2020-03-22RitonavirMulti-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04315948
2020-03-22HydroxychloroquineMulti-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04315948
2020-03-22Interferon beta-1aMulti-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04315948
2020-03-22LopinavirMulti-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsTreatment3Active Not RecruitingNCT04315948
2020-03-22GoldClinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kitDiagnostic0Active Not RecruitingChiCTR2000030833
2020-03-21Nitric OxideNitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild / Moderate COVID-19 : a Randomized Clinical TrialTreatment2Active Not RecruitingNCT04305457
2020-03-21HydroxychloroquineUse of Hydroxychloroquine in Patients With COVID-19 : A Randomized Controlled Clinical TrialTreatment2Active Not RecruitingNCT04394442
2020-03-21Nitric OxideNitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2 : a Randomized Clinical Trial.Treatment2Active Not RecruitingNCT04306393
2020-03-21IL15-NK CellA Phase I / II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19Treatment1, 2Active Not RecruitingNCT04324996
2020-03-21Natural Killer CellA Phase I / II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19Treatment1, 2Active Not RecruitingNCT04324996
2020-03-21NKG2D-ACE2 CAR-NK CellA Phase I / II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19Treatment1, 2Active Not RecruitingNCT04324996
2020-03-20OxycodoneEvaluation the effects of Oxycodone administration on pain control in patients with COVID-19Treatment3RecruitingIRCT20150107020592N24
2020-03-20Interferon beta-1bEvaluation of interferon treatment in high-risk covid19 patients in QomTreatment3RecruitingIRCT20160118026097N3
2020-03-20CyclosporineCyclosporin for the Prevention and Treatment of COVID-19 DiseaseTreatment3RecruitingIRCT20150107020592N22
2020-03-20Human Amniotic FluidA Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory FailureTreatment1Active Not RecruitingNCT04319731
2020-03-20QuercetinThe Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19PreventionNot AvailableActive Not RecruitingNCT04377789
2020-03-20Placental Mesenchymal Stem CellsPlacental Mesenchymal Stem cells for treatment of ARDS in Coronavirus infection, Phase 1 and 2 Clinical TrialsTreatment1, 2RecruitingIRCT20200413047063N1
2020-03-20RemdesivirA single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Treatment2, 3RecruitingIRCT20171122037571N2
2020-03-20ColchicineEffects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection : A Randomized Double Blind Clinical TrialTreatment2Active Not RecruitingNCT04360980
2020-03-20MetforminStudy of the metformin effect on the survival and recovery rate of COVID-19 patientsTreatment3Active Not RecruitingIRCT20160310026998N10
2020-03-20MetforminEffect of metformin in COVID-19 mortality rate and symptom improvementTreatment3Active Not RecruitingIRCT20160310026998N11
2020-03-20Human Umbilical Cord Mesenchymal Stem CellsEvaluation of the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosisTreatment2RecruitingChiCTR2000031430
2020-03-20GoldDeveloping and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19) : a retrospective studyDiagnosticNot AvailableActive Not RecruitingChiCTR2000030951
2020-03-20Human Embryonic Stem Cell-derived M CellSafety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)Treatment0RecruitingChiCTR2000031139
2020-03-20BCG vaccineREDUCING HEALTH CARE WORKERS ABSENTEEISM IN SARS-CoV-2 PANDEMIC BY ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION, A RANDOMIZED CONTROLLED TRIALTreatmentNot AvailableActive Not RecruitingNL8477
2020-03-20FavipiravirFavipiravir prophylactic to reduce the involvement of health care workers in the COVID-19 epidemicTreatment3RecruitingIRCT20150107020592N30
2020-03-20Borage oilEffectiveness of Borage based solutions in cytokine's levels in covid-19 ARDS patients with elevated Extravascular Lung Water( EVLW)Treatment3Active Not RecruitingIRCT20150107020592N28
2020-03-20PentaglobinThe effect of pentaglobin in the treatment of critically ill patients with COVID-19Treatment3Active Not RecruitingIRCT20150107020592N27
2020-03-20FavipiravirFavipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)Treatment3Active Not RecruitingIRCT20150107020592N26
2020-03-19PrednisoloneRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19TocilizumabRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19RitonavirRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19DexamethasoneRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19LopinavirRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19AzithromycinRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19Human immunoglobulin GRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19HydrocortisoneRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19Methylprednisolone hemisuccinateRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19HydroxychloroquineRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19COVID-19 convalescent plasmaRandomized evaluation of COVID-19 therapyTreatment2, 3RecruitingISRCTN50189673
2020-03-19NoscapineThe effect of NOSCOVID on pulmonary & other clinical manifestations of COVID-19 patientsTreatment2Active Not RecruitingIRCT20160625028622N1
2020-03-19TocilizumabMulticenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 PneumoniaTreatment2Active Not RecruitingNCT04317092
2020-03-19RitonavirEvaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19) : a randomized, open-label, controlled trialTreatmentNot AvailableRecruitingChiCTR2000031734
2020-03-19DanoprevirEvaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19) : a randomized, open-label, controlled trialTreatmentNot AvailableRecruitingChiCTR2000031734
2020-03-18RitonavirAn Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionTreatment4Active Not RecruitingNCT04345276
2020-03-18DanoprevirAn Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionTreatment4Active Not RecruitingNCT04345276
2020-03-18LopinavirA Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)Treatment2Active Not RecruitingNCT04330690
2020-03-18RitonavirA Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)Treatment2Active Not RecruitingNCT04330690
2020-03-18HydroxychloroquineA Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)Treatment2Active Not RecruitingNCT04330690
2020-03-18RemdesivirA Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO : Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)Treatment2Active Not RecruitingNCT04330690
2020-03-18SarilumabAn Adaptive Phase 2 / 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19Treatment2, 3Active Not RecruitingNCT04315298
2020-03-18HydroxychloroquineTreatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy : a Cluster Randomized Clinical Trial (PEP CoV-2 Study)Prevention3Active Not RecruitingNCT04304053
2020-03-18ChamomileEffect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19)TreatmentNot AvailableRecruitingIRCT20151228025732N51
2020-03-18Althea rootEffect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19)TreatmentNot AvailableRecruitingIRCT20151228025732N51
2020-03-18RibavirinComparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe SymptomsTreatment2Active Not RecruitingIRCT20200324046850N2
2020-03-18LopinavirComparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe SymptomsTreatment2Active Not RecruitingIRCT20200324046850N2
2020-03-18DaclatasvirComparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe SymptomsTreatment2Active Not RecruitingIRCT20200324046850N2
2020-03-18HydroxychloroquineComparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe SymptomsTreatment2Active Not RecruitingIRCT20200324046850N2
2020-03-18RitonavirComparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe SymptomsTreatment2Active Not RecruitingIRCT20200324046850N2
2020-03-18SofosbuvirComparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe SymptomsTreatment2Active Not RecruitingIRCT20200324046850N2
2020-03-18SofosbuvirEvaluating efficacy and safety of sofosbuvir / ledipasvir in treatment of COVID-19Treatment2, 3RecruitingIRCT20100228003449N29
2020-03-17COVID-19 convalescent plasmaPlasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19TreatmentNot AvailableActive Not RecruitingNCT04321421
2020-03-17HydroxychloroquinePost-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2 : A Pragmatic Randomized Clinical TrialTreatment3Active Not RecruitingNCT04308668
2020-03-17COVID-19 convalescent plasmaThe efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19) : a pragmatic, prospective cohort studyTreatment0Active Not RecruitingChiCTR2000031501
2020-03-17BevacizumabThe Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical TrialTreatmentNot AvailableActive Not RecruitingNCT04305106
2020-03-17Interferon beta-1aA randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG001) for SARS-CoV-2 infectionTreatment2Active Not RecruitingEUCTR2020-001023-14-GB
2020-03-17BCG vaccineReducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONATreatment4Active Not RecruitingEUCTR2020-000919-69-NL
2020-03-17COVID-19 convalescent plasmaA randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)TreatmentNot AvailableActive Not RecruitingChiCTR2000030929
2020-03-16mRNA-1273Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy AdultsPrevention1Active Not RecruitingNCT04283461
2020-03-16Ad5-nCoVA Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years OldPrevention1Active Not RecruitingNCT04313127
2020-03-16Interferon beta-1aA Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-ß1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 InfectionTreatment2Active Not RecruitingNCT04385095
2020-03-16BaricitinibBaricitinib Therapy in COVID-19 : A Pilot Study on Safety and Clinical ImpactTreatment2, 3Active Not RecruitingNCT04358614
2020-03-16FebuxostatThe effect of febuxostat against lung injury induced by COVID-19 virus in infected patients : A clinical trial studyTreatment3Active Not RecruitingIRCT20190727044343N1
2020-03-16Human Umbilical Cord Mesenchymal Stem CellsTreatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem CellsTreatment1Active Not RecruitingNCT04313322
2020-03-16ThymalfasinPerioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak periodTreatmentNot AvailableRecruitingChiCTR2000031023
2020-03-16GoldA comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)Diagnostic0Active Not RecruitingChiCTR2000030721
2020-03-16UlinastatinA randomized, open-label, controlled trial for the efficacy and safety of Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)Treatment4Active Not RecruitingChiCTR2000030779
2020-03-16TocilizumabClinical Characterisation Protocol for Severe Emerging Infections ISARIC / WHO : COVID-19Treatment4RecruitingRBR-3zdynp
2020-03-15RemdesivirA Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care TreatmentTreatment3Active Not RecruitingNCT04292730
2020-03-15CholecalciferolA Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferolTreatmentNot AvailableActive Not RecruitingNCT04399746
2020-03-15AzithromycinA Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferolTreatmentNot AvailableActive Not RecruitingNCT04399746
2020-03-15IvermectinA Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferolTreatmentNot AvailableActive Not RecruitingNCT04399746
2020-03-15HydroxychloroquineAntimalarial and Covid 19 in Rheumatoid ArthritisBasic ScienceNot AvailableActive Not RecruitingNCT04389320
2020-03-15Remestemcel-LMesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 1 and 2 clinical trialTreatment1, 2Active Not RecruitingIRCT20200217046526N1
2020-03-15TocilizumabEvaluation of the safety and efficacy of tocilizumab (AryoGen ?Pharmed Co., Iran) in patients with severe COVID-19?Treatment3RecruitingIRCT20150303021315N17
2020-03-15COVID-19 convalescent plasmaEvaluation of Convalescent Plasma as a Potential Therapy for COVID-19 infected patientsTreatmentNot AvailableRecruitingIRCT20200325046860N1
2020-03-15Interferon beta-1bEvaluating efficacy and safety of interferone ß-1b (IFN ß-1b) in the treatment of COVID-19Treatment2, 3RecruitingIRCT20100228003449N27
2020-03-15Interferon beta-1aEvaluating efficacy and safety of interferone ß-1a in the treatment COVID-19 infectionTreatment2, 3Active Not RecruitingIRCT20100228003449N28
2020-03-15HydroxychloroquineEvaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19Treatment2, 3RecruitingIRCT20100228003449N30
2020-03-15LopinavirEvaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19Treatment2, 3RecruitingIRCT20100228003449N30
2020-03-15RitonavirEvaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19Treatment2, 3RecruitingIRCT20100228003449N30
2020-03-15AtazanavirEvaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir / ritonavir combination in patients with COVID-19Treatment2, 3RecruitingIRCT20100228003449N30
2020-03-14FavipiravirA prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.Treatment2Active Not RecruitingJPRN-jRCTs031190226
2020-03-13Ascorbic acidUse of Ascorbic Acid in Patients With COVID 19TreatmentNot AvailableActive Not RecruitingNCT04323514
2020-03-13Natural Killer CellClinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)Treatment0Active Not RecruitingChiCTR2000030509
2020-03-12LeflunomideEfficacy and safety of leflunomide for Refractory novel coronavirus pneumonia (COVID-19) : A non-Randomized Controlled StudyTreatment0Active Not RecruitingChiCTR2000033372
2020-03-12MethylprednisoloneEarly Short Course Corticosteroids in Hospitalized Patients With COVID-19Basic ScienceNot AvailableActive Not RecruitingNCT04374071
2020-03-12TocilizumabTocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial PneumoniaTreatment2Active Not RecruitingNCT04315480
2020-03-12GoldUpper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patientsDiagnosticNot AvailableActive Not RecruitingChiCTR2000030993
2020-03-11RitonavirRandomized Controlled Clinical Trials of Lopinavir / Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04307693
2020-03-11HydroxychloroquineRandomized Controlled Clinical Trials of Lopinavir / Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04307693
2020-03-11LopinavirRandomized Controlled Clinical Trials of Lopinavir / Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)Treatment2Active Not RecruitingNCT04307693
2020-03-11HydroxychloroquineEvaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)Treatment2RecruitingIRCT20151227025726N13
2020-03-11TocilizumabEvaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)Treatment2RecruitingIRCT20151227025726N13
2020-03-11OseltamivirEvaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)Treatment2RecruitingIRCT20151227025726N13
2020-03-11LopinavirEvaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)Treatment2RecruitingIRCT20151227025726N13
2020-03-11RitonavirEvaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)Treatment2RecruitingIRCT20151227025726N13
2020-03-11GoldAccuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19DiagnosticNot AvailableActive Not RecruitingChiCTR2000030754
2020-03-10ChloroquinePhase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 PneumoniaTreatment2Active Not RecruitingNCT04428268
2020-03-10LosartanPhase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 PneumoniaTreatment2Active Not RecruitingNCT04428268
2020-03-10Human immunoglobulin GEffect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19) : A clinical trial studiesTreatment2RecruitingIRCT20200418047116N1
2020-03-10CrocinAssessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19Treatment2, 3Active Not RecruitingIRCT20160131026298N2
2020-03-10Linoleic acidAssessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19Treatment2, 3Active Not RecruitingIRCT20160131026298N2
2020-03-10Oleic AcidAssessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19Treatment2, 3Active Not RecruitingIRCT20160131026298N2
2020-03-10LevomentholAssessment of the effect of Pinen.Hydronoplacton.Ribonucleic acid (PHR) spray in pulmonary problems of the patients with Covid-19Treatment2, 3Active Not RecruitingIRCT20160131026298N2